

Tisagenlecleucel in Children and Young Adults with B-C

New England Journal of Medicine

378, 439-448

DOI: [10.1056/nejmoa1709866](https://doi.org/10.1056/nejmoa1709866)

Citation Report

#	ARTICLE	IF	CITATIONS
1	CAR T cell therapy efficacious against B-ALL across age groups. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 199-199.	12.5	4
2	Engineering a designer immunotherapy. <i>Science</i> , 2018, 359, 990-991.	6.0	11
3	Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1135-1141.	2.0	60
4	Introduction of Genetically Modified CD3 ζ Improves Proliferation and Persistence of Antigen-Specific CTLs. <i>Cancer Immunology Research</i> , 2018, 6, 733-744.	1.6	14
5	Tapping the RNA world for therapeutics. <i>Nature Structural and Molecular Biology</i> , 2018, 25, 357-364.	3.6	147
6	Beginning the CAR T cell therapy revolution in the US and EU. <i>Current Research in Translational Medicine</i> , 2018, 66, 62-64.	1.2	24
7	Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations. <i>Current Research in Translational Medicine</i> , 2018, 66, 59-61.	1.2	7
8	Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. <i>Current Research in Translational Medicine</i> , 2018, 66, 50-52.	1.2	100
9	Bispecific antibodies in haematological malignancies. <i>Cancer Treatment Reviews</i> , 2018, 65, 87-95.	3.4	55
10	Blinatumomab for MRD+ B-ALL: the evidence strengthens. <i>Blood</i> , 2018, 131, 1497-1498.	0.6	6
11	Chimeric antigen receptor ζ -modified T cells: CD19 and the road beyond. <i>Blood</i> , 2018, 131, 2621-2629.	0.6	126
12	Introduction to a review series on emerging immunotherapies for hematologic diseases. <i>Blood</i> , 2018, 131, 2617-2620.	0.6	7
13	Biomarkers in chimeric antigen receptor T-cell therapy. <i>Biomarkers in Medicine</i> , 2018, 12, 415-418.	0.6	14
14	Global efforts toward the cure of childhood acute lymphoblastic leukaemia. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 440-454.	2.7	83
15	CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications. <i>Human Gene Therapy</i> , 2018, 29, 559-568.	1.4	90
16	Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector. <i>Molecular Therapy</i> , 2018, 26, 1447-1456.	3.7	77
17	CAR T cell immunotherapy for human cancer. <i>Science</i> , 2018, 359, 1361-1365.	6.0	1,968
18	Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia. <i>Oncimmunology</i> , 2018, 7, e1448331.	2.1	7

#	ARTICLE	IF	CITATIONS
19	Keeping the Engine Running: The Relevance and Predictive Value of Preclinical Models for CAR-T Cell Development. <i>ILAR Journal</i> , 2018, 59, 276-285.	1.8	5
20	Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e23.	0.6	1
21	Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 574-578.	1.8	17
22	What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3183-3185.	0.8	8
23	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 3192-3202.	0.8	110
24	4-1BB enhancement of CAR T function requires NF- κ B and TRAFs. <i>JCI Insight</i> , 2018, 3, .	2.3	88
25	CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, e6-e15.	1.8	46
26	Epithelial-mesenchymal transition-induced metastasis could be a bait for natural killer cells. <i>Journal of Thoracic Disease</i> , 2018, 10, S3143-S3146.	0.6	4
27	Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer. <i>Cureus</i> , 2018, 10, e3486.	0.2	8
28	Cell and gene therapies at the forefront of innovative medical care: Implications for South Africa. <i>South African Medical Journal</i> , 2018, 109, 20.	0.2	4
29	Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy. <i>Journal of Immunotherapy</i> , 2018, 41, 406-410.	1.2	35
30	The potential of precision medicine for childhood acute lymphoblastic leukemia: opportunities and challenges. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 343-356.	0.4	1
31	CAR-T cell therapy, a door is open to find innumerable possibilities of treatments for cancer patients. <i>Turkish Journal of Haematology</i> , 2018, 35, 217-228.	0.2	9
32	CAR-T cells et leucĂ©mies aiguĂ©s lymphoblastiques de lâ€™enfant et de lâ€™adulte. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 1441-1451.	0.0	1
33	Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Era of Novel Agents and Targeted Therapies. <i>Journal of Stem Cell Biology and Transplantation</i> , 2018, 02, .	0.3	0
38	Precision medicine in pediatric oncology. <i>Molecular and Cellular Pediatrics</i> , 2018, 5, 6.	1.0	37
41	Immunotherapy in non-Hodgkin lymphoma. <i>Annals of Lymphoma</i> , 0, 2, 9-9.	4.5	0
42	Cytokine release syndrome and neurotoxicity after <sc>CD</sc> 19 chimeric antigen receptorâ€modified (<sc>CAR</sc>â€) T cell therapy. <i>British Journal of Haematology</i> , 2018, 183, 364-374.	1.2	131

#	ARTICLE	IF	CITATIONS
43	Natural killer cells as a therapeutic tool for infectious diseases - current status and future perspectives. <i>Oncotarget</i> , 2018, 9, 20891-20907.	0.8	33
44	Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, . .	0.8	0
45	Characteristics and Therapeutic Targeting of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1100, 127-139.	0.8	5
46	Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 513.	1.3	29
47	CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report. <i>BMC Cancer</i> , 2018, 18, 1143.	1.1	11
48	CAR T Cell Therapy for Neuroblastoma. <i>Frontiers in Immunology</i> , 2018, 9, 2380.	2.2	107
49	MÃ©dicaments de thÃ©rapie innovante : rÃ©glementation et applications cliniques. <i>Revue Francophone Des Laboratoires</i> , 2018, 2018, 44-51.	0.0	1
50	A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. <i>Cell Discovery</i> , 2018, 4, 62.	3.1	83
51	CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge. <i>Frontiers in Immunology</i> , 2018, 9, 2460.	2.2	101
52	Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments. <i>Molecular Therapy</i> , 2018, 26, 2717-2726.	3.7	71
53	Ethical considerations in the application of cell and gene therapies in children. <i>South African Medical Journal</i> , 2018, 108, 1027.	0.2	4
54	A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 141.	6.9	388
55	CARâ€™ cell therapy: personalised immunotherapy for cancer. <i>The Prescriber</i> , 2018, 29, 26-29.	0.1	1
56	74th Congress of the Italian Society of Pediatrics. <i>Italian Journal of Pediatrics</i> , 2018, 44, 149.	1.0	2
57	Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction. <i>Frontiers in Immunology</i> , 2018, 9, 2861.	2.2	27
58	A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 539.	1.3	32
59	Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 127-137.	2.0	191
60	CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs. <i>Frontiers in Immunology</i> , 2018, 9, 2618.	2.2	86

#	ARTICLE	IF	CITATIONS
61	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. , 2018, 6, 137.		182
62	CTLO19 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Design, Development and Therapy, 2018, Volume 12, 3885-3898.	2.0	78
63	Hematopoietic Stem Cell Transplantation and Immunotherapy for Pediatric Hematologic Malignancies. , 2018, , .		0
64	Universal CARs, universal T cells, and universal CAR T cells. Journal of Hematology and Oncology, 2018, 11, 132.	6.9	184
65	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. Frontiers in Immunology, 2018, 9, 2740.	2.2	58
66	Novel therapeutic agents for relapsed classical Hodgkin lymphoma. British Journal of Haematology, 2019, 184, 105-112.	1.2	16
67	Toward the potential cure of leukemias in the next decade. Cancer, 2018, 124, 4301-4313.	2.0	36
68	New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 3504-3519.	0.8	67
69	Cytokine release syndrome: grading, modeling, and new therapy. Journal of Hematology and Oncology, 2018, 11, 121.	6.9	99
70	Should immunologic strategies be incorporated into frontline ALL therapy?. Best Practice and Research in Clinical Haematology, 2018, 31, 367-372.	0.7	2
71	The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1573-1584.	0.9	16
72	Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2018, 24, e11-e19.	2.0	21
73	Ergebnisse des AMNOG-Erstattungsbetragsverfahrens. , 2018, , 217-238.		2
74	The adolescence of cancer immunotherapy: from a difficult childhood to a pillar of modern anticancer therapy. Memo - Magazine of European Medical Oncology, 2018, 11, 82-83.	0.3	0
75	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nature Medicine, 2018, 24, 1504-1506.	15.2	393
76	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine, 2018, 24, 1499-1503.	15.2	459
77	Allogeneic CAR-T Cells: More than Ease of Access?. Cells, 2018, 7, 155.	1.8	129
78	Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy. Current Hematologic Malignancy Reports, 2018, 13, 484-493.	1.2	7

#	ARTICLE	IF	CITATIONS
79	Chimeric Antigen Receptor Tâ€Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside. <i>Clinical and Translational Science</i> , 2018, 11, 537-539.	1.5	3
80	Cytokine release syndrome. <i>Journal of Oncological Science</i> , 2018, 4, 134-141.	0.1	11
81	Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1095-1106.	1.4	6
82	Engineering Cell Surfaces by Covalent Grafting of Synthetic Polymers to Metabolically-Labeled Glycans. <i>ACS Macro Letters</i> , 2018, 7, 1289-1294.	2.3	23
83	Chemoimmunotherapy with inotuzumab ozogamicin combined with miniâ€Hyperâ€CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018, 124, 4044-4055.	2.0	88
84	CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. <i>Leukemia</i> , 2018, 32, 2307-2315.	3.3	96
86	Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma. <i>Molecules</i> , 2018, 23, 2798.	1.7	45
87	Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. <i>CNS Drugs</i> , 2018, 32, 1091-1101.	2.7	175
88	Engineering CAR-T Cells for Improved Function Against Solid Tumors. <i>Frontiers in Immunology</i> , 2018, 9, 2493.	2.2	67
89	Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. <i>International Journal of Hematologic Oncology</i> , 2018, 7, IJH02.	0.7	26
90	Programmed cell death protein 1 activation preferentially inhibits CD28.CARâ€T cells. <i>Cytherapy</i> , 2018, 20, 1259-1266.	0.3	60
91	InÂVivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkinâ€™s Lymphomas. <i>Molecular Therapy</i> , 2018, 26, 2727-2737.	3.7	180
95	Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10898-E10906.	3.3	73
96	CAR-T immunotherapy: how will it change treatment for acute lymphoblastic leukemia and beyond?. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 563-566.	0.5	4
97	Neurotoxicity after CTL019 in a pediatric and young adult cohort. <i>Annals of Neurology</i> , 2018, 84, 537-546.	2.8	82
98	The biological basis and clinical symptoms of CAR-T therapy-associated toxicities. <i>Cell Death and Disease</i> , 2018, 9, 897.	2.7	90
99	Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1485-1492.	2.0	93
100	Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 6175-6184.	3.2	170

#	ARTICLE	IF	CITATIONS
101	Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 80.	2.8	68
102	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolimmunology</i> , 2018, 7, e15111506.	2.1	121
103	Consumption of β -glucans to spice up T cell treatment of tumors: a review. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1023-1040.	1.4	35
104	The hallmarks of successful anticancer immunotherapy. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	419
105	Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis. <i>Medical Oncology</i> , 2018, 35, 144.	1.2	7
106	Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies. <i>Current Protocols in Cytometry</i> , 2018, 86, e44.	3.7	27
107	Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment. <i>Frontiers in Immunology</i> , 2018, 9, 2103.	2.2	56
108	Novel CAR T Cells for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S134-S136.	0.2	0
109	T lymphocytes as therapeutic arsenal for patients with hematological malignancies. <i>Current Opinion in Oncology</i> , 2018, 30, 425-434.	1.1	4
110	Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review. <i>Immunotherapy</i> , 2018, 10, 913-917.	1.0	24
111	Chimeric antigen receptor T-cell therapy hits the market. <i>Immunotherapy</i> , 2018, 10, 911-912.	1.0	2
112	CAR T cells find strength in polyfunction. <i>Blood</i> , 2018, 132, 769-770.	0.6	2
113	Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL. <i>Blood Advances</i> , 2018, 2, 1382-1385.	2.5	59
114	Genetics and prognosis of ALL in children vs adults. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 137-145.	0.9	90
115	Are CAR T cells better than antibody or HCT therapy in B-ALL?. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 16-24.	0.9	21
116	No free rides: management of toxicities of novel immunotherapies in ALL, including financial. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 25-34.	0.9	29
117	Antibody-based therapies in patients with acute lymphoblastic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 9-15.	0.9	22
118	No free rides: management of toxicities of novel immunotherapies in ALL, including financial. <i>Blood Advances</i> , 2018, 2, 3393-3403.	2.5	41

#	ARTICLE	IF	CITATIONS
119	Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. <i>Nature Medicine</i> , 2018, 24, 739-748.	15.2	947
120	Myeloid lineage switch following chimeric antigen receptor T cell therapy in a patient with TCF3&ZNF384 fusion&positive B lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27265.	0.8	67
122	CAR T cells, immunologic and cellular therapies in hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 115-116.	0.7	1
123	Emerging Treatment Options for Acute Lymphoblastic Leukemia: Focus on CAR T-Cell Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 651-655.	2.3	4
124	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. <i>Nature</i> , 2018, 558, 307-312.	13.7	574
125	Next-generation sequencing in drug development: target identification and genetically stratified clinical trials. <i>Drug Discovery Today</i> , 2018, 23, 1776-1783.	3.2	46
126	IL-6 blockade for myocardial infarction. <i>International Journal of Cardiology</i> , 2018, 271, 19-20.	0.8	4
127	Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia. <i>Trends in Molecular Medicine</i> , 2018, 24, 729-731.	3.5	0
128	CAR-T in the clinic: drive with care. <i>Gene Therapy</i> , 2018, 25, 157-161.	2.3	10
129	CAR&T cell manufacture: snatching victory when defeat is looming. <i>Transfusion</i> , 2018, 58, 1335-1337.	0.8	1
130	Chimeric Antigen Receptor Therapy. <i>New England Journal of Medicine</i> , 2018, 379, 64-73.	13.9	1,488
131	Cousins at work: How combining medical with optical imaging enhances in vivo cell tracking. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 102, 40-50.	1.2	34
132	Cytokine release syndrome. , 2018, 6, 56.		1,055
133	Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 573-580.	0.7	5
134	Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. <i>Cancers</i> , 2018, 10, 244.	1.7	40
135	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. <i>Frontiers in Immunology</i> , 2018, 9, 1740.	2.2	155
136	Adoptive Cell Therapy in Treating Pediatric Solid Tumors. <i>Current Oncology Reports</i> , 2018, 20, 73.	1.8	12
137	The promise of CAR T-cell therapy in aggressive B-cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 293-298.	0.7	44

#	ARTICLE	IF	CITATIONS
138	Cancer immunotherapy with CAR-T cells “ behold the future. <i>Clinical Medicine</i> , 2018, 18, 324-328.	0.8	32
139	Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. <i>Frontiers in Immunology</i> , 2018, 9, 1104.	2.2	95
140	Current Strategies to Enhance Anti-Tumour Immunity. <i>Biomedicines</i> , 2018, 6, 37.	1.4	11
141	CARs versus BiTEs: A Comparison between T Cell “Redirection Strategies for Cancer Treatment. <i>Cancer Discovery</i> , 2018, 8, 924-934.	7.7	173
142	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27313.	0.8	11
143	Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. <i>Mammalian Genome</i> , 2018, 29, 739-756.	1.0	33
144	A survey of mobile technology usage and desires by caregivers of children with cancer. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27359.	0.8	25
145	Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL. <i>Experimental Hematology</i> , 2018, 66, 5-16.	0.2	5
146	Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis. <i>Blood</i> , 2018, 131, 2630-2639.	0.6	9
147	CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. <i>Journal of Hematology and Oncology</i> , 2018, 11, 41.	6.9	44
148	CAR T cells for childhood diffuse midline gliomas. <i>Nature Medicine</i> , 2018, 24, 534-535.	15.2	3
149	CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 396-406.	1.2	113
150	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. <i>Blood</i> , 2018, 132, 1495-1506.	0.6	100
151	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
152	The Next Phase of Human Gene-Therapy Oversight. <i>New England Journal of Medicine</i> , 2018, 379, 1393-1395.	13.9	79
153	Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 959-971.	1.1	19
154	Cancer Immunotherapy. <i>Glycobiology</i> , 2018, 28, 638-639.	1.3	5
155	Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. <i>Science Signaling</i> , 2018, 11, .	1.6	323

#	ARTICLE	IF	CITATIONS
156	A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. <i>Molecular Therapy</i> , 2018, 26, 2487-2495.	3.7	72
157	Tumor Antigen Escape from CAR T-cell Therapy. <i>Cancer Discovery</i> , 2018, 8, 1219-1226.	7.7	661
158	Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy. <i>Trends in Molecular Medicine</i> , 2018, 24, 642-653.	3.5	59
159	Novel Approaches to Acute Myeloid Leukemia Immunotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 5502-5515.	3.2	56
160	Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 135-148.	1.1	53
161	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. <i>Molecular Therapy</i> , 2018, 26, 1896-1905.	3.7	65
162	Immune Gene Therapy and the International Conference on Lymphocyte Engineering (ICLE 2018). <i>Human Gene Therapy</i> , 2018, 29, vii-ix.	1.4	0
163	Cancer immunotherapy: broadening the scope of targetable tumours. <i>Open Biology</i> , 2018, 8, .	1.5	162
164	Chimeric antigen receptor T cell therapy—a hematological success story. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 116-121.	0.3	6
165	Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?. <i>Blood</i> , 2018, 132, 351-361.	0.6	82
166	Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 132, 777-781.	0.6	105
167	Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 1413.	3.4	69
168	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 45-63.	12.5	178
169	Are We There Yet? How and When Specific Biotechnologies Will Improve Human Health. <i>Biotechnology Journal</i> , 2019, 14, e1800195.	1.8	7
170	Cross-sectional physician survey on the use of minimal residual disease testing in the management of pediatric and adult patients with acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 70-78.	0.7	6
171	Cancer immune therapy for lymphoid malignancies: recent advances. <i>Seminars in Immunopathology</i> , 2019, 41, 111-124.	2.8	15
172	Is it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 529-536.	0.7	23
173	Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	24

#	ARTICLE	IF	CITATIONS
174	Melanoma Immunology and Immunotherapy. , 2019, , 651-665.		0
175	CAR-T “ and a side order of IgG, to go? “ Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Reviews, 2019, 38, 100596.	2.8	109
176	SOHO State of the Art Updates and Next Questions: T-Cell“Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor“Modified T Cells and Bispecific T-Cell“Engaging Agents. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 537-544.	0.2	18
177	Cancer immunotherapy: Adoptive cell therapies, cytokine-related toxicities, and the kidneys. Journal of Onco-Nephrology, 2019, 3, 131-143.	0.3	0
178	Large-scale expansion and characterization of CD3+ T-cells in the QuantumÂ® Cell Expansion System. Journal of Translational Medicine, 2019, 17, 258.	1.8	21
179	Approach to the Adult Acute Lymphoblastic Leukemia Patient. Journal of Clinical Medicine, 2019, 8, 1175.	1.0	28
180	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiation Oncology, 2019, 14, 141.	1.2	285
182	Medicinal Biotechnology for Disease Modeling, Clinical Therapy, and Drug Discovery and Development. , 2019, , 89-128.		6
183	Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. Bone Marrow Transplantation, 2019, 54, 780-784.	1.3	52
184	Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. British Journal of Haematology, 2019, 187, e35-e38.	1.2	35
185	Introduction to Biotech Entrepreneurship: From Idea to Business. , 2019, , .		0
186	Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro. Frontiers in Immunology, 2019, 10, 1790.	2.2	12
188	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). Biology of Blood and Marrow Transplantation, 2019, 25, 2388-2397.	2.0	33
189	Development of adaptive immune effector therapies in solid tumors. Annals of Oncology, 2019, 30, 1740-1750.	0.6	35
190	T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression. OncoImmunology, 2019, 8, e1621676.	2.1	17
191	Single“center experience suggests donor lymphocyte infusion may promote long“term survival in children with high“risk acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27950.	0.8	6
192	Advances in measurable residual disease monitoring for adult acute lymphoblastic leukemia. Advances in Cell and Gene Therapy, 2019, 2, e67.	0.6	1
193	Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nature Reviews Drug Discovery, 2019, 18, 669-688.	21.5	176

#	ARTICLE	IF	CITATIONS
195	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. <i>Molecular Therapy</i> , 2019, 27, 1919-1929.	3.7	220
196	The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 810-814.	1.3	33
197	Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, e6.	13.9	3
198	An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 1691.	2.2	70
199	Chimeric antigen T cell receptor treatment in hematological malignancies. <i>Blood Research</i> , 2019, 54, 81-83.	0.5	10
200	Human gene therapy approaches for the treatment of Parkinson's disease: An overview of current and completed clinical trials. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 16-24.	1.1	40
201	Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. <i>Nature Communications</i> , 2019, 10, 3137.	5.8	120
202	<p>Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4543-4554.	1.0	6
203	Anti-CD19 chimeric antigen receptor-modified T cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. <i>American Journal of Hematology</i> , 2019, 94, 1113-1122.	2.0	97
204	Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment. <i>Current Treatment Options in Neurology</i> , 2019, 21, 40.	0.7	65
205	At the end of the beginning: immunotherapies as living drugs. <i>Nature Immunology</i> , 2019, 20, 955-962.	7.0	4
206	Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 5595-5607.	3.2	38
207	SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 471-479.	0.2	2
209	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e344-e351.	2.0	59
210	Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2246-2256.	0.8	186
211	Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. <i>Leukemia and Lymphoma</i> , 2019, 60, 3482-3492.	0.6	3
212	Multi-Specific CAR Targeting to Prevent Antigen Escape. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 451-459.	1.2	13
213	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Hematologic Malignancies. <i>Journal of Palliative Medicine</i> , 2019, 22, 1449-1454.	0.6	8

#	ARTICLE	IF	CITATIONS
214	Immunotherapies for the Treatment of Uveal Melanoma—History and Future. <i>Cancers</i> , 2019, 11, 1048.	1.7	56
215	CAR T-Cell Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 923.	3.8	10
216	Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e452-e463.	5.1	150
217	Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e443-e451.	5.1	66
218	Cellular therapy: Immune-related complications. <i>Immunological Reviews</i> , 2019, 290, 114-126.	2.8	55
219	T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. <i>Immunological Reviews</i> , 2019, 290, 127-147.	2.8	180
220	CAR T cells for brain tumors: Lessons learned and road ahead. <i>Immunological Reviews</i> , 2019, 290, 60-84.	2.8	151
221	Updates on CAR T-cell therapy in B-cell malignancies. <i>Immunological Reviews</i> , 2019, 290, 39-59.	2.8	61
222	Immunobiology of chimeric antigen receptor T cells and novel designs. <i>Immunological Reviews</i> , 2019, 290, 100-113.	2.8	16
223	Synergistic combination of oncolytic virotherapy with CAR T-cell therapy. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 164, 217-292.	0.9	15
224	Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies. <i>BioDrugs</i> , 2019, 33, 515-537.	2.2	42
225	CAR T cells take centre stage. <i>Clinical and Translational Immunology</i> , 2019, 8, e01068.	1.7	1
226	Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 28-34.	0.1	1
227	Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients. <i>Journal of Neuro-Oncology</i> , 2019, 144, 79-87.	1.4	11
228	Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects. <i>Protein and Cell</i> , 2019, 10, 764-769.	4.8	73
229	Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases. <i>Pharmaceutical Medicine</i> , 2019, 33, 83-88.	1.0	2
230	Myocarditis in the Setting of Cancer Therapeutics. <i>Circulation</i> , 2019, 140, 80-91.	1.6	278
231	Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience. <i>Oncology</i> , 2019, 97, 59-74.	0.9	13

#	ARTICLE	IF	CITATIONS
232	Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 1342.	2.2	33
233	Anti-GPRC5D/CD3 Bispecific T-Cellâ€“Redirecting Antibody for the Treatment of Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1555-1564.	1.9	49
234	Engineering switchable and programmable universal CARs for CAR T therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 69.	6.9	65
235	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263.	1.4	29
236	NK Cell-Based Immunotherapy for Hematological Malignancies. <i>Journal of Clinical Medicine</i> , 2019, 8, 1702.	1.0	54
237	Cost burden of diffuse large B-cell lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 645-661.	0.7	14
238	Challenges and Opportunities for Childhood Cancer Drug Development. <i>Pharmacological Reviews</i> , 2019, 71, 671-697.	7.1	13
239	Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing. <i>Human Gene Therapy</i> , 2019, 30, 1477-1493.	1.4	24
240	Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor. , 2019, 7, 259.		10
241	CAR-T cell therapy: a potential new strategy against prostate cancer. , 2019, 7, 258.		61
242	Immune-Based Therapies in Acute Leukemia. <i>Trends in Cancer</i> , 2019, 5, 604-618.	3.8	32
243	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2019, 20, 1710-1718.	5.1	65
244	Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109437.	2.5	45
245	Quality of life and CAR-T cell therapy in children, adolescents, and young adults with haematological malignancies. <i>Lancet Oncology, The</i> , 2019, 20, 1625-1626.	5.1	12
246	How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 2135-2143.	1.7	22
247	Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. , 2019, 7, 271.		45
248	Driving the CAR to the Bone Marrow Transplant Program. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 561-569.	1.2	10
249	Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2019, 110, 709-722.	0.7	6

#	ARTICLE	IF	CITATIONS
250	Immunotherapy for pediatric brain tumors: past and present. <i>Neuro-Oncology</i> , 2019, 21, 1226-1238.	0.6	32
251	Reply to Dr Stoddard. <i>Neuro-Oncology</i> , 2019, 21, 1211-1211.	0.6	1
252	Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5010.	1.8	35
253	Imaging of T-cells and their responses during anti-cancer immunotherapy. <i>Theranostics</i> , 2019, 9, 7924-7947.	4.6	77
254	Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances anti-glioma therapeutic function. <i>Journal of Neuro-Oncology</i> , 2019, 145, 429-439.	1.4	33
255	Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design. <i>Biochemistry</i> , 2019, 58, 4869-4881.	1.2	29
256	Immunomodulatory Effects of Genetic Alterations Affecting the Kynurenine Pathway. <i>Frontiers in Immunology</i> , 2019, 10, 2570.	2.2	31
257	Advances in Engineering Cells for Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 7889-7905.	4.6	44
258	Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. , 2019, 7, 276.		101
259	MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)â€”Current Treatment Options. Is There a Role for CAR-T Cell Therapy?. <i>Cells</i> , 2019, 8, 1341.	1.8	49
260	CAR-T â€œthe living drugsâ€”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 113.	6.9	69
262	Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. <i>Frontiers in Immunology</i> , 2019, 10, 2664.	2.2	214
263	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	3.3	47
264	Shortening the ex vivo culture of CD19â€”specific CAR Tâ€”cells retains potent efficacy against acute lymphoblastic leukemia without CAR Tâ€”cellâ€”related encephalopathy syndrome or severe cytokine release syndrome. <i>American Journal of Hematology</i> , 2019, 94, E322-E325.	2.0	16
265	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. <i>Journal of Clinical Oncology</i> , 2019, 37, 3377-3391.	0.8	169
267	Mature Bâ€”scp>NHL</scp> in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies. <i>British Journal of Haematology</i> , 2019, 185, 1071-1085.	1.2	27
268	Design of a Peptide-Based Electronegative Hydrogel for the Direct Encapsulation, 3D Culturing, in Vivo Syringe-Based Delivery, and Long-Term Tissue Engraftment of Cells. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 34688-34697.	4.0	44
269	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132

#	ARTICLE	IF	CITATIONS
272	Improving cancer immunotherapy through nanotechnology. <i>Nature Reviews Cancer</i> , 2019, 19, 587-602.	12.8	426
273	Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. <i>Nature Medicine</i> , 2019, 25, 1408-1414.	15.2	394
274	Clinical lessons learned from the first leg of the CAR T cell journey. <i>Nature Medicine</i> , 2019, 25, 1341-1355.	15.2	400
275	Rational Use of Medicine in Children—The Conflict of Interests Story. A Review. <i>Rambam Maimonides Medical Journal</i> , 2019, 10, e0018.	0.4	21
276	Principles of Cancer Treatment and Anticancer Drug Development. , 2019, , .		10
277	Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. <i>JCI Insight</i> , 2019, 4, .	2.3	46
278	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. <i>BMC Cancer</i> , 2019, 19, 895.	1.1	40
279	Engineered T Cell Therapy for Cancer in the Clinic. <i>Frontiers in Immunology</i> , 2019, 10, 2250.	2.2	267
280	Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i><i>BCR-ABL</i></i> Induced B-Cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 7527-7539.	3.2	13
281	Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 94.	6.9	70
282	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. <i>Frontiers in Immunology</i> , 2019, 10, 2109.	2.2	32
283	Genetically engineered T cells for cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 35.	7.1	153
284	The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study. <i>Pediatric Hematology and Oncology</i> , 2019, 36, 468-481.	0.3	12
285	T cell engineering for adoptive T cell therapy: safety and receptor avidity. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1701-1712.	2.0	41
286	Conventional CARs versus modular CARs. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1713-1719.	2.0	37
287	Childhood Acute Lymphoblastic Leukemia: How to Cure the Very High Risk?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S2-S5.	0.2	0
288	Debate: Is Transplant Still Necessary in the Era of Targeted Cellular Therapy for ALL? CON. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S60-S62.	0.2	0
289	The Future of Cellular Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S102-S105.	0.2	0

#	ARTICLE	IF	CITATIONS
290	Paradox-driven adventures in the development of cancer immunology and immunotherapy. <i>Genes and Diseases</i> , 2019, 6, 224-231.	1.5	3
291	Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541987635.	0.8	38
292	TCR-like antibodies in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 99.	6.9	39
293	CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. <i>Cancers</i> , 2019, 11, 1358.	1.7	98
294	CAR T cell viability release testing and clinical outcomes: is there a lower limit?. <i>Blood</i> , 2019, 134, 1873-1875.	0.6	24
295	Defining precision cellular immunotherapyâ€™s seeking biomarkers to predict and optimize outcomes of T cell therapies in cancer. <i>Precision Cancer Medicine</i> , 2019, 2, 25-25.	1.8	1
296	Current Perspectives in Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1472.	1.7	149
297	CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms. <i>BioDrugs</i> , 2019, 33, 647-659.	2.2	20
298	Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders. <i>Frontiers in Genetics</i> , 2019, 10, 868.	1.1	168
299	On the mark: genetically engineered immunotherapies for autoimmunity. <i>Current Opinion in Immunology</i> , 2019, 61, 69-73.	2.4	9
301	Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4624.	1.8	5
302	Industryâ€™s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 47-55.	1.2	12
303	Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment. <i>Current Oncology Reports</i> , 2019, 21, 4.	1.8	26
304	Improved expansion of T cells in culture when isolated with an equipment-free, high-throughput, flow-through microfluidic module versus traditional density gradient centrifugation. <i>Cytotherapy</i> , 2019, 21, 234-245.	0.3	9
305	Engineering and Design of Chimeric Antigen Receptors. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 145-156.	1.8	281
307	B-cell depleting immunotherapies: therapeutic opportunities and toxicities. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 497-509.	1.3	3
308	The Challenges of Pediatric Drug Development. <i>Current Therapeutic Research</i> , 2019, 90, 128-134.	0.5	34
309	Manufacturing chimeric antigen receptor T cells: issues and challenges. <i>Cytotherapy</i> , 2019, 21, 327-340.	0.3	91

#	ARTICLE	IF	CITATIONS
310	Unleash the power of the mighty T cells-basis of adoptive cellular therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 1-12.	2.0	20
311	Targeting the A&sub&3&adenosine receptor to treat cytokine release syndrome in cancer immunotherapy. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 491-497.	2.0	28
313	Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues. <i>Engineering</i> , 2019, 5, 122-131.	3.2	37
314	The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. <i>Blood Cancer Journal</i> , 2019, 9, 10.	2.8	57
315	Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be Aware and Prepared. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 20-23.	2.5	34
317	An introduction to chimeric antigen receptor (CAR) T cell immunotherapy for human cancer. <i>American Journal of Hematology</i> , 2019, 94, S3-S9.	2.0	340
319	Immunotherapy in pediatric B-cell acute lymphoblastic leukemia. <i>Human Immunology</i> , 2019, 80, 400-408.	1.2	22
320	Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 1099-1110.	1.2	23
321	CAR-Expressing Natural Killer Cells for Cancer Retargeting. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 4-13.	0.7	65
322	Allogeneic CD27-depleted cells in adoptive cell therapy. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e45.	0.6	1
323	Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer. <i>Cancers</i> , 2019, 11, 696.	1.7	23
324	CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2764.	1.8	20
325	Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy. <i>Journal of Immunological Methods</i> , 2019, 472, 55-64.	0.6	17
326	DLL3: an emerging target in small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 61.	6.9	115
327	Advances in cancer immunotherapy 2019 latest trends. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 268.	3.5	401
328	CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2839.	1.8	34
329	Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 813-822.	1.3	221
330	Target selection for CAR-T therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 62.	6.9	118

#	ARTICLE	IF	CITATIONS
331	Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?. <i>Haematologica</i> , 2019, 104, 1302-1308.	1.7	62
332	Towards Immunotherapy for Pediatric Brain Tumors. <i>Trends in Immunology</i> , 2019, 40, 748-761.	2.9	77
333	Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1615-1627.	1.9	8
334	Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care. , 2019, , 1-13.		1
335	Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins. <i>Molecular Pharmaceutics</i> , 2019, 16, 3544-3558.	2.3	29
336	CAR-T immunotherapies: Biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering. <i>Biotechnology Advances</i> , 2019, 37, 107411.	6.0	12
337	The making and function of CAR cells. <i>Immunology Letters</i> , 2019, 212, 53-69.	1.1	19
338	Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. <i>JCI Insight</i> , 2019, 4, .	2.3	71
339	CD123 CAR T cells for the treatment of myelodysplastic syndrome. <i>Experimental Hematology</i> , 2019, 74, 52-63.e3.	0.2	25
340	Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Philadelphia-negative acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2019, 103, 164-171.	1.1	10
341	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 990.	2.2	86
342	Principles of Immunotherapy. , 2019, , 295-304.		0
343	Novel Therapies in Paediatric NHL. , 2019, , 315-335.		0
344	Anti-CD1a CAR T cells to selectively target T-ALL. <i>Blood</i> , 2019, 133, 2246-2247.	0.6	9
345	Optimization and Stability of Cell-Polymer Hybrids Obtained by Clicking-Synthetic Polymers to Metabolically Labeled Cell Surface Glycans. <i>Biomacromolecules</i> , 2019, 20, 2726-2736.	2.6	28
346	Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee. <i>Transfusion</i> , 2019, 59, 2733-2748.	0.8	1
347	Immune cell therapy for hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 52.	6.9	90
348	The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies. <i>Cytotherapy</i> , 2019, 21, 769-781.	0.3	17

#	ARTICLE	IF	CITATIONS
349	Gene editing for immune cell therapies. <i>Nature Biotechnology</i> , 2019, 37, 1425-1434.	9.4	147
350	Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 2105-2119.	0.8	155
351	Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2019, 12, 57.	6.9	46
352	An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT. <i>Current Research in Translational Medicine</i> , 2019, 67, 79-88.	1.2	30
353	Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 59.	6.9	127
354	CAR T cell therapy: Full speed ahead. <i>Hematological Oncology</i> , 2019, 37, 95-100.	0.8	131
355	Managing the toxicities of CAR T cell therapy. <i>Hematological Oncology</i> , 2019, 37, 48-52.	0.8	214
356	Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 1230-1243.	2.5	43
357	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2019, 33, 2540-2544.	3.3	26
358	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e026644.	0.8	27
359	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. <i>Cancer Immunology Research</i> , 2019, 7, 1047-1053.	1.6	59
360	Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. <i>Cells</i> , 2019, 8, 472.	1.8	122
361	Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2469.	1.8	14
362	Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. <i>Nature Communications</i> , 2019, 10, 2087.	5.8	117
363	Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. <i>Annals of Neurology</i> , 2019, 86, 42-54.	2.8	124
364	Pediatric melanomaâ€”The whole (conflicts of interest) story. <i>International Journal of Women's Dermatology</i> , 2019, 5, 110-115.	1.1	20
365	Going to extremes: determinants of extraordinary response and survival in patients with cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 339-348.	12.8	35
366	2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 49.	6.9	117

#	ARTICLE	IF	CITATIONS
367	The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 433-444.	1.8	200
368	The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells. Immunology Letters, 2019, 211, 13-22.	1.1	77
369	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	1.3	86
370	Disparities in Survival and Health Outcomes in Childhood Leukemia. Current Hematologic Malignancy Reports, 2019, 14, 179-186.	1.2	20
371	More Is Not Always Better: The Perils of Treatment Intensification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2019, 37, 1601-1603.	0.8	7
372	Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clinical and Translational Immunology, 2019, 8, e1049.	1.7	205
373	Recent advances in the treatment of acute lymphoblastic leukemia. Leukemia and Lymphoma, 2019, 60, 2606-2621.	0.6	65
374	Viral-mediated gene therapy and genetically modified therapeutics: A primer on biosafety handling for the health-system pharmacist. American Journal of Health-System Pharmacy, 2019, 76, 795-802.	0.5	15
375	CAR T-Cells Targeting the Integrin $\alpha\text{v}\beta\text{6}$ and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies. Cancers, 2019, 11, 674.	1.7	130
376	Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma. , 2019, , 167-183.		1
377	Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1498-1504.	2.0	49
378	Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing. Frontiers in Immunology, 2019, 10, 957.	2.2	88
379	Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Molecular Therapy, 2019, 27, 1126-1138.	3.7	97
380	Timing of first-in-child trials of FDA-approved oncology drugs. European Journal of Cancer, 2019, 112, 49-56.	1.3	49
381	Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2019, 7, 50.	1.8	139
382	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 380, 1726-1737.	13.9	1,130
383	Novel approaches to promote CAR T-cell function in solid tumors. Expert Opinion on Biological Therapy, 2019, 19, 789-799.	1.4	5
384	Exploratory trial of a bi-epitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9543-9551.	3.3	266

#	ARTICLE	IF	CITATIONS
385	Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Biomarker Research</i> , 2019, 7, 9.	2.8	19
386	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
387	Next-Generation Cancer Immunotherapy Targeting Glypican-3. <i>Frontiers in Oncology</i> , 2019, 9, 248.	1.3	86
388	Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1217-1225.	0.5	12
389	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 453-470.	1.3	28
390	Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1281-1292.	2.0	28
391	EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. <i>Molecular Therapy</i> , 2019, 27, 933-946.	3.7	69
392	Theranostic CAR T cell targeting: A brief review. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 533-540.	0.5	20
393	CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. <i>Cancer Cell</i> , 2019, 35, 473-488.e6.	7.7	159
394	Engineering advanced cancer therapies with synthetic biology. <i>Nature Reviews Cancer</i> , 2019, 19, 187-195.	12.8	46
395	Mechanisms of resistance to CAR T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 372-385.	12.5	518
396	Developmental origins and emerging therapeutic opportunities for childhood cancer. <i>Nature Medicine</i> , 2019, 25, 367-376.	15.2	112
397	Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor T Cells. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 285-295.	1.3	83
398	Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. <i>British Journal of Haematology</i> , 2019, 185, 1158-1170.	1.2	60
399	What CAR Will Win the CD19 Race?. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 498-506.	1.9	8
400	Optimizing Precision Medicine for Public Health. <i>Frontiers in Public Health</i> , 2019, 7, 42.	1.3	58
401	Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells. <i>Advanced Materials</i> , 2019, 31, e1900192.	11.1	291
402	Recent landmark studies in follicular lymphoma. <i>Blood Reviews</i> , 2019, 35, 68-80.	2.8	9

#	ARTICLE	IF	CITATIONS
403	CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. <i>Nature</i> , 2019, 568, 112-116.	13.7	408
404	GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	229
405	Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 146.	1.3	123
406	Targeting immune cells for cancer therapy. <i>Redox Biology</i> , 2019, 25, 101174.	3.9	151
407	The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. <i>Trends in Immunology</i> , 2019, 40, 292-309.	2.9	61
408	Enhanced Transduction of Macaca fascicularis Hematopoietic Cells with Chimeric Lentiviral Vectors. <i>Human Gene Therapy</i> , 2019, 30, 1306-1323.	1.4	3
409	Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 47-54.	0.7	39
410	Recent Advances in Adult Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 106-118.	1.2	21
411	Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2019, 37, 834-849.	0.8	66
412	CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies. <i>AAPS Journal</i> , 2019, 21, 50.	2.2	13
413	Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy. <i>Transfusion Medicine and Hemotherapy</i> , 2019, 46, 15-24.	0.7	107
414	How Does Treating Chronic Hepatitis C Affect Individuals in Need of Organ Transplants in the United Kingdom?. <i>Value in Health</i> , 2019, 22, 669-676.	0.1	6
415	Telomerase-Targeted Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1823.	1.8	80
416	Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 1209-1217.	1.7	23
417	Applications of molecular engineering in Tâ€cellâ€based immunotherapies. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2019, 11, e1557.	3.3	6
418	Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. <i>Journal of Experimental Medicine</i> , 2019, 216, 1038-1049.	4.2	109
419	Critical testing and parameters for consideration when manufacturing and evaluating tumorâ€associated antigen-specific T cells. <i>Cytotherapy</i> , 2019, 21, 278-288.	0.3	9
420	Could the menagerie of the gut microbiome really cure cancer? Hope or hype. , 2019, 7, 92.		16

#	ARTICLE	IF	CITATIONS
421	Chemotherapy and Beyond. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 289-309.	1.9	34
422	Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 770-779.	0.8	64
423	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	1.3	218
424	Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. <i>Expert Review of Hematology</i> , 2019, 12, 195-205.	1.0	63
425	Taking a "BiTE out of ALL" blinatumomab approval for MRD-positive ALL. <i>Blood</i> , 2019, 133, 1715-1719.	0.6	39
426	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801320.	3.9	43
427	Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors. <i>Drugs</i> , 2019, 79, 401-415.	4.9	17
428	Cellular immunotherapy for acute myeloid leukemia: How specific should it be?. <i>Blood Reviews</i> , 2019, 35, 18-31.	2.8	23
429	Need for new thinking: Treatment of relapsed leukemia in children with Down syndrome. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27644.	0.8	6
430	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> , 2019, 133, 1652-1663.	0.6	277
431	Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. <i>American Journal of Hematology</i> , 2019, 94, S28-S33.	2.0	35
432	Immunotherapeutic advances in gastrointestinal malignancies. <i>Npj Precision Oncology</i> , 2019, 3, 4.	2.3	16
433	Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 1142-1157.	1.2	29
434	Case report: Impact of BiTE on CAR T cell expansion. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e50.	0.6	7
435	Induced pluripotent stem cells in disease modelling and drug discovery. <i>Nature Reviews Genetics</i> , 2019, 20, 377-388.	7.7	411
436	CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1126-1132.	1.4	42
437	Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?. <i>Cell Medicine</i> , 2019, 11, 215517901882278.	5.0	69
438	Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , 2019, 12, 17.	6.9	80

#	ARTICLE	IF	CITATIONS
439	CAR T cells: The future is already present. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 281-286.	0.1	0
440	Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies. <i>Transfusion</i> , 2019, 59, 1773-1780.	0.8	29
441	Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2019, 12, 15.	6.9	38
442	Chimeric Antigen Receptor T-Cells: The Future is Now. <i>Journal of Clinical Medicine</i> , 2019, 8, 207.	1.0	20
443	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 396-416.	3.6	66
444	CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions. <i>Journal of the National Cancer Institute</i> , 2019, 111, 646-654.	3.0	126
445	Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. <i>Journal of Biological Chemistry</i> , 2019, 294, 5430-5437.	1.6	114
446	Hematopoietic Stem Cell Transplant and Cellular Therapy. , 2019, , 109-158.		1
447	Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed CD19 selective pressure. <i>British Journal of Haematology</i> , 2019, 186, 333-336.	1.2	21
448	Driving CAR T cell translation forward. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	61
449	Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 94-105.	1.2	38
450	T Cell-Redirecting Strategies to CAR Tumor: Beyond CARs and Bispecific Antibodies. <i>Trends in Immunology</i> , 2019, 40, 243-257.	2.9	32
451	EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 205-232.	1.8	106
452	Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. <i>Leukemia</i> , 2019, 33, 2195-2207.	3.3	56
453	Early and late hematologic toxicity following CD19 CAR-T cells. <i>Bone Marrow Transplantation</i> , 2019, 54, 1643-1650.	1.3	254
454	CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. <i>Leukemia</i> , 2019, 33, 2090-2125.	3.3	30
455	Chimeric antigen receptor T cells for acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2019, 94, S24-S27.	2.0	32
456	Toxicities of CD19 CAR T cell immunotherapy. <i>American Journal of Hematology</i> , 2019, 94, S42-S49.	2.0	102

#	ARTICLE	IF	CITATIONS
457	Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e579-e602.	1.6	142
458	Engineered T Cell Therapies from a Drug Development Viewpoint. <i>Engineering</i> , 2019, 5, 140-149.	3.2	8
459	Emerging patient-specific treatment modalities in head and neck cancer – a systematic review. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 365-376.	1.9	3
460	From fiction to science: clinical potentials and regulatory considerations of gene editing. <i>Clinical and Translational Medicine</i> , 2019, 8, 27.	1.7	26
461	Pharmacologic control of CAR-T cell function using dasatinib. <i>Blood Advances</i> , 2019, 3, 711-717.	2.5	143
462	Toxicité hématoLOGIQUE précoce et tardive des cellules T à récepteurs antigéniques chimeriques anti-CD19. <i>Hématologie</i> , 2019, 25, 283-284.	0.0	0
463	Mechanisms of and approaches to overcoming resistance to immunotherapy. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 226-232.	0.9	23
464	Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. <i>Blood Advances</i> , 2019, 3, 2022-2034.	2.5	58
467	Pediatric Acute Lymphoblastic Leukemia: Recent Advances for a Promising Future. , 0, , .		3
468	Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2019, 10, 2856.	2.2	8
469	Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10989-10995.	1.0	6
470	Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review. <i>Future Oncology</i> , 2019, 15, 4235-4246.	1.1	5
471	Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. <i>Blood Advances</i> , 2019, 3, 2230-2236.	2.5	59
472	Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. <i>Blood</i> , 2019, 134, 2149-2158.	0.6	194
473	Beat pediatric ALL MRD: CD28 CAR T and transplant. <i>Blood</i> , 2019, 134, 2333-2335.	0.6	5
474	Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets. <i>Blood Advances</i> , 2019, 3, 3143-3156.	2.5	4
475	Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. <i>Blood Advances</i> , 2019, 3, 2317-2322.	2.5	69
476	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019, 3, 3062-3069.	2.5	74

#	ARTICLE	IF	CITATIONS
477	CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. <i>Blood Advances</i> , 2019, 3, 3539-3549.	2.5	145
478	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. <i>Blood Advances</i> , 2019, 3, 3590-3601.	2.5	52
479	Teaming up for CAR-T cell therapy. <i>Haematologica</i> , 2019, 104, 2335-2336.	1.7	7
480	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. <i>Blood</i> , 2019, 134, 2361-2368.	0.6	190
481	The earlier the better: timely mitigation of CRS. <i>Blood</i> , 2019, 134, 2119-2120.	0.6	8
482	Tâ€cell acute lymphoblastic leukemia: Current approach and future directions. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e70.	0.6	4
483	Cardiotoxicity of Immune Therapy. <i>Cardiology Clinics</i> , 2019, 37, 385-397.	0.9	54
485	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. <i>The Cochrane Library</i> , 2019, , .	1.5	2
486	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2019, 629, xxi-xl.	0.4	1
488	Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases. <i>Journal of Immunology Research</i> , 2019, 2019, 1-9.	0.9	30
489	Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). <i>Journal of the American College of Cardiology</i> , 2019, 74, 3099-3108.	1.2	225
490	Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3153-3163.	1.2	78
491	Gut microbiome and CAR-T therapy. <i>Experimental Hematology and Oncology</i> , 2019, 8, 31.	2.0	33
492	CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entitiesâ€Merits and Challenges. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5942.	1.8	38
493	Delivery strategies of cancer immunotherapy: recent advances and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 126.	6.9	96
494	Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 128.	6.9	106
495	Single variable domains from the T cell receptor Î² chain function as mono- and bifunctional CARs and TCRs. <i>Scientific Reports</i> , 2019, 9, 17291.	1.6	18
496	Translating current biomedical therapies for long duration, deep space missions. <i>Precision Clinical Medicine</i> , 2019, 2, 259-269.	1.3	24

#	ARTICLE	IF	CITATIONS
497	Cancer biomarkers for targeted therapy. Biomarker Research, 2019, 7, 25.	2.8	72
498	<p>Cytokine Release Syndrome: Current Perspectives</p>. ImmunoTargets and Therapy, 2019, Volume 8, 43-52.	2.7	116
499	c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature, 2019, 576, 293-300.	13.7	480
500	A highly soluble Sleeping Beauty transposase improves control of gene insertion. Nature Biotechnology, 2019, 37, 1502-1512.	9.4	63
501	Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia. Cancer Journal (Sudbury, Mass), 2019, 25, 217-222.	1.0	20
502	Escape From ALL-CARTaz. Cancer Journal (Sudbury, Mass), 2019, 25, 217-222.	1.0	20
503	Management of T-Cell Engaging Immunotherapy Complications. Cancer Journal (Sudbury, Mass), 2019, 25, 223-230.	1.0	15
504	Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer and Metastasis Reviews, 2019, 38, 595-610.	2.7	65
505	Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptorâ€T cell manufacture. Cytotherapy, 2019, 21, 1198-1205.	0.3	23
506	CAR T Cells: A Snapshot on the Growing Options to Design a CAR. HemaSphere, 2019, 3, e172.	1.2	34
507	Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 6223.	1.8	88
508	CAR T Cell Therapy for Hematological Malignancies. Current Medical Science, 2019, 39, 874-882.	0.7	22
509	Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Current Hematologic Malignancy Reports, 2019, 14, 515-522.	1.2	10
510	Developing neoantigen-targeted T cellâ€based treatments for solid tumors. Nature Medicine, 2019, 25, 1488-1499.	15.2	173
511	Azole antifungals and new targeted therapies for hematological malignancy. Current Opinion in Infectious Diseases, 2019, 32, 538-545.	1.3	49
512	CAR T Cell Toxicity: Current Management and Future Directions. HemaSphere, 2019, 3, e186.	1.2	121
513	In the Eye of the Storm: Immuneâ€mediated Toxicities Associated With CARâ€T Cell Therapy. HemaSphere, 2019, 3, e191.	1.2	80
514	EHA Guidance Document The process of CARâ€T cell therapy in Europe. HemaSphere, 2019, 3, e280.	1.2	7

#	ARTICLE	IF	CITATIONS
515	Introduction by the Guest Editor, Terry J. Fry. Cancer Journal (Sudbury, Mass), 2019, 25, 178-178.	1.0	0
516	Next Generation of Cancer Treatments: Chimeric Antigen Receptor T-Cell Therapy and Its Related Toxicities: A Review for Perioperative Physicians. Anesthesia and Analgesia, 2019, 129, 434-441.	1.1	11
517	Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL. HemaSphere, 2019, 3, e279.	1.2	20
518	Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody. Cancers, 2019, 11, 1966.	1.7	10
519	Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies. Frontiers in Oncology, 2019, 9, 1237.	1.3	106
520	Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer and Metastasis Reviews, 2019, 38, 573-594.	2.7	20
521	What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?. Journal of Pediatric Hematology/Oncology, 2019, 41, 337-344.	0.3	16
522	Advances in T-cell Immunotherapies. Hematology/Oncology Clinics of North America, 2019, 33, 825-837.	0.9	5
523	Redirecting T cells to treat solid pediatric cancers. Cancer and Metastasis Reviews, 2019, 38, 611-624.	2.7	3
524	Outcome of Relapsed Pediatric Patients After Second Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study From a Single Institution. Journal of Pediatric Hematology/Oncology, 2019, 41, e506-e509.	0.3	2
525	Cytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management. Frontiers in Immunology, 2019, 10, 3009.	2.2	109
526	Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. Drugs in Context, 2019, 8, 1-14.	1.0	29
527	Gene therapy for visual loss: Opportunities and concerns. Progress in Retinal and Eye Research, 2019, 68, 31-53.	7.3	78
528	Principles of adoptive T cell therapy in cancer. Seminars in Immunopathology, 2019, 41, 49-58.	2.8	141
529	Will CAR T cell therapy have a role in AML? Promises and pitfalls. Seminars in Hematology, 2019, 56, 155-163.	1.8	45
530	Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan. Clinical Therapeutics, 2019, 41, 174-184.e3.	1.1	2
531	Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e123-e127.	2.0	220
532	Haematological problems in the intensive care unit. Anaesthesia and Intensive Care Medicine, 2019, 20, 19-24.	0.1	0

#	ARTICLE	IF	CITATIONS
533	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 625-638.	2.0	1,741
534	Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. <i>BioDrugs</i> , 2019, 33, 45-60.	2.2	61
535	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
536	Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. <i>Bone Marrow Transplantation</i> , 2019, 54, 969-972.	1.3	13
537	The Meanings of “Pediatric Drug Development” Therapeutic Innovation and Regulatory Science, 2019, 53, 767-774.	0.8	22
538	Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2019, 111, 719-726.	3.0	82
539	Cost-Effective But Unaffordable: The CAR-T Conundrum. <i>Journal of the National Cancer Institute</i> , 2019, 111, 644-645.	3.0	12
540	Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. <i>Clinical Chemistry</i> , 2019, 65, 519-529.	1.5	4
541	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. <i>Cancer Immunology Research</i> , 2019, 7, 100-112.	1.6	220
542	Cancer Immunotherapy: Beyond Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2019, 3, 55-75.	2.3	102
543	Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors. <i>Cancer Research</i> , 2019, 79, 387-396.	0.4	96
544	Entering the Modern Era of Gene Therapy. <i>Annual Review of Medicine</i> , 2019, 70, 273-288.	5.0	311
545	Teaching an old dog new tricks: next-generation CAR T cells. <i>British Journal of Cancer</i> , 2019, 120, 26-37.	2.9	240
546	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. <i>Clinical Cancer Research</i> , 2019, 25, 2042-2048.	3.2	77
547	The Future of Chimeric Antigen Receptor T Cell Therapy for the Treatment of Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e73-e75.	2.0	4
548	How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia. <i>Blood</i> , 2019, 133, 130-136.	0.6	62
549	Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. <i>Blood Reviews</i> , 2019, 34, 45-55.	2.8	570
550	Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD?. <i>Bone Marrow Transplantation</i> , 2019, 54, 3-5.	1.3	7

#	ARTICLE	IF	CITATIONS
551	High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. <i>British Journal of Cancer</i> , 2019, 120, 79-87.	2.9	36
552	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. <i>Blood</i> , 2019, 133, 697-709.	0.6	408
553	Adoptive cellular therapies: the current landscape. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 449-461.	1.4	261
554	How I treat infant leukemia. <i>Blood</i> , 2019, 133, 205-214.	0.6	82
555	First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval. <i>Clinical Cancer Research</i> , 2019, 25, 1133-1135.	3.2	18
556	Advances in hematopoietic cell transplant for the treatment of hematologic malignancies. <i>Current Opinion in Pediatrics</i> , 2019, 31, 3-13.	1.0	4
557	Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and comorbidities. <i>Microbial Biotechnology</i> , 2019, 12, 58-65.	2.0	17
558	HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. <i>Cancer Research</i> , 2019, 79, 899-904.	0.4	84
559	Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 3180.	2.2	46
560	Delivery technologies for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 175-196.	21.5	1,562
561	Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 1055-1070.	1.2	16
562	Novel treatment approaches and future perspectives in follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071882051.	1.1	11
563	CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond. <i>Leukemia and Lymphoma</i> , 2019, 60, 1346-1348.	0.6	3
564	Celular CAR T: el futuro ya es presente. <i>Medicina Clínica</i> , 2019, 152, 281-286.	0.3	1
565	CAR T cell therapy: inroads to response and resistance. <i>Nature Reviews Immunology</i> , 2019, 19, 73-74.	10.6	148
566	Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cells. <i>Oncolmmunology</i> , 2019, 8, 1542917.	2.1	23
567	Top Five Gene Therapy Stories of 2019. <i>Human Gene Therapy</i> , 2019, 30, 1-2.	1.4	2
568	Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond. <i>Neurotherapeutics</i> , 2019, 16, 319-347.	2.1	32

#	ARTICLE	IF	CITATIONS
569	Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2019, 11, 47.	1.7	54
570	Cell therapy products: focus on issues with manufacturing and quality control of chimeric antigen receptor T cell therapies. <i>Journal of Chemical Technology and Biotechnology</i> , 2019, 94, 1008-1016.	1.6	22
571	Is it time to reform oversight of clinical gene therapy in the EU?. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 8-10.	1.1	6
572	Gene Therapy for Neurologic Disease: A Neurosurgical Review. <i>World Neurosurgery</i> , 2019, 121, 261-273.	0.7	11
573	Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 594-602.	1.4	23
574	Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 12, 19-31.	1.8	46
575	FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 1142-1146.	3.2	174
576	Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 357-366.	0.9	9
577	FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1831-1838.	0.5	12
578	Emerging Cellular Therapies for Cancer. <i>Annual Review of Immunology</i> , 2019, 37, 145-171.	9.5	263
579	Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. <i>Clinical Infectious Diseases</i> , 2019, 69, 909-920.	2.9	57
580	Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density. <i>Journal of the American Chemical Society</i> , 2019, 141, 251-261.	6.6	59
581	Chimeric Antigen Receptor-T Cells for Leukemias in Adults: Methods, Data and Challenges. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 75-92.	0.0	0
582	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019, 380, 45-56.	13.9	2,594
583	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 31-42.	5.1	1,467
584	Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e155-e162.	2.0	56
585	Immune biomarkers for predicting response to adoptive cell transfer as cancer treatment. <i>Immunogenetics</i> , 2019, 71, 71-86.	1.2	7
586	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 301-306.	2.0	27

#	ARTICLE	IF	CITATIONS
587	American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 26-33.	2.0	55
588	Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 1-6.	0.6	12
589	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. <i>Annals of Emergency Medicine</i> , 2020, 75, 264-286.	0.3	3
590	Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2020, 55, 595-602.	1.3	17
591	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 34-43.	2.0	93
592	CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity. <i>Leukemia</i> , 2020, 34, 709-720.	3.3	13
593	The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2020, 25, e321-e327.	1.9	81
594	CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 112-122.	2.3	111
595	Advances of functional nanomaterials for cancer immunotherapeutic applications. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1574.	3.3	10
596	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 26-33.	2.0	222
597	TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment. <i>Haematologica</i> , 2020, 105, 1306-1316.	1.7	9
598	Techniques for the generation of humanized mouse models for immuno-oncology. <i>Methods in Enzymology</i> , 2020, 636, 351-368.	0.4	5
599	Gene Replacement Therapy: A Primer for the Health-system Pharmacist. <i>Journal of Pharmacy Practice</i> , 2020, 33, 846-855.	0.5	28
600	Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?. <i>Leukemia and Lymphoma</i> , 2020, 61, 7-17.	0.6	6
601	Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. <i>Regenerative Engineering and Translational Medicine</i> , 2020, 6, 29-49.	1.6	16
602	Future prospects of chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e72.	0.6	0
603	The treatment of adolescents and young adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 18-26.	0.6	5
604	The Biology of B-Progenitor Acute Lymphoblastic Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a034835.	2.9	40

#	ARTICLE	IF	CITATIONS
606	Allogeneic haematopoietic cell transplantation after CAR T-cell therapy: safe, effective and contentious. <i>British Journal of Haematology</i> , 2020, 189, 21-23.	1.2	2
607	Late Events After CD-19 CAR-T Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e1-e2.	2.0	2
608	Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2020, 111, 303-310.	0.7	7
609	Determinants of response and resistance to CAR T cell therapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 80-90.	4.3	59
610	CART manufacturing process and reasons for academy-pharma collaboration. <i>Immunology Letters</i> , 2020, 217, 39-48.	1.1	9
611	How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 1541-1554.	3.2	79
612	When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2020, 126, 253-255.	2.0	2
613	Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 207-223.	1.2	20
614	Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>CNS Drugs</i> , 2020, 34, 127-145.	2.7	26
615	Immunoglobulin replacement and quality of life after CAR T-cell therapy – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e7.	5.1	3
616	Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, E89-E91.	2.0	11
617	Immunoglobulin replacement and quality of life after CAR T-cell therapy. <i>Lancet Oncology</i> , The, 2020, 21, e6.	5.1	3
618	An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. <i>Science</i> , 2020, 367, 446-453.	6.0	286
619	Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion. <i>Gene Therapy</i> , 2020, 27, 85-95.	2.3	27
620	A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	70
621	Using CD19 chimeric antigen receptor cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28155.	0.8	4
622	Development of therapeutic antibodies for the treatment of diseases. <i>Journal of Biomedical Science</i> , 2020, 27, 1.	2.6	1,277
623	Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. <i>Journal of Hematology and Oncology</i> , 2020, 13, 1.	6.9	244

#	ARTICLE	IF	CITATIONS
625	Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. <i>Science China Life Sciences</i> , 2020, 63, 180-205.	2.3	40
626	The approved gene therapy drugs worldwide: from 1998 to 2019. <i>Biotechnology Advances</i> , 2020, 40, 107502.	6.0	216
627	Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. <i>Current Research in Translational Medicine</i> , 2020, 68, 17-22.	1.2	24
628	Current challenges and emerging opportunities of CAR-T cell therapies. <i>Journal of Controlled Release</i> , 2020, 319, 246-261.	4.8	78
629	Application of Genetic Engineering in Biotherapeutics Development. <i>Journal of Pharmaceutical Innovation</i> , 2020, 15, 232-254.	1.1	4
630	Engineering strategies to overcome the current roadblocks in CAR T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 147-167.	12.5	786
631	Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. <i>MAbs</i> , 2020, 12, 1688616.	2.6	71
632	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109625.	2.5	92
633	Important aspects of T cell collection by apheresis for manufacturing chimeric antigen receptor T cells. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e75.	0.6	6
634	Treatment of Testicular Relapse of B-cell Acute Lymphoblastic Leukemia With CD19-specific Chimeric Antigen Receptor T Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 366-370.	0.2	19
635	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 798-804.	2.0	28
636	Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 1102-1115.	3.3	63
637	Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e77-e85.	2.0	41
638	“Off-the-shelf” allogeneic CAR T cells: development and challenges. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 185-199.	21.5	632
639	Bioengineering strategies for gene delivery. , 2020, , 107-148.		4
640	The therapeutic landscape for cells engineered with chimeric antigen receptors. <i>Nature Biotechnology</i> , 2020, 38, 233-244.	9.4	147
641	Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 29-41.	1.3	17
642	Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 136-144.	1.8	89

#	ARTICLE	IF	CITATIONS
643	Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. <i>Current Opinion in Hematology</i> , 2020, 27, 41-48.	1.2	14
644	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 415-422.	0.8	162
646	Challenges and solutions to the study of rare childhood tumors. <i>Current Opinion in Pediatrics</i> , 2020, 32, 7-12.	1.0	8
647	Mechanisms of resistance to CAR T cell therapies. <i>Seminars in Cancer Biology</i> , 2020, 65, 91-98.	4.3	31
648	Challenges and Opportunities to Improve CAR T-Cell Therapy. , 2020, , 63-80.		1
649	Memory T cell, exhaustion, and tumor immunity. <i>Immunological Medicine</i> , 2020, 43, 1-9.	1.4	118
650	Bortezomibâ€based fourâ€drug induction does induce a response in advanced relapsed ALL but cure remains elusive. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28115.	0.8	5
651	Pathogen-Boosted Adoptive Cell Transfer Therapy Induces Endogenous Antitumor Immunity through Antigen Spreading. <i>Cancer Immunology Research</i> , 2020, 8, 7-18.	1.6	16
652	The NOTCHâ€FOXM1 Axis Plays a Key Role in Mitochondrial Biogenesis in the Induction of Human Stem Cell Memoryâ€like CAR-T Cells. <i>Cancer Research</i> , 2020, 80, 471-483.	0.4	57
653	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 108-123.	12.5	244
654	Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). <i>Leukemia and Lymphoma</i> , 2020, 61, 940-943.	0.6	75
655	Valuing Chimeric Antigen Receptor T-Cell Therapy: Current Evidence, Uncertainties, and Payment Implications. <i>Journal of Clinical Oncology</i> , 2020, 38, 359-366.	0.8	17
656	CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia. <i>Paediatric Drugs</i> , 2020, 22, 1-11.	1.3	10
657	Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?. <i>Leukemia</i> , 2020, 34, 21-34.	3.3	117
658	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	1.7	230
659	Subcutaneous immunoglobulin replacement following CD19â€specific chimeric antigen receptor Tâ€cell therapy for Bâ€cell acute lymphoblastic leukemia in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28092.	0.8	29
660	Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 865-875.	2.0	51
661	Role of CAR-T cell therapy in B-cell acute lymphoblastic leukemia. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 36-42.	0.3	3

#	ARTICLE	IF	CITATIONS
662	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. <i>Leukemia Research</i> , 2020, 88, 106283.	0.4	32
664	The future of cellular immunotherapy for childhood leukemia. <i>Current Opinion in Pediatrics</i> , 2020, 32, 13-25.	1.0	13
665	Blinatumomab vs historic standard of care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia. <i>European Journal of Haematology</i> , 2020, 104, 299-309.	1.1	17
666	B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis. <i>European Journal of Haematology</i> , 2020, 104, 318-327.	1.1	41
667	Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 1606-1615.	3.2	49
668	CAR T-Cell: Cell Processing Laboratory Considerations. , 2020, , 17-28.		1
669	Peri-CAR T-Cell Management. , 2020, , 29-44.		1
670	Management of Cytokine Release Syndrome. , 2020, , 45-64.		1
671	Special Considerations for ICU Management of Patients Receiving CAR Therapy. , 2020, , 65-81.		0
672	Neurotoxicities After CAR T-Cell Immunotherapy. , 2020, , 83-105.		7
673	Hematologic and Non-CRS Toxicities. , 2020, , 107-112.		2
674	Response Assessment and Post-CAR T-Cell Therapy Management. , 2020, , 113-127.		0
675	Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR T-Cell Therapy. , 2020, , 129-136.		0
676	CAR 2.0: The Next Generation of Synthetic Receptor-Based Cellular Therapy for Cancer. , 2020, , 199-208.		0
677	Chimeric Antigen Receptor Therapies. , 2020, , 349-359.		0
678	New approaches to therapeutic drug development for childhood cancers. <i>Current Opinion in Pediatrics</i> , 2020, 32, 35-40.	1.0	2
679	Advances in chimeric antigen receptor T cells. <i>Current Opinion in Hematology</i> , 2020, 27, 368-377.	1.2	24
680	T-cell agonists in cancer immunotherapy. , 2020, 8, e000966.		69

#	ARTICLE	IF	CITATIONS
681	Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites. , 2020, 8, 251513552094435.	1.4	2
682	Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3805-3815.	0.8	129
683	Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7222.	1.8	28
684	A Hydrogel-Integrated Culture Device to Interrogate T Cell Activation with Physicochemical Cues. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 47355-47367.	4.0	27
685	Investment Planning in Personalised Medicine. <i>Computer Aided Chemical Engineering</i> , 2020, , 49-54.	0.3	3
686	Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. <i>Current Opinion in Oncology</i> , 2020, 32, 603-612.	1.1	5
687	ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma. <i>Frontiers in Immunology</i> , 2020, 11, 581468.	2.2	22
688	Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies. <i>International Immunopharmacology</i> , 2020, 89, 107072.	1.7	6
689	Activation and degranulation of CAR-T cells using engineered antigen-presenting cell surfaces. <i>PLoS ONE</i> , 2020, 15, e0238819.	1.1	6
690	Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. <i>Cell</i> , 2020, 183, 126-142.e17.	13.5	269
691	Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies. <i>Cell Systems</i> , 2020, 11, 215-228.e5.	2.9	52
692	Antibody and antibody fragments for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2020, 328, 395-406.	4.8	63
693	NK cells and ILCs in tumor immunotherapy. <i>Molecular Aspects of Medicine</i> , 2021, 80, 100870.	2.7	134
694	TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 979-992.	0.4	11
695	Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1029-1042.	1.3	8
696	Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting) Tj ETQq1 1 0.784314 rgBT ₆ /Overlook	1.7	17
697	Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 1594.	1.3	46
698	Iatrogenic Neuropathology of Systemic Therapies. <i>Surgical Pathology Clinics</i> , 2020, 13, 331-342.	0.7	4

#	ARTICLE	IF	CITATIONS
699	Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 2020. <i>Seminars in Hematology</i> , 2020, 57, 137-141.	1.8	7
700	Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	9
701	Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo. <i>MedComm</i> , 2020, 1, 338-350.	3.1	12
702	Precision medicine in acute lymphoblastic leukemia. <i>Frontiers of Medicine</i> , 2020, 14, 689-700.	1.5	74
703	Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. <i>Current Research in Translational Medicine</i> , 2020, 68, 159-170.	1.2	24
704	Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy. <i>Scientific Reports</i> , 2020, 10, 17753.	1.6	29
705	Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells. <i>Scientific Reports</i> , 2020, 10, 17884.	1.6	14
706	Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting. <i>Oncolmmunology</i> , 2020, 9, 1825177.	2.1	26
707	Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors. <i>Cancers</i> , 2020, 12, 2818.	1.7	0
708	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
709	Point mutation in <i>CD19</i> facilitates immune escape of B cell lymphoma from CAR-T cell therapy. , 2020, 8, e001150.		47
710	Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 879-891.	1.1	2
711	Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR. <i>Cancers</i> , 2020, 12, 2820.	1.7	13
712	Paediatric Oncology at the Crossroads: A Call for Change. <i>Pharmaceutical Medicine</i> , 2020, 34, 297-300.	1.0	5
713	Tisagenlecleucel in Children and Young Adults: Reverse Translational Research by Using Real-World Safety Data. <i>Pharmaceuticals</i> , 2020, 13, 258.	1.7	6
714	Colorectal Cancer Immunotherapy: Options and Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1624.	2.2	207
715	Intracellular Delivery of mRNA in Adherent and Suspension Cells by Vapor Nanobubble Photoporation. <i>Nano-Micro Letters</i> , 2020, 12, 185.	14.4	42
716	Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2211-2216.	2.0	40

#	ARTICLE	IF	CITATIONS
717	A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks. <i>Cytotherapy</i> , 2020, 22, 511-518.	0.3	6
718	Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2020, 22, 755-761.	0.3	33
719	PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors. <i>Cancer Research</i> , 2020, 80, 4731-4740.	0.4	24
720	Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1233-1244.	5.2	661
721	Central nervous system injury from novel cancer immunotherapies. <i>Current Opinion in Neurology</i> , 2020, 33, 723-735.	1.8	9
722	Latest Advances for the <i>Sleeping Beauty</i> Transposon System: 23 Years of Insomnia but Prettier than Ever. <i>BioEssays</i> , 2020, 42, e2000136.	1.2	29
723	Immunotherapy for advanced hepatocellular carcinoma, where are we?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188441.	3.3	52
724	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nature Medicine</i> , 2020, 26, 1569-1575.	15.2	266
725	Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies. <i>Cancers</i> , 2020, 12, 1915.	1.7	30
726	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. <i>Cytotherapy</i> , 2020, 22, 474-481.	0.3	29
727	Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. <i>Frontiers in Immunology</i> , 2020, 11, 1965.	2.2	85
728	Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2341-2348.	1.4	11
729	T cell receptor therapy against melanoma" Immunotherapy for the future?. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12927.	1.3	8
730	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
731	Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2166.	1.0	25
732	Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17543-17550.	3.3	54
733	A multicenter evaluation of heterogeneity in cellular therapy processing laboratory procedure times to assess workload capacity. <i>Transfusion</i> , 2020, 60, 1811-1820.	0.8	3
734	Immunotherapy with CAR-T cells in paediatric haematology-oncology. <i>Anales De Pediatrãa (English) Tj ETQq1 1 0.784314 rgBT /Overlo</i>	0.1	0

#	ARTICLE	IF	CITATIONS
735	Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 805-813.	2.0	7
736	Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy. <i>Contemporary Clinical Trials</i> , 2020, 96, 106083.	0.8	9
737	Direct Delivery of piggyBac CD19 CAR T Cells Has Potent Anti-tumor Activity against ALL Cells in CNS in a Xenograft Mouse Model. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 37-46.	2.0	8
738	Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. <i>Nature Communications</i> , 2020, 11, 3549.	5.8	103
739	Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity. <i>Clinical and Translational Immunology</i> , 2020, 9, e1147.	1.7	7
740	COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4953.	1.8	41
741	Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. <i>Leukemia</i> , 2020, 34, 3050-3054.	3.3	3
742	Immunotherapies and Combination Strategies for Immuno-Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5009.	1.8	63
744	Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B-cell acute lymphoblastic leukaemia. <i>Clinical and Translational Immunology</i> , 2020, 9, e1151.	1.7	5
745	Engineered T cells Flt around their targets. <i>Nature Immunology</i> , 2020, 21, 831-832.	7.0	0
746	Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD19 chimeric antigen receptor T cell therapy. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1678-1681.	0.2	7
747	How to Combine the Two Landmark Treatment Methods "Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?. <i>Frontiers in Immunology</i> , 2020, 11, 611710.	2.2	14
748	Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. <i>Journal of Clinical Medicine</i> , 2020, 9, 3626.	1.0	4
749	Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. <i>Nature Communications</i> , 2020, 11, 5902.	5.8	55
750	Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8655.	1.8	13
751	Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies. <i>Molecular Cancer</i> , 2020, 19, 162.	7.9	8
752	Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. <i>International Immunopharmacology</i> , 2020, 89, 107069.	1.7	26
753	Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. <i>Nature Communications</i> , 2020, 11, 5928.	5.8	34

#	ARTICLE	IF	CITATIONS
754	Next-generation cell therapies: the emerging role of CAR-NK cells. <i>Blood Advances</i> , 2020, 4, 5868-5876.	2.5	85
755	Complications after CD19+ CAR T-Cell Therapy. <i>Cancers</i> , 2020, 12, 3445.	1.7	32
756	Antitumor activity without on-target off-tumor toxicity of GD2 α chimeric antigen receptor T cells in patients with neuroblastoma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	108
757	Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia. , 2020, 8, e001563.		22
758	Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease. <i>Seminars in Hematology</i> , 2020, 57, 157-163.	1.8	11
759	Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. <i>Frontiers in Immunology</i> , 2020, 11, 564099.	2.2	32
760	Editorial: CAR T-Cell Therapies in Hematologic Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 588134.	1.3	2
761	Chimeric antigen receptor T cell therapies for acute myeloid leukemia. <i>Frontiers of Medicine</i> , 2020, 14, 701-710.	1.5	2
762	CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. <i>Nature Communications</i> , 2020, 11, 6171.	5.8	20
763	Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?. <i>Biomarker Research</i> , 2020, 8, 66.	2.8	26
764	Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 579673.	1.3	3
765	CAR T cells vs allogeneic HSCT for poor-risk ALL. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 501-507.	0.9	9
766	Next-generation cell therapies: the emerging role of CAR-NK cells. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 570-578.	0.9	27
767	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
768	Immunosenescence: a key player in cancer development. <i>Journal of Hematology and Oncology</i> , 2020, 13, 151.	6.9	198
769	<p>Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020, Volume 10, 7-20.	1.2	14
770	How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application. <i>Frontiers in Immunology</i> , 2020, 11, 593610.	2.2	14
771	Cardiotoxicity of Contemporary Anticancer Immunotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 62.	0.4	34

#	ARTICLE	IF	CITATIONS
772	Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers. <i>Frontiers in Immunology</i> , 2020, 11, 565236.	2.2	9
773	Natural killer cells in cancer biology and therapy. <i>Molecular Cancer</i> , 2020, 19, 120.	7.9	344
774	Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. <i>Immunity</i> , 2020, 53, 456-470.e6.	6.6	83
775	Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092947.	1.1	19
776	A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes. <i>Frontiers in Immunology</i> , 2020, 11, 1704.	2.2	21
777	Emerging Therapies in Thoracic Malignancies—Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non—Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 555-569.	0.6	6
778	Evolution of the role of haploidentical stem cell transplantation: past, present, and future. <i>Expert Review of Hematology</i> , 2020, 13, 835-850.	1.0	11
779	Immune-Checkpoint Blockade Therapy in Lymphoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5456.	1.8	24
780	The Chimeric Antigen Receptor Detection Toolkit. <i>Frontiers in Immunology</i> , 2020, 11, 1770.	2.2	34
781	Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR. <i>Cancers</i> , 2020, 12, 1970.	1.7	23
782	Building Canadian capacity for CAR—T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study. <i>British Journal of Haematology</i> , 2020, 191, e14-e19.	1.2	1
783	Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 960.	1.6	15
784	Acute life-threatening toxicity from CAR T-cell therapy. <i>Intensive Care Medicine</i> , 2020, 46, 1723-1726.	3.9	14
785	Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 713-719.	0.2	9
786	Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer. <i>Journal of Theoretical Biology</i> , 2020, 505, 110403.	0.8	5
787	Hodgkin lymphoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 61.	18.1	103
788	From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 1423.	2.2	5
789	Advances in gene therapy for hematologic disease and considerations for transfusion medicine. <i>Seminars in Hematology</i> , 2020, 57, 83-91.	1.8	5

#	ARTICLE	IF	CITATIONS
790	CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 1243.	1.3	63
791	Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 272-281.	2.0	68
792	A Head Start: CAR-T Cell Therapy for Primary Malignant Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2020, 21, 73.	1.3	1
793	CAR-T design: Elements and their synergistic function. <i>EBioMedicine</i> , 2020, 58, 102931.	2.7	144
794	Pediatric cancer mortality and survival in the United States, 2001-2016. <i>Cancer</i> , 2020, 126, 4379-4389.	2.0	75
795	Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-Clk Cells Modified with an Improved SB Transposon System. <i>Molecular Therapy</i> , 2020, 28, 1974-1986.	3.7	33
796	Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. <i>Molecular Therapy</i> , 2020, 28, 2367-2378.	3.7	32
797	Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. <i>American Journal of Hematology</i> , 2020, 95, 1324-1333.	2.0	89
798	Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e280-e285.	2.0	35
799	PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 226-235.	2.0	25
800	Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities. <i>Frontiers in Oncology</i> , 2020, 10, 1227.	1.3	1
801	Natural Born Killers: NK Cells in Cancer Therapy. <i>Cancers</i> , 2020, 12, 2131.	1.7	44
802	Improving CAR T-cells: The next generation. <i>Seminars in Hematology</i> , 2020, 57, 115-121.	1.8	13
803	Emerging trends in gene-modified-based chimeric antigen receptor-engineered T-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 719-724.	0.6	2
804	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 3776-3787.	2.5	162
805	Chimeric Antigen Receptor T Cells: Clinical Applications, Advances and Challenges. , 2020, , 319-333.		1
806	Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system. <i>Frontiers of Medicine</i> , 2020, 14, 726-745.	1.5	9
807	Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. <i>Advanced Science</i> , 2020, 7, 2001447.	5.6	30

#	ARTICLE	IF	CITATIONS
808	VAV1-overexpressing YT cells display improved cytotoxicity against malignant cells. <i>Biotechnology and Applied Biochemistry</i> , 2020, 68, 849-855.	1.4	2
809	Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 371-377.	0.6	8
810	Chimeric antigen receptor T-cell therapy for haematological malignancies. <i>Medical Journal of Australia</i> , 2020, 213, 404.	0.8	1
811	Manufacturing and Management of CAR T-Cell Therapy in "COVID-19's Time": Central Versus Point of Care Proposals. <i>Frontiers in Immunology</i> , 2020, 11, 573179.	2.2	12
812	Hyper-CVAD: a regimen for all seasons. <i>Lancet Haematology</i> , 2020, 7, e501-e502.	2.2	1
813	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. <i>Blood Advances</i> , 2020, 4, 5174-5183.	2.5	30
814	Toward a cure in relapsed ALL: we must do better. <i>Leukemia and Lymphoma</i> , 2020, 61, 2544-2545.	0.6	0
815	Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 578349.	2.2	11
816	Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2020, 4, 5078-5088.	2.5	23
817	High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing. <i>Scientific Reports</i> , 2020, 10, 18045.	1.6	37
818	Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant. <i>Frontiers in Oncology</i> , 2020, 10, 573822.	1.3	35
819	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2382-2394.	1.4	77
820	Mapping and targeting of the leukemic microenvironment. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	29
821	Tailoring precision immunotherapy: coming to a clinic soon?. <i>ESMO Open</i> , 2020, 5, e000631.	2.0	8
822	How I treat adverse effects of CAR-T cell therapy. <i>ESMO Open</i> , 2020, 4, e000746.	2.0	19
823	Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 940-948.	1.5	78
824	Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. <i>Journal of the American Chemical Society</i> , 2020, 142, 18874-18885.	6.6	16
825	Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	3

#	ARTICLE	IF	CITATIONS
826	Targeting signalling pathways and the immune microenvironment of cancer stem cells – a clinical update. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 204-232.	12.5	431
827	Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells. , 2020, 8, e001052.		7
828	Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy. <i>Frontiers in Microbiology</i> , 2020, 11, 575072.	1.5	40
829	Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro. <i>Cancer Science</i> , 2020, 111, 4051-4060.	1.7	19
830	Emerging immunotherapies in multiple myeloma. <i>BMJ, The</i> , 2020, 370, m3176.	3.0	62
831	Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity. , 2020, 8, e001046.		16
832	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3943-3951.	2.5	69
833	How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S8-S11.	0.2	3
834	Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 1985.	2.2	7
835	Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases. <i>Pharmaceutics</i> , 2020, 12, 767.	2.0	23
836	Emerging Roles of 1D Vertical Nanostructures in Orchestrating Immune Cell Functions. <i>Advanced Materials</i> , 2020, 32, e2001668.	11.1	45
837	pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review. <i>Nanomaterials</i> , 2020, 10, 1613.	1.9	51
838	Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. <i>Annals of Hematology</i> , 2020, 99, 2215-2229.	0.8	29
839	Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges. <i>Paediatric Drugs</i> , 2020, 22, 485-499.	1.3	21
840	Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 1973.	2.2	148
841	Podoplanin as an Attractive Target of CAR T Cell Therapy. <i>Cells</i> , 2020, 9, 1971.	1.8	8
842	Nucleic Acid-Based Approaches for Tumor Therapy. <i>Cells</i> , 2020, 9, 2061.	1.8	40
844	Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report. , 2020, 8, e001073.		2

#	ARTICLE	IF	CITATIONS
845	Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 122.	6.9	44
846	CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens. <i>Frontiers in Immunology</i> , 2020, 11, 1568.	2.2	20
847	Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. , 2020, 8, e001159.		55
848	Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2523.	1.7	27
849	Engineering Immune Cells for in vivo Secretion of Tumor-Specific T Cell-Redirecting Bispecific Antibodies. <i>Frontiers in Immunology</i> , 2020, 11, 1792.	2.2	14
850	The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview. <i>Cancers</i> , 2020, 12, 2567.	1.7	70
851	Evaluation of the upregulation and surface expression of hypoxanthine guanine phosphoribosyltransferase in acute lymphoblastic leukemia and Burkitt's B cell lymphoma. <i>Cancer Cell International</i> , 2020, 20, 375.	1.8	1
852	JSH practical guidelines for hematological malignancies, 2018: I. leukemia—3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). <i>International Journal of Hematology</i> , 2020, 112, 439-458.	0.7	1
853	Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions. <i>Current Opinion in Oncology</i> , 2020, 32, 434-441.	1.1	3
854	Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage—Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5776.	1.8	18
855	CD19-directed CAR T-cell therapy in B-cell NHL. <i>Current Opinion in Oncology</i> , 2020, 32, 408-417.	1.1	26
856	Overhauling CAR T Cells to Improve Efficacy, Safety and Cost. <i>Cancers</i> , 2020, 12, 2360.	1.7	9
857	Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5845.	1.8	51
858	Combining T cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B cell lines in vitro. <i>Hematological Oncology</i> , 2020, 38, 705-714.	0.8	7
859	Orbital extramedullary leukemia relapse in a pediatric patient post-CART cell therapy—Case report. <i>Pediatric Transplantation</i> , 2021, 25, e13852.	0.5	1
860	Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials. <i>Frontiers in Pharmacology</i> , 2020, 11, 544754.	1.6	12
861	Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 547653.	1.8	44
862	Hematopoietic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. <i>Frontiers in Oncology</i> , 2020, 10, 608916.	1.3	13

#	ARTICLE	IF	CITATIONS
863	Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. <i>Vaccines</i> , 2020, 8, 753.	2.1	7
864	The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices. <i>Frontiers in Neuroscience</i> , 2020, 14, 603647.	1.4	24
865	Case Report: Humanized Selective CD19CAR-T Treatment Induces MRD-Negative Remission in a Pediatric B-ALL Patient With Primary Resistance to Murine-Based CD19CAR-T Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 581116.	2.2	2
866	Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 620312.	2.2	21
867	Function and evolution of the prototypic CD28 \uparrow and 4-1BB \uparrow chimeric antigen receptors. <i>Immuno-Oncology Technology</i> , 2020, 8, 2-11.	0.2	8
869	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. <i>Lancet, The</i> , 2020, 396, 1885-1894.	6.3	206
870	Practical aspects of building a new immunotherapy program: the future of cell therapy. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 579-584.	0.9	2
871	4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 539654.	2.2	18
872	Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML). <i>Cancers</i> , 2020, 12, 3617.	1.7	7
873	Recent Advancements in Hematology: Knowledge, Methods and Dissemination. <i>Hemato</i> , 2020, 1, 5-6.	0.2	0
874	The Application of CAR-T Cells in Haematological Malignancies. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 34.	1.0	19
875	The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review. <i>Therapie</i> , 2020, 75, 183-193.	0.6	0
876	Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future. <i>Frontiers in Immunology</i> , 2020, 11, 594271.	2.2	34
877	Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	10
878	Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020. <i>Seminars in Hematology</i> , 2020, 57, 102-114.	1.8	6
879	Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 5414-5424.	2.5	263
880	Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 449-457.	1.3	21
881	Fungal Infections Associated With the Use of Novel Immunotherapeutic Agents. <i>Current Clinical Microbiology Reports</i> , 2020, 7, 142-149.	1.8	12

#	ARTICLE	IF	CITATIONS
882	Immune Therapy for Central Nervous System Metastasis. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 627-639.	0.8	0
883	Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. <i>Haematologica</i> , 2020, 106, 173-184.	1.7	25
884	Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. <i>Leukemia</i> , 2020, 34, 2688-2703.	3.3	52
885	Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers. <i>Cancers</i> , 2020, 12, 1075.	1.7	57
886	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. <i>Drug Resistance Updates</i> , 2020, 51, 100702.	6.5	53
887	<p>Immunotherapy for Medulloblastoma: Current Perspectives</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 57-77.	2.7	33
888	A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptorâ€“positive cells. <i>Blood</i> , 2020, 135, 505-509.	0.6	25
889	Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1559-1566.	2.0	6
890	Recent Advances in Managing Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 330-342.	1.8	40
891	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. <i>Vaccines</i> , 2020, 8, 224.	2.1	47
892	Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 566-580.	0.6	13
893	Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2020, 4, 2158-2162.	2.5	15
894	T Cells Expressing a TCR-Like Antibody Selected Against the Heteroclitic Variant of a Shared MAGE-A Epitope Do Not Recognise the Cognate Epitope. <i>Cancers</i> , 2020, 12, 1255.	1.7	2
895	CARs: Beyond T Cells and T Cell-Derived Signaling Domains. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3525.	1.8	19
897	Advances in CAR T Therapy for Hematologic Malignancies. <i>Pharmacotherapy</i> , 2020, 40, 741-755.	1.2	11
898	Toward â€œoffâ€“theâ€“shelfâ€“allogeneic CAR T cells. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e86.	0.6	20
899	Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress. <i>Annals of Hematology</i> , 2020, 99, 1681-1699.	0.8	5
900	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , 2020, 135, 1650-1660.	0.6	222

#	ARTICLE	IF	CITATIONS
901	Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e89-e106.	1.8	17
902	Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?. Cells, 2020, 9, 1337.	1.8	32
903	Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, , .	0.8	4
904	MLL-rearranged infant leukaemia: A thorn in the side™ of a remarkable success story. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2020, 1863, 194564.	0.9	13
905	Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers. Journal of Emergency Medicine, 2020, 59, 61-74.	0.3	5
906	Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines. Nature Biomedical Engineering, 2020, 4, 636-648.	11.6	44
907	Update on Biology of Cutaneous T-Cell Lymphoma. Frontiers in Oncology, 2020, 10, 765.	1.3	20
908	Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. Blood, 2020, 136, 1407-1418.	0.6	91
909	Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer. Cancers, 2020, 12, 1389.	1.7	25
910	Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells, 2020, 9, 1182.	1.8	81
911	CAR T cell therapy: newer approaches to counter resistance and cost. Heliyon, 2020, 6, e03779.	1.4	19
912	A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity. Molecular Therapy - Oncolytics, 2020, 17, 278-292.	2.0	9
913	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1575-1580.	2.0	20
914	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
915	Editing of Endogenous Genes in Cellular Immunotherapies. Current Hematologic Malignancy Reports, 2020, 15, 235-240.	1.2	4
916	Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. Cancer Immunology, Immunotherapy, 2020, 69, 2139-2145.	2.0	14
917	Innovative synthetic signaling technologies for immunotherapy. Current Opinion in Biomedical Engineering, 2020, 16, 1-8.	1.8	1
918	Rethinking Cancer Immunotherapy by Embracing and Engineering Complexity. Trends in Biotechnology, 2020, 38, 1054-1065.	4.9	10

#	ARTICLE	IF	CITATIONS
919	Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplantation, 2020, 55, 1706-1715.	1.3	66
920	Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Advances, 2020, 4, 2325-2338.	2.5	122
921	Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e275-e291.	1.8	32
922	Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells. Frontiers in Immunology, 2020, 11, 873.	2.2	20
923	Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. Cancer Cell, 2020, 37, 850-866.e7.	7.7	42
924	Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults. Open Forum Infectious Diseases, 2020, 7, ofaa121.	0.4	85
925	The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Research, 2020, 30, 507-519.	5.7	480
926	Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab. Therapeutic Advances in Hematology, 2020, 11, 204062072091963.	1.1	4
927	Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. Blood, 2020, 136, 137-139.	0.6	51
928	A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. Cancers, 2020, 12, 1333.	1.7	9
929	Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice. Current Oncology, 2020, 27, 115-123.	0.9	26
930	Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice. Leukemia and Lymphoma, 2020, 61, 2324-2334.	0.6	6
931	CAR T-cell immunotherapy of B-cell malignancy: the story so far. , 2020, 8, 251513552092716.	1.4	30
932	From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2020, 21, 4067.	1.8	18
933	Cost of decentralized CAR T-cell production in an academic nonprofit setting. International Journal of Cancer, 2020, 147, 3438-3445.	2.3	45
934	Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15148-15159.	3.3	30
935	Vascular effects of cancer treatments. Vascular Medicine, 2020, 25, 226-234.	0.8	12
936	Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review. Current Oncology Reports, 2020, 22, 72.	1.8	5

#	ARTICLE	IF	CITATIONS
937	Towards greater impact in health technology assessment: horizon scanning for new and emerging technologies in Singapore. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 304-310.	0.2	1
938	Development of CAR-T cell therapies for multiple myeloma. <i>Leukemia</i> , 2020, 34, 2317-2332.	3.3	68
939	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 595-610.	12.5	124
940	Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery. <i>Molecular Therapy</i> , 2020, 28, 2237-2251.	3.7	50
941	Using Pharmacology to Squeeze the Life Out of Childhood Leukemia, and Potential Strategies to Achieve Breakthroughs in Medulloblastoma Treatment. <i>Pharmacological Reviews</i> , 2020, 72, 668-691.	7.1	6
942	Mechanisms of immune escape in the cancer immune cycle. <i>International Immunopharmacology</i> , 2020, 86, 106700.	1.7	85
943	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	2.2	45
944	Minor Histocompatibility Antigen-Specific T Cells. <i>Frontiers in Pediatrics</i> , 2020, 8, 284.	0.9	20
945	CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3906.	1.8	50
946	Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas. <i>Targeted Oncology</i> , 2020, 15, 365-375.	1.7	14
947	Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. <i>Biomarker Research</i> , 2020, 8, 18.	2.8	51
948	Neurotoxicity of CAR T-cell therapy: what the neurologist needs to know. <i>Practical Neurology</i> , 2020, 20, 285-293.	0.5	30
949	Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 621-629.	0.9	12
950	Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield. <i>Leukemia and Lymphoma</i> , 2020, 61, 1777-1779.	0.6	1
951	Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies. <i>Stem Cell Research and Therapy</i> , 2020, 11, 234.	2.4	55
952	The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology. <i>Frontiers in Immunology</i> , 2020, 11, 1608.	2.2	57
953	Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092757.	1.1	13
954	Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. <i>Blood</i> , 2020, 136, 1632-1644.	0.6	119

#	ARTICLE	IF	CITATIONS
955	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. <i>Journal of Hematology and Oncology</i> , 2020, 13, 70.	6.9	100
956	Neurologic Toxicities of Cancer Immunotherapies: a Review. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 27.	2.0	17
957	Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. <i>Biomarker Research</i> , 2020, 8, 19.	2.8	42
958	Impact of Ligand Size and Conjugation Chemistry on the Performance of Universal Chimeric Antigen Receptor T-Cells for Tumor Killing. <i>Bioconjugate Chemistry</i> , 2020, 31, 1775-1783.	1.8	12
959	Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2020, 11, 1128.	2.2	29
960	Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 777.	1.3	6
961	Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 541-550.	5.1	202
962	Nivolumab in paediatric cancer: children are not little adults. <i>Lancet Oncology</i> , The, 2020, 21, 474-476.	5.1	7
963	CAR T Cell Therapy–Related Cardiovascular Outcomes and–Management. <i>JACC: CardioOncology</i> , 2020, 2, 97-109.	1.7	73
964	Self-Assembled Multivalent Aptamer Nanoparticles with Potential CAR-like Characteristics Could Activate T Cells and Inhibit Melanoma Growth. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 9-20.	2.0	27
965	Chimeric antigen receptor T–cell therapies: Optimising the dose. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1678-1689.	1.1	25
966	T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment. <i>Journal of Neuro-Oncology</i> , 2020, 147, 281-295.	1.4	32
967	Tuning the Antigen Density Requirement for CAR T-cell Activity. <i>Cancer Discovery</i> , 2020, 10, 702-723.	7.7	296
968	Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. <i>Biomedicines</i> , 2020, 8, 61.	1.4	36
969	Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review. <i>Frontiers in Immunology</i> , 2020, 11, 326.	2.2	70
970	Immune-Based Approaches for the Treatment of Pediatric Malignancies. <i>Annual Review of Cancer Biology</i> , 2020, 4, 353-370.	2.3	7
971	Antibody–Based CAR T Cells Produced by Lentiviral Transduction. <i>Current Protocols in Immunology</i> , 2020, 128, e93.	3.6	10
972	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1247-1256.	2.0	139

#	ARTICLE	IF	CITATIONS
973	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
974	Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 189, 826-843.	1.2	26
975	A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 262.	1.3	48
976	You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy. <i>Cancers</i> , 2020, 12, 706.	1.7	73
977	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
978	Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells. <i>Molecular Therapy</i> , 2020, 28, 1392-1416.	3.7	44
979	Human chimeric antigen receptor macrophages for cancer immunotherapy. <i>Nature Biotechnology</i> , 2020, 38, 947-953.	9.4	692
980	Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 448-454.	1.8	28
981	Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2311-2317.	1.0	11
982	Acute lymphoblastic leukaemia. <i>Lancet, The</i> , 2020, 395, 1146-1162.	6.3	343
983	De novo design of protein logic gates. <i>Science</i> , 2020, 368, 78-84.	6.0	151
984	4-1BB costimulation promotes CAR T cell survival through noncanonical NF- κ B signaling. <i>Science Signaling</i> , 2020, 13, .	1.6	115
985	Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer. <i>Cancers</i> , 2020, 12, 842.	1.7	21
986	Ten things the hematologist wants you to know about CAR-T cells. <i>Intensive Care Medicine</i> , 2020, 46, 1243-1245.	3.9	5
987	Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. <i>Clinical Immunology</i> , 2020, 214, 108382.	1.4	40
989	High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2019, 10, 3123.	2.2	67
990	CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. <i>Frontiers in Immunology</i> , 2020, 11, 99.	2.2	42
991	A Preclinical Embryonic Zebrafish Xenograft Model to Investigate CAR T Cells in Vivo. <i>Cancers</i> , 2020, 12, 567.	1.7	25

#	ARTICLE	IF	CITATIONS
992	Building a better blast-trap. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 1-4.	0.3	0
993	Prospects and challenges for use of CAR T cell therapies in solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 503-516.	1.4	37
994	Recent Advances in the Management of Acute Lymphoblastic Leukaemia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 23.	1.3	16
995	Next-generation CAR T cells to overcome current drawbacks. <i>International Journal of Hematology</i> , 2020, 114, 532-543.	0.7	7
996	HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo. <i>Molecular Therapy</i> , 2020, 28, 1585-1599.	3.7	29
997	Neurological Complications of CAR T Cell Therapy. <i>Current Oncology Reports</i> , 2020, 22, 83.	1.8	16
998	Immobilization of Growth Factors for Cell Therapy Manufacturing. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 620.	2.0	23
999	Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. <i>Frontiers in Immunology</i> , 2020, 11, 1217.	2.2	69
1000	Advances in Supportive Care for Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 276-293.	1.2	8
1001	Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. <i>Oncotarget</i> , 2020, 9, 1777046.	2.1	24
1002	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. <i>Blood</i> , 2020, 136, 2308-2318.	0.6	133
1003	Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 849-860.	0.6	5
1004	Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges. <i>Cancers</i> , 2020, 12, 1699.	1.7	27
1005	Harnessing the power of the immune system in cancer immunotherapy and cancer prevention. <i>Molecular Carcinogenesis</i> , 2020, 59, 675-678.	1.3	5
1006	CAR-T cells: the Chinese experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1293-1308.	1.4	4
1007	Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. <i>Blood</i> , 2020, 136, 1722-1734.	0.6	37
1008	Recent advances in CAR-T cell engineering. <i>Journal of Hematology and Oncology</i> , 2020, 13, 86.	6.9	192
1009	Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. <i>PLoS ONE</i> , 2020, 15, e0235518.	1.1	26

#	ARTICLE	IF	CITATIONS
1010	Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models. <i>Molecular Therapy</i> , 2020, 28, 2271-2285.	3.7	45
1011	Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. <i>OncImmunology</i> , 2020, 9, 1785608.	2.1	35
1012	Infections associated with the new ã€ˆnibs and mabsã€™ and cellular therapies. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 281-289.	1.3	10
1013	A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 238-254.	1.8	45
1014	Oncolytic virus-derived type I interferon restricts CAR T cell therapy. <i>Nature Communications</i> , 2020, 11, 3187.	5.8	61
1015	Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospitalã€™s Perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 971-980.	0.5	7
1016	<p>Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 253-264.	0.7	19
1017	100th Anniversary of Macromolecular Science Viewpoint: Re-Engineering Cellular Interfaces with Synthetic Macromolecules Using Metabolic Glycan Labeling. <i>ACS Macro Letters</i> , 2020, 9, 991-1003.	2.3	14
1018	Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Acute Myeloid Leukemia. <i>Toxicological Sciences</i> , 2020, 177, 94-107.	1.4	5
1020	How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. <i>Blood</i> , 2020, 136, 925-935.	0.6	158
1021	How I treat relapsed acute lymphoblastic leukemia in the pediatric population. <i>Blood</i> , 2020, 136, 1803-1812.	0.6	90
1022	Inotuzumab ozogamicin resistance associated with a novel <i>CD22</i> truncating mutation in a case of Bã€ˆacute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 123-126.	1.2	5
1023	A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. <i>Blood</i> , 2020, 136, 1813-1823.	0.6	61
1024	Acute lymphoblastic leukemia: From aminopterin to CAR T cells. <i>Medicina Clãƒnica (English Edition)</i> , 2020, 154, 269-274.	0.1	1
1025	Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy. <i>Trends in Immunology</i> , 2020, 41, 665-675.	2.9	42
1026	CAR-T immunotherapy in paediatric haemato-oncologyã€ˆ present and future. <i>Anales De Pediatrãƒa (English Edition)</i> , 2020, 93, 1-3.	0.1	0
1028	Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1759-1769.	2.0	9
1029	Thoracic duct lymphatic fluid harbors phenotypically naive T cells for use in adoptive T-cell therapy. <i>Cytotherapy</i> , 2020, 22, 529-535.	0.3	2

#	ARTICLE	IF	CITATIONS
1030	Inefficient CAR-proximal signaling blunts antigen sensitivity. <i>Nature Immunology</i> , 2020, 21, 848-856.	7.0	83
1031	Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. <i>Current Treatment Options in Oncology</i> , 2020, 21, 16.	1.3	19
1032	CAR T cells and checkpoint inhibition for the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 579-591.	1.4	37
1033	Chimeric antigen receptor T cell therapy in patients with neurologic comorbidities. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28199.	0.8	12
1034	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1084-1090.	2.0	19
1035	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. <i>Pharmaceutics</i> , 2020, 12, 194.	2.0	40
1036	Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. <i>Leukemia</i> , 2020, 34, 3064-3069.	3.3	33
1037	Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands. <i>Nature Protocols</i> , 2020, 15, 1507-1524.	5.5	17
1039	Harnessing immunotherapy for pediatric T-cell malignancies. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 361-371.	1.3	12
1040	Advanced biomaterials for cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 911-927.	2.8	62
1041	Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02. <i>Blood Cancer Journal</i> , 2020, 10, 23.	2.8	23
1042	Identification of hurdles in the development of cell-based therapies. <i>Cytotherapy</i> , 2020, 22, 53-56.	0.3	1
1043	Stimuli-responsive nanoparticle-assisted immunotherapy: a new weapon against solid tumours. <i>Journal of Materials Chemistry B</i> , 2020, 8, 1823-1840.	2.9	32
1044	Combination therapy with oncolytic viruses and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 635-652.	1.4	36
1045	Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 653-664.	1.4	39
1046	Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. <i>Cancer</i> , 2020, 126, 1837-1855.	2.0	20
1047	Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia. <i>Chinese Medical Journal</i> , 2020, 133, 474-482.	0.9	9
1048	Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090353.	1.1	23

#	ARTICLE	IF	CITATIONS
1049	Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy. <i>Frontiers in Oncology</i> , 2020, 9, 1529.	1.3	23
1050	Safety and efficacy of blinatumomab: a real world data. <i>Annals of Hematology</i> , 2020, 99, 835-838.	0.8	19
1051	Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. <i>Journal of Critical Care</i> , 2020, 57, 124-129.	1.0	25
1052	Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 242-250.	2.7	6
1053	Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1071-1076.	2.0	63
1054	The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 799-812.	1.4	5
1055	CAR T-Cell-Associated Neurotoxicity. <i>Critical Care Nursing Quarterly</i> , 2020, 43, 191-204.	0.4	28
1056	AML“is it time to drive a CAR(-)?”. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 50-54.	0.3	3
1057	All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. <i>Current Opinion in Biotechnology</i> , 2020, 65, 75-87.	3.3	33
1058	Analytical Performance of an Immunoprofiling Assay Based on RNA Models. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 555-570.	1.2	6
1059	Engineering adeno-associated virus vectors for gene therapy. <i>Nature Reviews Genetics</i> , 2020, 21, 255-272.	7.7	634
1060	Recent Advances in Allogeneic CAR-T Cells. <i>Biomolecules</i> , 2020, 10, 263.	1.8	68
1061	Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype. <i>Bone Marrow Transplantation</i> , 2020, 55, 1337-1346.	1.3	4
1062	A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. <i>Cancer Medicine</i> , 2020, 9, 2317-2329.	1.3	13
1063	Autologous CAR T-cell therapies supply chain: challenges and opportunities?. <i>Cancer Gene Therapy</i> , 2020, 27, 799-809.	2.2	46
1064	Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds. <i>Nature Protocols</i> , 2020, 15, 773-798.	5.5	42
1065	Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 370.	1.8	25
1066	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1

#	ARTICLE	IF	CITATIONS
1067	Implications of T cell receptor biology on the development of new T cell therapies for cancer. <i>Immunotherapy</i> , 2020, 12, 89-103.	1.0	9
1068	A review of cancer immunotherapy toxicity. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 86-104.	157.7	753
1069	Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 381.	1.8	12
1070	Involvement of the central nervous system in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 173-187.	2.7	56
1071	Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. <i>American Journal of Kidney Diseases</i> , 2020, 76, 63-71.	2.1	74
1072	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	1.8	58
1073	Gasdermin Eâ€‘mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. <i>Science Immunology</i> , 2020, 5, .	5.6	314
1074	Results from an international phase 2 study of the antiâ€‘CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood Bâ€‘lineage acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28112.	0.8	16
1075	Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective. <i>Expert Review of Proteomics</i> , 2020, 17, 1-10.	1.3	13
1076	Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. <i>Briefings in Functional Genomics</i> , 2020, 19, 175-182.	1.3	59
1077	Methods to edit T cells for cancer immunotherapy. <i>Methods in Enzymology</i> , 2020, 631, 107-135.	0.4	5
1078	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	1.3	52
1079	Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. <i>Pediatric Neurology</i> , 2020, 107, 7-15.	1.0	2
1080	Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062071989989.	1.1	31
1081	Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. <i>Cancer Discovery</i> , 2020, 10, 552-567.	7.7	184
1082	Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly. <i>International Journal of Molecular Sciences</i> , 2020, 21, 883.	1.8	24
1083	Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 515.	1.8	49
1084	Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e013755.	1.6	37

#	ARTICLE	IF	CITATIONS
1085	Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada. <i>JAMA Oncology</i> , 2020, 6, 393.	3.4	28
1086	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
1087	The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. <i>Cytotherapy</i> , 2020, 22, 57-69.	0.3	70
1088	CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 359-368.	1.8	22
1089	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. <i>New England Journal of Medicine</i> , 2020, 382, 545-553.	13.9	1,252
1090	Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation. <i>Chonnam Medical Journal</i> , 2020, 56, 6.	0.5	1
1091	Development of CAR-T cell therapy for B-ALL using a point-of-care approach. <i>Oncolmunology</i> , 2020, 9, 1752592.	2.1	23
1092	Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 683.	2.2	102
1093	The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptorâ€”T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. <i>Cytotherapy</i> , 2020, 22, 214-226.	0.3	29
1094	Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e27-e34.	1.8	25
1095	Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells. <i>Frontiers in Genetics</i> , 2020, 11, 312.	1.1	27
1096	Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 187-193.	1.2	1
1097	Welcome to the CART cocktail reception. <i>Blood</i> , 2020, 135, 3-4.	0.6	1
1098	Bâ€”cell maturation antigenâ€”specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. <i>International Journal of Cancer</i> , 2020, 147, 2029-2041.	2.3	10
1099	Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment. <i>Clinical and Translational Oncology</i> , 2020, 22, 1923-1937.	1.2	14
1101	Blood components from pluripotent stem cells. , 2020, , 765-784.		0
1103	IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly. <i>Blood Reviews</i> , 2020, 44, 100677.	2.8	29
1104	The Emerging Landscape of Immune Cell Therapies. <i>Cell</i> , 2020, 181, 46-62.	13.5	247

#	ARTICLE	IF	CITATIONS
1105	Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients. <i>Cell Death and Disease</i> , 2020, 11, 207.	2.7	19
1106	Enhancing CAR T cell efficacy: the next step toward a clinical revolution?. <i>Expert Review of Hematology</i> , 2020, 13, 533-543.	1.0	10
1107	Efficacy and safety of humanized anti-CD19 CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 191, 212-222.	1.2	35
1108	EHA evaluation of the ESMO Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	2.0	10
1109	Car-T Treatment for Hematological Malignancies. <i>Journal of Investigative Medicine</i> , 2020, 68, 956-964.	0.7	20
1110	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. , 2020, 8, e000148.		42
1111	Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. , 2020, 8, e000471.		8
1112	Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A. <i>Haematologica</i> , 2020, 105, 322-324.	1.7	14
1113	Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches. <i>Frontiers in Immunology</i> , 2020, 11, 519.	2.2	7
1114	Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. <i>Haematologica</i> , 2020, 106, 46-55.	1.7	29
1115	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	1.8	31
1116	Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. <i>Clinical and Experimental Medicine</i> , 2020, 20, 469-480.	1.9	8
1117	Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. <i>Clinical Drug Investigation</i> , 2020, 40, 511-518.	1.1	148
1118	Implantable Therapeutic Reservoir Systems for Diverse Clinical Applications in Large Animal Models. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000305.	3.9	13
1119	Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102769.	0.5	19
1120	Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL. <i>Blood</i> , 2020, 135, 387-391.	0.6	112
1121	CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1938-1950.	0.8	273
1122	Haemodynamic management during hyperthermic intraperitoneal chemotherapy: A systematic review. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 531-542.	0.6	7

#	ARTICLE	IF	CITATIONS
1123	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. <i>Journal of Critical Care</i> , 2020, 58, 58-64.	1.0	31
1124	Dissecting the Tumor Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. <i>Clinical Cancer Research</i> , 2020, 26, 3505-3513.	3.2	18
1125	How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. <i>Frontiers in Physiology</i> , 2020, 11, 154.	1.3	27
1127	Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e183-e191.	2.0	25
1128	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1239-1246.	2.0	56
1129	Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma. <i>Translational Oncology</i> , 2020, 13, 100770.	1.7	29
1130	Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view. <i>European Journal of Haematology</i> , 2020, 105, 203-215.	1.1	29
1131	Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies. <i>Cell Transplantation</i> , 2020, 29, 096368972091943.	1.2	16
1132	Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy. <i>Blood</i> , 2020, 135, 668-679.	0.6	7
1133	Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e132-e143.	1.8	15
1134	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 2862-2871.	0.8	102
1135	Not So FAST: Tumor Cells Resisting Death Drive CAR T-cell Dysfunction. <i>Cancer Discovery</i> , 2020, 10, 492-494.	7.7	3
1136	Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. <i>Blood</i> , 2020, 135, 597-609.	0.6	134
1137	How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. <i>Blood</i> , 2020, 135, 804-813.	0.6	34
1138	A CAR against CAR for unintended consequences. <i>Blood</i> , 2020, 135, 460-462.	0.6	0
1139	The one-two punch (of CAR T cells). <i>Blood</i> , 2020, 135, 303-304.	0.6	5
1140	Supercharging your CAR. <i>Blood</i> , 2020, 135, 593-594.	0.6	2
1141	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. <i>Blood Advances</i> , 2020, 4, 560-572.	2.5	88

#	ARTICLE	IF	CITATIONS
1142	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020, 4, 676-686.	2.5	101
1143	Chimeric antigen receptorâ€T cells with cytokine neutralizing capacity. <i>Blood Advances</i> , 2020, 4, 1419-1431.	2.5	27
1144	Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. <i>Blood Advances</i> , 2020, 4, 1432-1439.	2.5	54
1145	Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. <i>Blood Advances</i> , 2020, 4, 1440-1447.	2.5	29
1146	Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 30.	6.9	187
1147	Chimeric antigen receptor Tâ€cell therapy toxicities. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2414-2424.	1.1	19
1148	Revvng the CAR â€ Combination strategies to enhance CAR T cell effectiveness. <i>Blood Reviews</i> , 2021, 45, 100695.	2.8	22
1149	Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. <i>Blood Reviews</i> , 2021, 45, 100707.	2.8	137
1150	Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 98-102.	1.7	11
1151	A primer to gene therapy: Progress, prospects, and problems. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 54-71.	1.7	9
1152	Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells. <i>Bone Marrow Transplantation</i> , 2021, 56, 91-100.	1.3	18
1153	Immune modulation via T regulatory cell enhancement: Diseaseâ€modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseasesâ€”An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 90-113.	2.7	24
1154	Cellular immunotherapies for cancer. <i>Irish Journal of Medical Science</i> , 2021, 190, 41-57.	0.8	45
1155	Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy. <i>Immunological Medicine</i> , 2021, 44, 10-15.	1.4	14
1156	Developing cell therapies as drug products. <i>British Journal of Pharmacology</i> , 2021, 178, 262-279.	2.7	6
1157	CAR-T cells: Early successes in blood cancer and challenges in solid tumors. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1129-1147.	5.7	47
1158	Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study. <i>Annals of Hematology</i> , 2021, 100, 197-208.	0.8	3
1159	Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. <i>Molecular Therapy</i> , 2021, 29, 505-520.	3.7	48

#	ARTICLE	IF	CITATIONS
1160	Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 376-386.	1.3	11
1161	Cancer and antineoplastic therapies and the risk of infection in the pediatric cancer patient. , 2021, , 22-33.e3.		0
1162	The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. <i>Bone Marrow Transplantation</i> , 2021, 56, 257-266.	1.3	11
1163	Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. <i>Annual Review of Medicine</i> , 2021, 72, 365-382.	5.0	34
1164	Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations. <i>Annals of Pharmacotherapy</i> , 2021, 55, 466-479.	0.9	6
1165	Adaptive T cell immunotherapy in cancer. <i>Science China Life Sciences</i> , 2021, 64, 363-371.	2.3	13
1166	Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. <i>International Journal of Cancer</i> , 2021, 148, 419-428.	2.3	42
1167	Nanotechnology-Based CAR-T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, .	7.8	13
1168	Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28739.	0.8	8
1170	Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103096.	2.0	10
1171	The changing face of gastric cancer: epidemiologic trends and advances in novel therapies. <i>Cancer Gene Therapy</i> , 2021, 28, 390-399.	2.2	23
1172	Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 95-103.	0.6	0
1173	Pharmacology of Chimeric Antigen Receptor-Modified T Cells. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 805-829.	4.2	7
1174	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , 2021, 137, 323-335.	0.6	111
1175	Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. <i>Infection</i> , 2021, 49, 215-231.	2.3	63
1176	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. <i>Molecular Therapy</i> , 2021, 29, 636-644.	3.7	80
1177	Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. <i>Leukemia</i> , 2021, 35, 1563-1570.	3.3	49
1178	Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy. <i>Immunotherapy</i> , 2021, 13, 5-10.	1.0	10

#	ARTICLE	IF	CITATIONS
1179	Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET. <i>Clinical Cancer Research</i> , 2021, 27, 1058-1068.	3.2	53
1180	CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. <i>Blood</i> , 2021, 137, 1037-1049.	0.6	45
1181	The Spectrum of COVID-19 Disease in Adolescents. <i>Archivos De Bronconeumologia</i> , 2021, 57, 84-85.	0.4	6
1182	CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models. <i>Communications in Nonlinear Science and Numerical Simulation</i> , 2021, 94, 105570.	1.7	20
1183	A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). <i>Blood</i> , 2021, 137, 1582-1590.	0.6	48
1184	Acute Leukemias. <i>Hematologic Malignancies</i> , 2021, , .	0.2	2
1185	CD28 Costimulatory Domainâ€“Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function. <i>Cancer Immunology Research</i> , 2021, 9, 62-74.	1.6	29
1186	Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. <i>Bone Marrow Transplantation</i> , 2021, 56, 552-566.	1.3	113
1187	Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy â€“ what are we doing; where are we going?. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 627-637.	1.4	25
1188	Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation. <i>Blood Reviews</i> , 2021, 47, 100779.	2.8	2
1189	New cancer therapies. Are haematopoietic cell transplants a dead duck?. <i>Bone Marrow Transplantation</i> , 2021, 56, 1086-1089.	1.3	3
1190	Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. <i>Biomaterials</i> , 2021, 268, 120584.	5.7	40
1191	CAR-T cell therapy and infection: a review. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 749-758.	2.0	47
1192	Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. <i>Neuro-Oncology Practice</i> , 2021, 8, 259-265.	1.0	3
1193	Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia. <i>Translational Oncology</i> , 2021, 14, 100978.	1.7	6
1194	The role of immunotherapy in relapse/refractory precursorâ€“B acute lymphoblastic leukaemia: realâ€“life UK/Ireland experience in children and young adults. <i>British Journal of Haematology</i> , 2021, 192, e42-e44.	1.2	0
1195	A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes VÎ³9VÎ³2 T cellâ€“Mediated Antitumor Responses in Human B-cell Malignancies. <i>Cancer Immunology Research</i> , 2021, 9, 50-61.	1.6	23
1196	CARâ€“T TREK through the lymphoma universe, to boldly go where no other therapy has gone before. <i>British Journal of Haematology</i> , 2021, 193, 449-465.	1.2	17

#	ARTICLE	IF	CITATIONS
1197	Combinatorial CAR design improves target restriction. <i>Journal of Biological Chemistry</i> , 2021, 296, 100116.	1.6	7
1198	Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management. <i>Clinical Cancer Research</i> , 2021, 27, 1242-1246.	3.2	62
1199	Chimeric antigen receptor (CAR) natural killer (NK) cell therapy: leveraging the power of innate immunity. <i>British Journal of Haematology</i> , 2021, 193, 216-230.	1.2	61
1200	IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. <i>Leukemia</i> , 2021, 35, 1380-1391.	3.3	26
1201	Counteracting CAR T cell dysfunction. <i>Oncogene</i> , 2021, 40, 421-435.	2.6	76
1202	Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 222-229.	0.6	27
1203	Opportunities and Challenges in Drug Development for Pediatric Cancers. <i>Cancer Discovery</i> , 2021, 11, 545-559.	7.7	25
1204	Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1089-1099.	1.6	37
1205	CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. <i>Cancer Discovery</i> , 2021, 11, 1192-1211.	7.7	78
1206	Prolonged neurotoxicity in a lymphoma patient after CD19-directed CAR T cell therapy: A case report and brief review of the literature. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, e104.	0.6	1
1207	Blueprint for cancer research: Critical gaps and opportunities. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 107-139.	157.7	47
1208	CAR T Cell and BiTE Therapy—New Therapies, New Risks?. <i>Current Cardiovascular Risk Reports</i> , 2021, 15, 1.	0.8	1
1209	PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. <i>Human Immunology</i> , 2021, 82, 130-138.	1.2	25
1210	Engineering precision therapies: lessons and motivations from the clinic. <i>Synthetic Biology</i> , 2021, 6, ysaa024.	1.2	5
1211	Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28839.	0.8	3
1212	A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect. <i>Statistical Methods in Medical Research</i> , 2021, 30, 904-915.	0.7	5
1213	Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e334-e347.	0.2	36
1214	Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. <i>Annals of Oncology</i> , 2021, 32, 34-48.	0.6	231

#	ARTICLE	IF	CITATIONS
1215	Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. <i>Journal of Geriatric Oncology</i> , 2021, 12, 235-238.	0.5	9
1216	CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. <i>American Journal of Transplantation</i> , 2021, 21, 809-814.	2.6	44
1217	Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 841-852.	1.3	12
1218	Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 250-258.	0.7	14
1219	Neurological updates: neurological complications of CAR-T therapy. <i>Journal of Neurology</i> , 2021, 268, 1544-1554.	1.8	37
1220	Cytokine syndromes associated with hematopoietic cellular therapy. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, .	0.6	1
1221	Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. <i>Cancer Gene Therapy</i> , 2021, 28, 321-334.	2.2	25
1222	Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 168-177.	0.6	35
1223	Graphical Analyses in the Regulatory Evaluation of Gene Therapy Applications. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 346-359.	0.8	2
1224	Exploring the NK cell platform for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 85-100.	12.5	605
1225	Monitoring CAR ⁺ T cells using flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 218-224.	0.7	45
1226	Recent advances in acute lymphoblastic leukemia. <i>Journal of Hematopoietic Cell Transplantation</i> , 2021, 10, 72-80.	0.1	0
1228	CAR T Toxicity Management: Cytokine Release Syndrome and Neurotoxicity. , 2021, , 915-928.		0
1229	Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection. , 2021, 9, e001225.		6
1230	Direct control of CAR T cells through small molecule-regulated antibodies. <i>Nature Communications</i> , 2021, 12, 710.	5.8	30
1231	Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies. <i>Cell Transplantation</i> , 2021, 30, 096368972110255.	1.2	16
1232	Allogeneic CAR Cell Therapy—More Than a Pipe Dream. <i>Frontiers in Immunology</i> , 2020, 11, 618427.	2.2	64
1233	Recent advances and discoveries in the mechanisms and functions of CAR T cells. <i>Nature Reviews Cancer</i> , 2021, 21, 145-161.	12.8	436

#	ARTICLE	IF	CITATIONS
1234	Cancer Immunology. , 2021, , .		0
1235	A paradigm shift. , 2021, , 27-42.		0
1237	Acute Lymphoblastic Leukemia. , 2021, , 251-270.		0
1238	Medicina di precisione: miti e realtà. Medico E Bambino, 2021, 40, 18-24.	0.1	0
1239	Current status of immunotherapy in acute myeloid leukemia. E3S Web of Conferences, 2021, 271, 03025.	0.2	0
1240	An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. Expert Opinion on Biological Therapy, 2021, 21, 1025-1034.	1.4	4
1241	Genetic Disease and Therapy. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 145-166.	9.6	21
1242	Alternol triggers immunogenic cell death <i>via</i> reactive oxygen species generation. OncoImmunology, 2021, 10, 1952539.	2.1	17
1243	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Advances, 2021, 5, 593-601.	2.5	28
1244	CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells. Nature Communications, 2021, 12, 240.	5.8	28
1245	A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia, 2021, 35, 2243-2257.	3.3	24
1246	Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Current Cardiology Reports, 2021, 23, 11.	1.3	35
1247	HSCT in Malignancies. Organ and Tissue Transplantation, 2021, , 99-114.	0.0	0
1248	The Future of Transplantation: Hope, Investigative Discipline, and Fairness. Organ and Tissue Transplantation, 2021, , 733-740.	0.0	0
1249	Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Stem Cell Investigation, 2021, 8, 1-1.	1.3	17
1250	Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML. OncoImmunology, 2021, 10, 1945804.	2.1	16
1251	Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2. Blood Advances, 2021, 5, 584-592.	2.5	7
1252	Genome editing of immune cells using CRISPR/Cas9. BMB Reports, 2021, 54, 59-69.	1.1	8

#	ARTICLE	IF	CITATIONS
1253	Latest Developments in Cellular Therapy for Multiple Myeloma. <i>Oncology & Hematology Review</i> , 2021, 16, 111.	0.2	1
1255	Blockade of AIM2 inflammasome or Î±1-AR ameliorates IL-1Î² release and macrophage-mediated immunosuppression induced by CAR-T treatment. , 2021, 9, e001466.		31
1256	Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110374.	0.8	1
1257	Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors. <i>BMB Reports</i> , 2021, 54, 44-58.	1.1	7
1258	Preclinical development of CD126 CAR-T cells with broad antitumor activity. <i>Blood Cancer Journal</i> , 2021, 11, 3.	2.8	16
1259	Potency analysis of cellular therapies: the role of molecular assays. , 2021, , 49-70.		0
1260	Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 334.	1.7	44
1261	Have CD19-directed immunotherapy and haploidentical hematopoietic cell transplantation transformed pediatric B-cell acute lymphoblastic leukemia into a chronic disease?. <i>Oncolmunology</i> , 2021, 10, 1956125.	2.1	0
1262	Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids. , 2021, , .		0
1263	CAR T cells better than BiTEs. <i>Blood Advances</i> , 2021, 5, 602-606.	2.5	17
1264	InÂvitro T lymphopoiesis. , 2021, , 23-53.		0
1265	Auswirkungen von Chemotherapeutika auf zirkulierende Leukozytenpopulationen: MÃ¶gliche Implikationen fÃ¼r den Erfolg von CAR-T-Zell-Therapien. <i>Karger Kompass Onkologie</i> , 2021, 8, 116-127.	0.0	0
1266	Minors and a Dawning Paradigm Shift in â€œPediatricâ€•Drug Development. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 736-739.	1.0	6
1267	Challenges at the interface of science, drug development, and drug approval beyond specific disease areas. , 2021, , 271-336.		0
1268	Translation of gene therapies. , 2021, , 683-697.		0
1269	Cardio-Oncology in the COVID-19 Era. , 2021, , 291-306.		0
1270	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 143-155.	2.5	92
1271	Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1026.	1.8	31

#	ARTICLE	IF	CITATIONS
1272	IFN Signaling and Myeloid Cells in the Setting of CAR T: A Central Role for the Induction of Endogenous Anti-tumor Immunity. , 2021, 18, .		0
1273	The dual role of Natural Killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies. , 2021, , 305-347.		0
1274	CARâ€NKG cells: the next wave of cellular therapy for cancer. Clinical and Translational Immunology, 2021, 10, e1274.	1.7	66
1275	BiTEs better than CAR T cells. Blood Advances, 2021, 5, 607-612.	2.5	59
1276	Challenges of Cellular Therapy During the COVID-19 Pandemic. Advances in Experimental Medicine and Biology, 2021, 1318, 657-672.	0.8	4
1277	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Advances, 2021, 5, 861-871.	2.5	23
1278	Humanized <scp>CD19</scp>-targeted chimeric antigen receptor <scp>T</scp> (<scp>CARâ€T</scp>) cells for relapsed/refractory pediatric acute lymphoblastic leukemia. American Journal of Hematology, 2021, 96, E162-E165.	2.0	12
1280	Clinical development of natural killer cells expressing chimeric antigen receptors. Transfusion and Apheresis Science, 2021, 60, 103065.	0.5	0
1281	CAR-T Therapy, the End of a Chapter or the Beginning of a New One?. Cancers, 2021, 13, 853.	1.7	5
1282	Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Frontiers in Immunology, 2021, 12, 611366.	2.2	41
1283	Immune cartography of macrophage activation syndrome in the COVID-19 era. Nature Reviews Rheumatology, 2021, 17, 145-157.	3.5	75
1284	Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19â€negative acute lymphoblastic leukemia after CARâ€T cell therapy. Pediatric Blood and Cancer, 2021, 68, e28980.	0.8	0
1285	Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. Cancer Immunology, Immunotherapy, 2021, 70, 2503-2515.	2.0	28
1286	Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nature Communications, 2021, 12, 865.	5.8	81
1287	Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. Frontiers in Immunology, 2020, 11, 618387.	2.2	38
1288	CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nature Communications, 2021, 12, 877.	5.8	143
1289	Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges. Frontiers in Oncology, 2021, 11, 615704.	1.3	27
1290	Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept. Cancers, 2021, 13, 703.	1.7	12

#	ARTICLE	IF	CITATIONS
1291	Pediatric high-grade glioma: moving toward subtype-specific multimodal therapy. <i>FEBS Journal</i> , 2021, 288, 6127-6141.	2.2	40
1293	CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. <i>Clinical Toxicology</i> , 2021, 59, 376-385.	0.8	4
1294	Polymeric Micelles in Cancer Immunotherapy. <i>Molecules</i> , 2021, 26, 1220.	1.7	22
1295	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancer Discovery</i> , 2021, 11, 1440-1453.	7.7	137
1296	CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 2764-2772.	3.2	122
1297	GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. <i>Frontiers in Immunology</i> , 2021, 12, 626098.	2.2	21
1298	Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity. <i>Blood</i> , 2021, 137, 3306-3309.	0.6	26
1299	How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. <i>Journal of Clinical Oncology</i> , 2021, 39, 456-466.	0.8	21
1300	CAR-T treatment of pediatric AML: a long and winding road. <i>Blood</i> , 2021, 137, 1004-1006.	0.6	5
1301	BCMA-targeting approaches for treatment of multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 28-36.	0.2	4
1302	Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer. <i>Cancer Discovery</i> , 2021, 11, 560-574.	7.7	12
1303	CRISPR Takes the Front Seat in CART-Cell Development. <i>BioDrugs</i> , 2021, 35, 113-124.	2.2	10
1304	The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 617583.	2.2	20
1305	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	12.5	31
1306	Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1225-1234.	0.8	8
1307	Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. <i>Leukemia and Lymphoma</i> , 2021, 62, 1692-1701.	0.6	22
1308	A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2150.	1.8	60
1309	Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2021, 100, 1003-1012.	0.8	21

#	ARTICLE	IF	CITATIONS
1310	Immunogenicity of CAR T cells in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 379-393.	12.5	128
1311	Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series. <i>British Journal of Haematology</i> , 2021, 193, 1172-1177.	1.2	15
1312	Driving CAR T cells towards dermatologic oncology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 359-362.	0.4	5
1313	Understanding the Feasibility of Implementing Car T-Cell Therapies from a Canadian Perspective. <i>Healthcare Policy</i> , 2021, 16, 89-105.	0.3	0
1314	Regulatory challenges and considerations for the clinical application of CAR T cell therapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 549-552.	1.4	1
1315	La terapia con células CAR-T. <i>Medicina Clínica</i> , 2021, 156, 123-125.	0.3	0
1316	CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1642-1650.	1.3	14
1317	Xenograft models for pediatric cancer therapies. <i>Faculty Reviews</i> , 2021, 10, 11.	1.7	2
1318	Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells. <i>HemaSphere</i> , 2021, 5, e533.	1.2	8
1319	Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell Model. <i>Cancers</i> , 2021, 13, 867.	1.7	9
1320	Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. <i>Frontiers in Immunology</i> , 2020, 11, 569117.	2.2	26
1321	Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. <i>Neurosurgery</i> , 2021, 88, 1056-1064.	0.6	14
1322	Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 608485.	2.2	4
1323	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	7.7	16
1324	Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. <i>Cancer Science</i> , 2021, 112, 1357-1368.	1.7	19
1326	Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. <i>Biomarkers in Medicine</i> , 2021, 15, 201-217.	0.6	1
1327	Invasive Fungal Infections after Anti-CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy: State of the Evidence and Future Directions. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 156.	1.5	25
1328	CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. <i>Molecular Therapy</i> , 2021, 29, 571-586.	3.7	124

#	ARTICLE	IF	CITATIONS
1329	Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 476-486.	0.8	8
1330	Genetic engineering of T cells for immunotherapy. <i>Nature Reviews Genetics</i> , 2021, 22, 427-447.	7.7	63
1332	CAR-T cell therapy. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 123-125.	0.1	0
1333	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. <i>Hemato</i> , 2021, 2, 79-88.	0.2	0
1334	New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2404.	1.8	4
1335	Comment on: A review of the experience with pediatric written requests issued for oncology drug products. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28972.	0.8	0
1336	Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond. <i>Leukemia and Lymphoma</i> , 2021, 62, 1795-1804.	0.6	3
1337	Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins. <i>Molecular Therapy</i> , 2021, 29, 718-733.	3.7	13
1338	Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells. <i>Gene Therapy</i> , 2021, 28, 602-612.	2.3	9
1339	Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction. <i>Frontiers in Immunology</i> , 2021, 12, 627764.	2.2	28
1340	Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells "off the shelf"™?. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 195-196.	12.5	21
1341	Spatiotemporal in vivo tracking of polyclonal human regulatory T cells (Tregs) reveals a role for innate immune cells in Treg transplant recruitment. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 324-336.	1.8	16
1342	Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 535-541.	1.8	5
1343	Chimeric Antigen Receptor T-Cell Therapy. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 089-092.	0.1	0
1344	Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?. <i>Cancers</i> , 2021, 13, 1106.	1.7	16
1345	Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. <i>Scientific Reports</i> , 2021, 11, 6276.	1.6	35
1346	Understanding and treating the inflammatory adverse events of cancer immunotherapy. <i>Cell</i> , 2021, 184, 1575-1588.	13.5	111
1347	The Role of Granulocyte Transfusions in Optimizing Candidacy for Chimeric Antigen Receptor T-Cell Therapy in Patients With Treatment-refractory Infections. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, .	0.3	2

#	ARTICLE	IF	CITATIONS
1348	Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1568.	1.7	21
1349	Acute Lymphoblastic Leukemia in Adolescents and Young Adults. , 0, , .		0
1350	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 255.e1-255.e9.	0.6	6
1351	Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 20.	1.0	19
1352	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 233-240.	0.6	24
1353	Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity. <i>Immunology</i> , 2021, 163, 389-398.	2.0	5
1354	Adoptive Cellular Therapy for Solid Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 57-65.	1.8	10
1355	Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy. <i>Cancers</i> , 2021, 13, 1481.	1.7	20
1356	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 920-930.	0.8	110
1357	Identification of NY-ESO-1157â€™165 Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 644520.	2.2	8
1358	Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 433-468.	0.9	7
1359	Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 626818.	1.3	13
1360	Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 387-398.	2.0	20
1361	Have any strategies in Ph-like ALL been shown to be effective?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101242.	0.7	10
1362	Managing older adults with Ph-negative ALL: What is new? Recent advances in treating older adults with ALL. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101258.	0.7	1
1363	Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2476.	1.8	10
1364	Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases. <i>Cancers</i> , 2021, 13, 1124.	1.7	5
1365	T cell circuits that sense antigen density with an ultrasensitive threshold. <i>Science</i> , 2021, 371, 1166-1171.	6.0	99

#	ARTICLE	IF	CITATIONS
1366	The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. <i>Frontiers in Immunology</i> , 2021, 12, 639818.	2.2	60
1367	Neonatal Leukemia. <i>Clinics in Perinatology</i> , 2021, 48, 15-33.	0.8	9
1368	Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 2052-2063.	0.6	16
1369	The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2021, 288, 20210229.	1.2	22
1370	Relative expansion of CD19 ⁺ negative very early normal B ⁺ cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR ⁺ T cell therapy: implications for flow cytometric detection of minimal residual disease. <i>British Journal of Haematology</i> , 2021, 193, 602-612.	1.2	30
1371	Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 640082.	2.2	64
1372	Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?. <i>Lancet Haematology</i> , 2021, 8, e216-e228.	2.2	41
1373	Rational nanocarrier design towards clinical translation of cancer nanotherapy. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 032005.	1.7	14
1374	Cell ⁺ Based Delivery Systems: Emerging Carriers for Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2100088.	7.8	60
1375	Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. <i>PLoS ONE</i> , 2021, 16, e0247717.	1.1	10
1376	Cellular Therapy in Pediatric Hematologic Malignancies. <i>Clinics in Laboratory Medicine</i> , 2021, 41, 121-132.	0.7	2
1379	CAR T in adult ALL: When and for whom?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101256.	0.7	2
1380	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	39
1381	A BCMAxCD3 bispecific T cell ⁺ engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. <i>Blood Advances</i> , 2021, 5, 1291-1304.	2.5	32
1382	In ⁺ vivo CART cell imaging: Paving the way for success in CART cell therapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 625-633.	2.0	14
1383	Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons. <i>Frontiers in Immunology</i> , 2021, 12, 658753.	2.2	59
1384	Immune checkpoint inhibitor ⁺ associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
1385	Clinical Design and Analysis Strategies for the Development of Gene Therapies: Considerations for Quantitative Drug Development in the Age of Genetic Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1207-1215.	2.3	4

#	ARTICLE	IF	CITATIONS
1386	A single-chain antibody generation system yielding CAR-T cells with superior antitumor function. <i>Communications Biology</i> , 2021, 4, 273.	2.0	14
1387	Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3495.	1.8	9
1388	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-“hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-“negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	2.0	24
1389	Off-the-Shelf Chimeric Antigen Receptor T Cells. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 176-181.	1.0	4
1390	Chimeric Antigen Receptor-“Modified Immune Effector Cell Therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 90-91.	1.0	0
1391	Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 98-106.	1.0	2
1392	Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy. <i>Journal of Immunology</i> , 2021, 206, 1561-1568.	0.4	36
1393	Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy. <i>Seminars in Ophthalmology</i> , 2021, 36, 329-334.	0.8	4
1394	Taking T-Cell Oncotherapy Off-the-Shelf. <i>Trends in Immunology</i> , 2021, 42, 261-272.	2.9	14
1395	Pyroptosis: mechanisms and diseases. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 128.	7.1	821
1396	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 833.	3.8	177
1397	Leucemia linfoblística aguda del niño y el adolescente. <i>EMC Pediatría</i> , 2021, 56, 1-9.	0.0	1
1398	A new era in the treatment of acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 1563-1564.	0.6	3
1399	T Cell Subsets During Early Life and Their Implication in the Treatment of Childhood Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 582539.	2.2	3
1400	How Do We Meet the Challenge of Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors?. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 134-142.	1.0	1
1401	Boosting Immunity against Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1221.	1.7	8
1402	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 186.	1.5	18
1403	Combination of <sc>CD19</sc> and <sc>CD22 CAR</sc> cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. <i>American Journal of Hematology</i> , 2021, 96, 671-679.	2.0	62

#	ARTICLE	IF	CITATIONS
1404	Chimeric Antigen Receptor Design Today and Tomorrow. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 92-97.	1.0	3
1405	Neurotoxicity Biology and Management. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 126-133.	1.0	7
1406	Improving and Maintaining Responses in Pediatric B-Cell Acute Lymphoblastic Leukemia Chimeric Antigen Receptor- T Cell Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 151-158.	1.0	0
1407	CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus. <i>Cancers</i> , 2021, 13, 1050.	1.7	17
1408	Trispecific CD19-CD20-CD22- targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	77
1409	Post-Transplant Cyclophosphamide and Tacrolimus- Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1173.	1.0	10
1410	Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model. <i>Frontiers in Immunology</i> , 2021, 12, 628906.	2.2	31
1411	An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2021, 13, 1632.	1.7	6
1412	Detection of CAR-T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 622-631.	0.7	6
1413	Perspectives in membranous nephropathy. <i>Cell and Tissue Research</i> , 2021, 385, 405-422.	1.5	16
1414	Leukemic extracellular vesicles induce chimeric antigen receptor T-cell dysfunction in chronic lymphocytic leukemia. <i>Molecular Therapy</i> , 2021, 29, 1529-1540.	3.7	43
1415	Pharmacologic Control of CAR T Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4320.	1.8	9
1416	What is CAR T-cell therapy?. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 73-76.	0.3	2
1417	Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy. <i>Cancer Discovery</i> , 2021, 11, 2186-2199.	7.7	85
1418	Vector engineering, strategies and targets in cancer gene therapy. <i>Cancer Gene Therapy</i> , 2022, 29, 402-417.	2.2	18
1419	Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. <i>Pharmaceutics</i> , 2021, 13, 520.	2.0	25
1420	CAR-T cell persistence in the treatment of leukemia and lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2587-2599.	0.6	13
1421	Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. <i>JCI Insight</i> , 2021, 6, .	2.3	18

#	ARTICLE	IF	CITATIONS
1422	Industrializing engineered autologous T cells as medicines for solid tumours. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 476-488.	21.5	12
1423	Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development. <i>Biomolecules</i> , 2021, 11, 611.	1.8	27
1424	CAR T cell therapy in solid tumors: a short review. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 143-149.	0.3	17
1425	Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 203-215.	0.4	2
1426	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	0.6	90
1427	Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 1926.	1.0	86
1428	The Complex Integration of T-cell Metabolism and Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 1636-1643.	7.7	64
1429	The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. <i>Biomedicines</i> , 2021, 9, 389.	1.4	21
1430	The effect of tocilizumab on severe COVID-19 infection: Review of current evidence. <i>Tuberkuloz Ve Toraks</i> , 2021, 69, 74-83.	0.2	3
1431	Recent progress in the treatment of cancer in children. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 315-332.	157.7	43
1432	CAR-T cells : nouvelle option thérapeutique dans les hémopathies malignes. <i>Revue Francophone Des Laboratoires</i> , 2021, 2021, 28-33.	0.0	0
1433	Prognostic significance of various 11q23/KMT2A rearrangements in infants with acute lymphoblastic leukemia. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2021, 20, 27-39.	0.1	2
1434	State-of-Art of Cellular Therapy for Acute Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4590.	1.8	12
1435	Engineering the fate and function of human T-Cells via 3D bioprinting. <i>Biofabrication</i> , 2021, 13, 035016.	3.7	15
1436	Splice-Switching Antisense Oligonucleotides as a Targeted Intrinsic Engineering Tool for Generating Armored Redirected T Cells. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 145-154.	2.0	3
1437	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. <i>Cancers</i> , 2021, 13, 1781.	1.7	17
1438	Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 218-233.	1.2	4
1439	Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications. <i>Nature Chemistry</i> , 2021, 13, 540-548.	6.6	42

#	ARTICLE	IF	CITATIONS
1440	Reactions Related to CAR-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 663201.	2.2	54
1441	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. <i>Nature Medicine</i> , 2021, 27, 842-850.	15.2	88
1442	CAR-T cell therapy: current limitations and potential strategies. <i>Blood Cancer Journal</i> , 2021, 11, 69.	2.8	871
1443	The evolution of commercial drug delivery technologies. <i>Nature Biomedical Engineering</i> , 2021, 5, 951-967.	11.6	539
1444	Metabolic barriers to cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2021, 21, 785-797.	10.6	245
1445	Immunotherapy to get on point with base editing. <i>Drug Discovery Today</i> , 2021, 26, 2350-2357.	3.2	4
1446	CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3501-3511.	2.0	12
1447	Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 123-140.	2.7	7
1448	Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. <i>Leukemia</i> , 2021, 35, 3092-3100.	3.3	22
1449	Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. <i>American Journal of Hematology</i> , 2021, 96, 650-658.	2.0	52
1450	Mechanisms of response and resistance to CAR T cell therapies. <i>Current Opinion in Immunology</i> , 2021, 69, 56-64.	2.4	18
1451	CAR T Cells. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 249-263.	0.8	3
1452	A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses. <i>Journal of Medical Toxicology</i> , 2022, 18, 43-55.	0.8	18
1453	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	1.7	27
1454	In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment. <i>Cells</i> , 2021, 10, 1020.	1.8	21
1455	Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. <i>Blood Advances</i> , 2021, 5, 2128-2136.	2.5	26
1456	Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. , 2021, 9, e002056.		52
1457	Commentary: Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. <i>Neurosurgery</i> , 2021, 89, E68-E69.	0.6	1

#	ARTICLE	IF	CITATIONS
1458	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. <i>British Journal of Haematology</i> , 2021, 193, 1060-1075.	1.2	13
1459	CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success. <i>BioDrugs</i> , 2021, 35, 281-302.	2.2	30
1460	mRNA therapeutics in cancer immunotherapy. <i>Molecular Cancer</i> , 2021, 20, 69.	7.9	168
1461	Surface expression of the immunotherapeutic target $CD2$ in osteosarcoma depends on cell confluency. <i>Cancer Reports</i> , 2021, 4, e1394.	0.6	6
1464	Targeted Therapies for Multiple Myeloma. <i>Journal of Personalized Medicine</i> , 2021, 11, 334.	1.1	9
1465	CAR-T cell therapy: practical guide to routine laboratory monitoring. <i>Pathology</i> , 2021, 53, 408-415.	0.3	10
1466	Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients. <i>ACS Synthetic Biology</i> , 2021, 10, 1184-1198.	1.9	9
1467	A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29047.	0.8	8
1468	Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. <i>Future Oncology</i> , 2021, 17, 1269-1283.	1.1	20
1469	Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. <i>Blood</i> , 2021, 138, 531-543.	0.6	42
1470	Preventive Healthcare and Management for Acute Lymphoblastic Leukaemia in Adults: Case Report and Literature Review. <i>Healthcare (Switzerland)</i> , 2021, 9, 531.	1.0	1
1471	Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2021, 12, 605766.	2.2	34
1472	Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. <i>Cancers</i> , 2021, 13, 2225.	1.7	21
1473	Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5536.	1.8	17
1474	Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia. <i>Medicine (United States)</i> , 2021, 100, e25786.	0.4	10
1475	BCMA CARs in multiple myeloma: room for more?. <i>Blood</i> , 2021, 137, 2859-2860.	0.6	1
1476	Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 670088.	2.2	10
1477	Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications. <i>Frontiers in Immunology</i> , 2021, 12, 658314.	2.2	28

#	ARTICLE	IF	CITATIONS
1478	Folate Receptor Beta as a Direct and Indirect Target for Antibody-Based Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5572.	1.8	11
1479	Cardiovascular Toxicities of CAR T-cell Therapy. <i>Current Oncology Reports</i> , 2021, 23, 78.	1.8	10
1480	Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. <i>Cancers</i> , 2021, 13, 2712.	1.7	13
1481	CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 82.	6.9	63
1482	Neurological complications of cancer immunotherapy (CAR T cells). <i>Journal of the Neurological Sciences</i> , 2021, 424, 117405.	0.3	10
1483	Targeting HDL in tumor microenvironment: New hope for cancer therapy. <i>Journal of Cellular Physiology</i> , 2021, 236, 7853-7873.	2.0	15
1484	Current Treatment Options in CLL. <i>Cancers</i> , 2021, 13, 2468.	1.7	20
1485	T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. <i>Leukemia</i> , 2021, 35, 1843-1863.	3.3	123
1486	Updates in Childhood Leukemia. <i>Advances in Oncology</i> , 2021, 1, 169-180.	0.1	0
1487	Machine learning-based cytokine microarray digital immunoassay analysis. <i>Biosensors and Bioelectronics</i> , 2021, 180, 113088.	5.3	26
1488	Chimeric Antigen Receptor T Cells for Glioblastoma. <i>Neurology</i> , 2021, 97, 218-230.	1.5	19
1489	Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 3383-3393.	3.3	77
1491	An owner's manual for CD19 α -CAR T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia. <i>Blood Reviews</i> , 2021, 50, 100848.	2.8	4
1493	Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 611-620.	1.9	4
1494	Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. <i>Nature Cancer</i> , 2021, 2, 629-642.	5.7	59
1495	Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. <i>Blood</i> , 2021, 137, 2657-2661.	0.6	15
1496	Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	6
1497	Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1105-1117.	2.5	3

#	ARTICLE	IF	CITATIONS
1498	Expression of NK Cell Receptor Ligands on Leukemic Cells Is Associated with the Outcome of Childhood Acute Leukemia. <i>Cancers</i> , 2021, 13, 2294.	1.7	7
1499	CAR T-Cells for CNS Lymphoma: Driving into New Terrain?. <i>Cancers</i> , 2021, 13, 2503.	1.7	15
1500	Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5449.	1.8	3
1501	CAR T cells – the future for cancer therapy. <i>Medicine</i> , 2021, 49, 322-324.	0.2	0
1502	Place des CAR T cells dans les leucémies aiguës pédiatriques. <i>Perfectionnement En Pédiatrie</i> , 2021, 4, E7-E8.	0.0	0
1504	CAR T cells for T-cell leukemias: Insights from mathematical models. <i>Communications in Nonlinear Science and Numerical Simulation</i> , 2021, 96, 105684.	1.7	16
1505	Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management. <i>Cancer</i> , 2021, 127, 3067-3081.	2.0	18
1506	Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. , 2021, 9, e002328.		31
1507	Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e355-e364.	2.2	43
1508	Immune Cells and Immunotherapy for Cardiac Injury and Repair. <i>Circulation Research</i> , 2021, 128, 1766-1779.	2.0	93
1509	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. , 2021, 9, e002392.		9
1510	A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells. <i>Cellular Immunology</i> , 2021, 363, 104342.	1.4	11
1511	Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients. <i>Medicine (United States)</i> , 2021, 100, e25832.	0.4	10
1512	Advances in Cellular Immunotherapy in Hematologic Malignancies. <i>Advances in Oncology</i> , 2021, 1, 223-236.	0.1	0
1513	An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cells. <i>Cellular Immunology</i> , 2021, 363, 104314.	1.4	5
1514	The antigen-binding moiety in the driver's seat of CARs. <i>Medicinal Research Reviews</i> , 2022, 42, 306-342.	5.0	21
1515	Antibody-based cancer therapy. <i>Oncogene</i> , 2021, 40, 3655-3664.	2.6	42
1516	Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine. <i>British Journal of Haematology</i> , 2021, 194, 158-167.	1.2	5

#	ARTICLE	IF	CITATIONS
1517	Investigation of product-derived lymphoma following infusion of <i>piggyBac</i>-modified CD19 chimeric antigen receptor T cells. <i>Blood</i> , 2021, 138, 1391-1405.	0.6	87
1518	Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. <i>British Journal of Haematology</i> , 2021, 195, 660-668.	1.2	37
1519	Base-edited CAR T cells for combinational therapy against T cell malignancies. <i>Leukemia</i> , 2021, 35, 3466-3481.	3.3	63
1520	Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2022, 22, 85-96.	10.6	315
1522	TARP as antigen in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3061-3068.	2.0	2
1523	CNS relapse of B-lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation: therapy with donor CD19-specific CAR-T cells. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2021, 20, 143-147.	0.1	0
1524	Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland. <i>Advances in Therapy</i> , 2021, 38, 3427-3443.	1.3	14
1525	Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. <i>Journal of Clinical Oncology</i> , 2021, 39, 1650-1659.	0.8	173
1526	Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study. <i>Journal of Affective Disorders</i> , 2021, 286, 33-39.	2.0	6
1527	A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	12
1528	The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 670286.	2.2	16
1529	Nanotechnology synergized immunoengineering for cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 163, 72-101.	2.0	8
1530	Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Genes</i> , 2021, 12, 864.	1.0	4
1531	Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel. <i>American Journal of Hematology</i> , 2021, 96, 1087-1100.	2.0	3
1532	Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 668-678.	1.0	20
1533	CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma. <i>HemaSphere</i> , 2021, 5, e596.	1.2	11
1534	Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo. <i>Journal of Clinical Medicine</i> , 2021, 10, 2634.	1.0	5
1535	Taking a BiTE out of the CAR T space race. <i>British Journal of Haematology</i> , 2021, 195, 689-697.	1.2	5

#	ARTICLE	IF	CITATIONS
1536	Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success. <i>Cancers</i> , 2021, 13, 2816.	1.7	8
1537	Improving the Delivery of Drugs and Nucleic Acids to T Cells Using Nanotechnology. <i>Small Structures</i> , 2021, 2, 2100026.	6.9	7
1538	Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 345-356.	1.2	21
1539	Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. <i>International Journal of Hematologic Oncology</i> , 2021, 10, IJH33.	0.7	11
1540	60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. <i>Cancer Research</i> , 2021, 81, 4373-4384.	0.4	19
1541	Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL. <i>Frontiers in Oncology</i> , 2021, 11, 640166.	1.3	12
1542	Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. <i>Frontiers in Immunology</i> , 2021, 12, 684642.	2.2	57
1543	Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts. , 2021, 9, e001514.		10
1544	CAR T-Cell Therapy: An Update for Radiologists. <i>American Journal of Roentgenology</i> , 2021, 217, 1461-1474.	1.0	20
1545	Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact. <i>Journal of Clinical Oncology</i> , 2021, 39, 1752-1765.	0.8	13
1546	CARTmathâ€”A Mathematical Model of CAR-T Immunotherapy in Preclinical Studies of Hematological Cancers. <i>Cancers</i> , 2021, 13, 2941.	1.7	27
1547	Tisagenlecleucel for treatment of children and young adults with relapsed/refractory Bâ€cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29123.	0.8	15
1548	CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e246-e265.	1.8	27
1549	Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells. <i>Journal of Immunology</i> , 2021, 206, 2862-2874.	0.4	4
1550	Direct long-read RNA sequencing identifies a subset of questionable exons likely arising from reverse transcription artifacts. <i>Genome Biology</i> , 2021, 22, 190.	3.8	20
1551	Molecular-based and antibody-based targeted pharmacological approaches in childhood acute lymphoblastic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1871-1887.	0.9	1
1552	Engineering Gene Therapy: Advances and Barriers. <i>Advanced Therapeutics</i> , 2021, 4, 2100040.	1.6	23
1553	Highly Efficient Transfection of Human Primary T Lymphocytes Using Droplet-Enabled Mechanoporation. <i>ACS Nano</i> , 2021, 15, 12888-12898.	7.3	36

#	ARTICLE	IF	CITATIONS
1554	Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. <i>Cancers</i> , 2021, 13, 2782.	1.7	21
1555	The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. <i>Cells</i> , 2021, 10, 1511.	1.8	3
1556	T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 102.	6.9	64
1557	Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 237-246.	1.8	20
1558	Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients. <i>Journal of Translational Medicine</i> , 2021, 19, 265.	1.8	20
1559	Recent progress in targeted delivery vectors based on biomimetic nanoparticles. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 225.	7.1	115
1560	Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. <i>IScience</i> , 2021, 24, 102619.	1.9	33
1561	Current Status of CAR T Cell Therapy for Leukemias. <i>Current Treatment Options in Oncology</i> , 2021, 22, 62.	1.3	15
1562	MRI Guided Focused Ultrasound-Mediated Delivery of Therapeutic Cells to the Brain: A Review of the State-of-the-Art Methodology and Future Applications. <i>Frontiers in Neurology</i> , 2021, 12, 669449.	1.1	12
1563	HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells. <i>Cancers</i> , 2021, 13, 2857.	1.7	11
1565	Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins. <i>Blood Cancer Journal</i> , 2021, 11, 108.	2.8	17
1566	IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 675179.	1.6	12
1567	Chimeric antigen receptor (CAR) T cells safety: A pharmacovigilance and meta-analysis study. <i>American Journal of Hematology</i> , 2021, 96, 1101-1111.	2.0	14
1568	Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 734-740.	0.2	23
1569	CAR-based cell therapy: evaluation with bibliometrics and patent analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4374-4382.	1.4	2
1570	New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 702644.	1.3	24
1571	Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 42-53.	1.8	5
1572	Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 194, 403-413.	1.2	3

#	ARTICLE	IF	CITATIONS
1573	Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma. <i>Leukemia</i> , 2021, 35, 3581-3584.	3.3	13
1574	Taking Aim at the Undruggable. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e145-e152.	1.8	14
1575	A Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6371.	1.8	8
1576	Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products. <i>Pharmaceutical Research</i> , 2021, 38, 931-945.	1.7	18
1577	Avoiding Stops and Overcoming Roadblocks: Considerations for Improving Patient Access to CAR-Based Cell Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e100-e104.	1.8	17
1578	Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19 ⁺ positive malignancies. <i>Oncology Reports</i> , 2021, 46, .	1.2	12
1579	Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. <i>Leukemia</i> , 2021, 35, 3044-3058.	3.3	29
1580	Immunotherapy in endometrial cancer: rationale, practice and perspectives. <i>Biomarker Research</i> , 2021, 9, 49.	2.8	53
1581	Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 2600-2611.	0.6	9
1582	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. <i>Frontiers in Immunology</i> , 2021, 12, 693016.	2.2	45
1583	Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 773-784.	1.9	8
1584	Anti-CD19 CAR T cells administration was feasible in a child with primary hepatitis B infection. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29208.	0.8	0
1585	Infusion reactions in natural killer cell immunotherapy: a retrospective review. <i>Cytotherapy</i> , 2021, 23, 627-634.	0.3	7
1586	Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. , 2021, 223, 107892.		11
1587	New Insights in Role of Cart-T Cell Therapy in Hematological. <i>The Egyptian Journal of Hospital Medicine</i> , 2021, 84, 1846-1851.	0.0	0
1588	The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 265-277.	3.0	10
1589	Allogeneic hematopoietic cell transplant overcomes the poor prognostic value of CDKN2 deletion in adult B-lineage acute lymphoblastic leukemia. <i>Cancer Letters</i> , 2021, 510, 59-66.	3.2	2
1590	CD4 ⁺ CD25 ⁺ CD127 ^{low} regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. <i>International Immunopharmacology</i> , 2021, 96, 107742.	1.7	7

#	ARTICLE	IF	CITATIONS
1591	CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. <i>Lung Cancer</i> , 2021, 157, 48-59.	0.9	16
1592	Novel strategies for immuno-oncology breakthroughs with cell therapy. <i>Biomarker Research</i> , 2021, 9, 62.	2.8	18
1593	Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. <i>Bone Marrow Transplantation</i> , 2021, 56, 2630-2636.	1.3	11
1594	Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient. <i>Kidney Medicine</i> , 2021, 3, 665-668.	1.0	10
1595	Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada. <i>European Journal of Cancer</i> , 2021, 151, 126-135.	1.3	6
1596	Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1830-1842.	0.6	40
1597	Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123. <i>Viruses</i> , 2021, 13, 1365.	1.5	16
1598	The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. <i>Pharmaceutics</i> , 2021, 13, 1016.	2.0	9
1599	Non-viral transfection technologies for next-generation therapeutic T cell engineering. <i>Biotechnology Advances</i> , 2021, 49, 107760.	6.0	33
1600	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	15.2	273
1601	Exploiting Single-Cell Tools in Gene and Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 702636.	2.2	21
1602	Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. , 2021, 9, e002475.		6
1604	A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. <i>Cell Reports Medicine</i> , 2021, 2, 100344.	3.3	14
1605	A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 715-727.	12.5	136
1607	Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 698607.	1.3	25
1608	Immunotherapy in Glioblastoma: A Clinical Perspective. <i>Cancers</i> , 2021, 13, 3721.	1.7	16
1609	Targeted Therapy in Acute Lymphoblastic Leukaemia. <i>Journal of Personalized Medicine</i> , 2021, 11, 715.	1.1	8
1610	Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation—a report from the Adult Acute Lymphoblastic Leukemia Working Group of the ISTCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2842-2848.	1.3	2

#	ARTICLE	IF	CITATIONS
1611	Acute lymphoblastic leukemia in infants: A quarter century of nationwide efforts in Japan. <i>Pediatrics International</i> , 2022, 64, .	0.2	5
1612	Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future. <i>Frontiers in Immunology</i> , 2021, 12, 718686.	2.2	19
1613	Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. , 2021, 9, e001587.		10
1615	Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29256.	0.8	10
1616	EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations. <i>Neuro-Oncology</i> , 2022, 24, 313-325.	0.6	16
1617	Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. , 2021, 9, e002723.		92
1618	Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology. <i>Biotechnology and Bioengineering</i> , 2021, 118, 3691-3705.	1.7	13
1619	Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 805-811.	1.2	5
1620	CAR T and other Adoptive Cell Therapies for B-cell Malignancies. <i>Journal of the National Cancer Center</i> , 2021, , .	3.0	4
1621	Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing. <i>Clinical Cancer Research</i> , 2021, 27, 6298-6306.	3.2	37
1622	Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review. <i>Advances in Therapy</i> , 2021, 38, 4178-4194.	1.3	4
1623	In Situ Programming of CAR T Cells. <i>Annual Review of Biomedical Engineering</i> , 2021, 23, 385-405.	5.7	33
1624	Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies. <i>Paediatric Drugs</i> , 2021, 23, 445-455.	1.3	1
1625	Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 558-570.	0.6	36
1626	Objectives, benefits and challenges of bioreactor systems for the clinical-scale expansion of T lymphocyte cells. <i>Biotechnology Advances</i> , 2021, 49, 107735.	6.0	9
1627	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , 2021, 9, 1035-1046.	1.6	14
1628	Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7652.	1.8	33
1629	Doing less, accomplishing more for childhood acute lymphoblastic leukaemia (ALL). <i>British Journal of Haematology</i> , 2021, 194, 661-662.	1.2	1

#	ARTICLE	IF	CITATIONS
1630	Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. <i>European Journal of Cancer</i> , 2021, 151, 175-189.	1.3	27
1631	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. <i>Critical Care Medicine</i> , 2022, 50, 81-92.	0.4	13
1632	Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 702642.	1.3	21
1633	Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 831-840.	0.2	1
1634	Clinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e895-e902.	0.2	1
1635	Toxicity of Immunotherapeutic Agents. <i>Critical Care Clinics</i> , 2021, 37, 605-624.	1.0	2
1636	Tumor rejection in <i>Cblb</i> ^Δ mice depends on IL-9 and Th9 cells. , 2021, 9, e002889.		11
1637	Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 131.	2.8	28
1638	Extracorporeal cytokine removal in chimeric antigen receptor T-cell therapy associated cytokine release syndrome in patient with acute lymphoblastic leukemia. Case report. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 811-817.	0.2	1
1639	Toxicities associated with adoptive cellular therapies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101287.	0.7	9
1640	Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. <i>Viruses</i> , 2021, 13, 1528.	1.5	45
1641	CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia. <i>Lancet</i> , The, 2021, 398, 466-467.	6.3	12
1642	Editorial: The Role of Metabolism in MSC-Mediated Immunomodulation. <i>Frontiers in Immunology</i> , 2021, 12, 751865.	2.2	2
1644	Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 3912.	1.7	25
1645	PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches. <i>Cancers</i> , 2021, 13, 4040.	1.7	21
1646	Early-phenotype CAR-T cells for the treatment of pediatric cancers. <i>Annals of Oncology</i> , 2021, 32, 1366-1380.	0.6	14
1647	Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. <i>Stem Cell Research and Therapy</i> , 2021, 12, 465.	2.4	69
1649	Evidence-Based Recommendations for Nurse Monitoring and Management of Immunotherapy-Induced Cytokine Release Syndrome: A Systematic Review from the Children's Oncology Group. <i>Journal of Pediatric Oncology Nursing</i> , 2021, 38, 399-409.	1.5	5

#	ARTICLE	IF	CITATIONS
1650	Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 703087.	1.3	3
1651	Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells. <i>Cytotherapy</i> , 2021, 23, 715-723.	0.3	11
1652	CAR T-Cell Therapy in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8996.	1.8	73
1653	Chimeric antigen receptor T-cells (CARs) in cancer treatment. <i>Current Molecular Pharmacology</i> , 2021, 14, .	0.7	1
1655	Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. <i>BMJ Open</i> , 2021, 11, e046707.	0.8	2
1656	Engineering-enhanced CAR T cells for improved cancer therapy. <i>Nature Cancer</i> , 2021, 2, 780-793.	5.7	60
1658	Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy. <i>Cell Reports Medicine</i> , 2021, 2, 100374.	3.3	30
1659	Advances in Adoptive Cell Therapy for Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 761-768.	0.5	9
1660	The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 3790.	1.0	10
1661	Role of Toll-like receptors in natural killer cell function in acute lymphoblastic leukemia (Review). <i>Oncology Letters</i> , 2021, 22, 748.	0.8	3
1662	Anti-PD-1 blocker to rescue NK activity from PD-1-mediated tumor escape mechanisms. <i>FASEB Journal</i> , 2021, 35, e21750.	0.2	5
1663	Advances in CAR design. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101304.	0.7	4
1664	Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. <i>Leukemia and Lymphoma</i> , 2021, 62, 3333-3347.	0.6	2
1665	Cancer Informatics for Cancer Centers: Scientific Drivers for Informatics, Data Science, and Care in Pediatric, Adolescent, and Young Adult Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 881-896.	1.0	3
1666	TGF- β /IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8706.	1.8	16
1667	Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. <i>Frontiers in Pharmacology</i> , 2021, 12, 720692.	1.6	20
1668	Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 689-703.	2.0	22
1669	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. <i>Lancet, The</i> , 2021, 398, 491-502.	6.3	315

#	ARTICLE	IF	CITATIONS
1670	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 4980-4991.	2.5	12
1671	A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients. <i>Value in Health</i> , 2022, 25, 47-58.	0.1	6
1672	Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T). <i>Cmaj</i> , 2021, 193, E1300-E1302.	0.9	2
1673	A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 4190-4197.	2.0	6
1674	Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner. <i>Frontiers in Immunology</i> , 2021, 12, 717850.	2.2	10
1675	Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models. <i>Cancers</i> , 2021, 13, 4301.	1.7	7
1676	Collapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report. <i>Kidney Medicine</i> , 2021, 3, 1086-1090.	1.0	8
1677	Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 384-393.	1.2	4
1678	Mitochondria as Playmakers of CAR T-cell Fate and Longevity. <i>Cancer Immunology Research</i> , 2021, 9, 856-861.	1.6	12
1679	Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	16
1680	Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia. <i>Experimental Hematology</i> , 2021, 100, 1-11.	0.2	19
1681	NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. , 2021, 9, e002866.		21
1682	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-Î´ and Î³. <i>Frontiers in Immunology</i> , 2021, 12, 718621.	2.2	16
1683	Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 3352-3363.	0.8	59
1684	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	45
1685	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
1686	Current advances in transfusion medicine 2020: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. <i>Transfusion</i> , 2021, 61, 2756-2767.	0.8	1
1687	Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry. <i>Leukemia and Lymphoma</i> , 2021, 62, 3264-3270.	0.6	3

#	ARTICLE	IF	CITATIONS
1688	Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. <i>Science Signaling</i> , 2021, 14, .	1.6	67
1689	Engineering the next generation of CAR-NK immunotherapies. <i>International Journal of Hematology</i> , 2021, 114, 554-571.	0.7	37
1690	Production and Application of CAR T Cells: Current and Future Role of Europe. <i>Frontiers in Medicine</i> , 2021, 8, 713401.	1.2	15
1691	Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2228-2239.	1.9	8
1692	Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101305.	0.7	4
1693	Janus Kinase Inhibitors and Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 740847.	2.2	4
1694	The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. <i>Cancers</i> , 2021, 13, 4701.	1.7	6
1695	CAR T-cell Therapy in Indolent Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S178-S179.	0.2	0
1696	Monitoring and safety of CAR-T therapy in clinical practice. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 363-371.	1.0	0
1697	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. <i>Nature Communications</i> , 2021, 12, 5271.	5.8	17
1698	Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy. <i>Cell Discovery</i> , 2021, 7, 84.	3.1	16
1699	Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells. <i>Blood Reviews</i> , 2021, 51, 100884.	2.8	1
1700	Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 6384-6392.	3.2	27
1701	Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. <i>Immunologic Research</i> , 2021, 69, 471-486.	1.3	8
1702	Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race. <i>JCO Oncology Practice</i> , 2022, 18, e193-e203.	1.4	0
1703	Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children. <i>Bone Marrow Transplantation</i> , 2021, 56, 2981-2989.	1.3	3
1704	Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. , 2021, 9, e003149.		28
1705	The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. <i>Annals of Hematology</i> , 2021, 100, 3017-3027.	0.8	0

#	ARTICLE	IF	CITATIONS
1706	Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting. <i>Stem Cell Investigation</i> , 2021, 8, 18-18.	1.3	12
1707	Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2021, 138, 2138-2142.	0.6	5
1708	Inflammaging, an Imbalanced Immune Response That Needs to Be Restored for Cancer Prevention and Treatment in the Elderly. <i>Cells</i> , 2021, 10, 2562.	1.8	13
1709	Recent advances in regenerative medicine strategies for cancer treatment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111875.	2.5	38
1710	Establishing a robust chimeric antigen receptor T-cell therapy program in Australia: the Royal Prince Alfred Hospital experience. <i>Cytotherapy</i> , 2022, 24, 45-48.	0.3	2
1711	Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. <i>International Journal of Hematology</i> , 2021, 114, 544-553.	0.7	6
1713	Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproduction. <i>Reproductive BioMedicine Online</i> , 2022, 44, 81-92.	1.1	6
1714	Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse. <i>Cancer Research and Treatment</i> , 2022, 54, 917-925.	1.3	9
1715	Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia—Therapy and Toxicity Mechanisms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9827.	1.8	13
1716	Hematopathologic Correlates of CAR T-Cell Therapy. <i>Clinics in Laboratory Medicine</i> , 2021, 41, 325-339.	0.7	3
1718	Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy. <i>Cancers</i> , 2021, 13, 4785.	1.7	15
1719	Haematological problems in the intensive care unit. <i>Anaesthesia and Intensive Care Medicine</i> , 2021, , .	0.1	0
1720	Recent Advances in Pediatric Cancer Research. <i>Cancer Research</i> , 2021, 81, 5783-5799.	0.4	8
1721	The Evolving Role of Radiotherapy for Pediatric Cancers With Advancements in Molecular Tumor Characterization and Targeted Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 679701.	1.3	6
1722	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021, 5, 4465-4475.	2.5	28
1723	Genomics in medicine: A new era in medicine. <i>World Journal of Methodology</i> , 2021, 11, 231-242.	1.1	5
1724	Future generation of combined multimodal approach to treat brain glioblastoma multiforme and potential impact on micturition control. <i>Reviews in the Neurosciences</i> , 2022, 33, 313-326.	1.4	1
1725	Anti-tumor effects of vascular endothelial growth factor/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells. <i>Cytotherapy</i> , 2021, 23, 810-819.	0.3	14

#	ARTICLE	IF	CITATIONS
1726	Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 3044-3055.	0.8	94
1727	State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 973-987.	0.6	25
1728	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. <i>Cancers</i> , 2021, 13, 4797.	1.7	12
1729	Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia. <i>Current Opinion in Hematology</i> , 2021, 28, 373-379.	1.2	10
1730	Optimal Time for CAR T: Is it Time of MRD?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S102-S103.	0.2	0
1731	Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy. <i>Clinical Lung Cancer</i> , 2022, 23, 14-20.	1.1	4
1732	Engineering stem cells for cancer immunotherapy. <i>Trends in Cancer</i> , 2021, 7, 1059-1073.	3.8	22
1733	Bortezomib-based Anthracycline-free Induction for Pediatric Relapsed ALL as a Bridge to Immunotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, .	0.3	1
1734	Chimeric antigen receptor T cell therapy in cancer: Advances and challenges. <i>Aging Pathobiology and Therapeutics</i> , 2021, 3, 46-47.	0.3	0
1735	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. <i>The Cochrane Library</i> , 2021, 2021, CD013365.	1.5	18
1736	Hematopoietic stem cell transplantation for infants with high-risk <i>KMT2A</i> gene rearranged acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 3891-3899.	2.5	12
1737	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6580-6590.	3.2	15
1738	New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology. <i>Biomedicines</i> , 2021, 9, 1201.	1.4	4
1739	Antigen Loss after Targeted Immunotherapy in Hematological Malignancies. <i>Clinics in Laboratory Medicine</i> , 2021, 41, 341-357.	0.7	7
1740	Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment. <i>Oral Oncology</i> , 2021, 120, 105420.	0.8	20
1741	Options for imaging cellular therapeutics in vivo: a multi-stakeholder perspective. <i>Cytotherapy</i> , 2021, 23, 757-773.	0.3	9
1742	Individual cell-based modeling of tumor cell plasticity-induced immune escape after CAR-T therapy. <i>Computational and Systems Oncology</i> , 2021, 1, e21029.	1.1	1
1743	Conditional control of chimeric antigen receptor T-cell activity through a destabilizing domain switch and its chemical ligand. <i>Cytotherapy</i> , 2021, 23, 1085-1096.	0.3	2

#	ARTICLE	IF	CITATIONS
1744	The promise and perils of immunotherapy. <i>Blood Advances</i> , 2021, 5, 3709-3725.	2.5	23
1745	Therapeutic cancer vaccines revamping: technology advancements and pitfalls. <i>Annals of Oncology</i> , 2021, 32, 1537-1551.	0.6	36
1746	CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29323.	0.8	8
1747	Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 407-421.	1.4	1
1748	Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors. <i>Human Gene Therapy</i> , 2021, 32, 1011-1028.	1.4	14
1749	Titratable Pharmacological Regulation of CAR T Cells Using Zinc Finger-Based Transcription Factors. <i>Cancers</i> , 2021, 13, 4741.	1.7	7
1750	CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?. <i>Cancers</i> , 2021, 13, 4664.	1.7	10
1751	Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?. <i>Cytotherapy</i> , 2021, 23, 985-990.	0.3	12
1752	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. <i>Blood</i> , 2022, 139, 1026-1038.	0.6	67
1753	BCMA in Multiple Myeloma—A Promising Key to Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4088.	1.0	25
1754	Short- and Long-Term Outcomes of Hematologic Malignancy Patients After Cardiopulmonary Resuscitation: Experience of a Large Oncology Center. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 705-714.	0.2	1
1755	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1079-1109.	2.3	96
1756	Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy. <i>Tissue Engineering and Regenerative Medicine</i> , 2022, 19, 263-280.	1.6	11
1757	CAR T cells in CNS-relapsed leukaemia: one step forward. <i>Lancet Haematology</i> , 2021, 8, e675-e676.	2.2	1
1758	The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2021, 109, 106647.	0.4	2
1759	CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. <i>Lancet Haematology</i> , 2021, 8, e711-e722.	2.2	57
1760	Stuck Moments and Silver-Linings: The Spectrum of Adaptation Among Non-Bereaved and Bereaved Parents of Adolescents and Young Adults With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 709-719.	0.6	13
1761	Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria. <i>Frontiers in Neurology</i> , 2021, 12, 706169.	1.1	21

#	ARTICLE	IF	CITATIONS
1762	Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 5387-5395.	2.5	7
1763	Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma. <i>Translational Oncology</i> , 2021, 14, 101227.	1.7	2
1764	Chimeric antigen receptor T-cell therapy: An emergency medicine focused review. <i>American Journal of Emergency Medicine</i> , 2021, 50, 369-375.	0.7	2
1765	Advances in clinical immunotherapy for gastric cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188615.	3.3	153
1766	Delivery strategies to overcome tumor immunotherapy resistance. , 2022, , 529-547.		0
1767	Comparison of therapeutic strategies for immuno-oncology. , 2022, , 439-461.		0
1768	Improving the safety of iPSC-derived T cell therapy. , 2022, , 95-115.		3
1769	Adoptive Cell Therapy. , 2021, , 419-427.		0
1770	Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2021, 10, 35.	2.5	11
1771	Cellular Therapy. <i>Organ and Tissue Transplantation</i> , 2021, , 741-761.	0.0	0
1772	Pediatric Bone Marrow Transplantation. <i>Organ and Tissue Transplantation</i> , 2021, , 577-616.	0.0	0
1773	The process of modern drug development and the challenge of young patients. , 2021, , 1-12.		0
1774	Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report. <i>Leukemia Research Reports</i> , 2021, 15, 100241.	0.2	0
1775	Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy. <i>Pharmaceuticals</i> , 2021, 14, 57.	1.7	27
1776	Ultrasensitive Detection and Depletion of Rare Leukemic B Cells in T Cell Populations via Immunomagnetic Cell Ranking. <i>Analytical Chemistry</i> , 2021, 93, 2327-2335.	3.2	10
1777	A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1236-1253.	0.9	6
1778	Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. <i>Oncolmmunology</i> , 2021, 10, 1959102.	2.1	19
1779	Bcl-2 Enhances Chimeric Antigen Receptor T Cell Persistence by Reducing Activation-Induced Apoptosis. <i>Cancers</i> , 2021, 13, 197.	1.7	20

#	ARTICLE	IF	CITATIONS
1780	Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. <i>Clinical and Translational Immunology</i> , 2021, 10, e1286.	1.7	11
1781	Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds. <i>Aging Cell</i> , 2021, 20, e13309.	3.0	14
1782	High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Clinical Hematology International</i> , 2021, 3, 96.	0.7	7
1783	Cancer Immunotherapy. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 1-41.	0.1	0
1784	Study on Relationships of Tumor Status and Gene Polymorphism With Blood Concentration of MTX and Toxicities in 63 Pediatric Mature B Cell Lymphoma in Chinese Population. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382199528.	0.8	5
1785	Glycans as Targets and Mediators of T-Cell Immunotherapy. , 2021, , 508-518.		0
1786	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 271.	1.7	39
1787	CAR T Cells for Hematologic Malignancies. , 2021, , 829-846.		0
1789	Introduction: specific disease areas. , 2021, , 43-262.		0
1790	Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 363-378.	12.5	37
1791	Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. <i>Cancer Gene Therapy</i> , 2021, 28, 1365-1375.	2.2	18
1792	Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea. <i>Cancer Research and Treatment</i> , 2021, 53, 1184-1194.	1.3	3
1793	Infectious complications of CAR T-cell therapy: a clinical update. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110367.	1.1	28
1794	Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. <i>Nature Communications</i> , 2021, 12, 409.	5.8	109
1795	Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28870.	0.8	8
1796	Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System. <i>Methods in Molecular Biology</i> , 2020, 2086, 131-137.	0.4	5
1797	Engineering T Cells Using CRISPR/Cas9 for Cancer Therapy. <i>Methods in Molecular Biology</i> , 2020, 2115, 419-433.	0.4	8
1798	Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview. <i>Methods in Molecular Biology</i> , 2021, 2174, 219-244.	0.4	7

#	ARTICLE	IF	CITATIONS
1801	CAR T-Cells. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 215-233.	0.8	24
1802	Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1257, 109-131.	0.8	7
1803	Chimeric Antigen Receptors for the Tumour Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1263, 117-143.	0.8	8
1804	Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. <i>Journal of Gastroenterology</i> , 2020, 55, 369-382.	2.3	48
1805	Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 294-304.	1.2	17
1806	Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia. <i>Current Oncology Reports</i> , 2020, 22, 11.	1.8	13
1807	Emerging CAR landscape for cancer immunotherapy. <i>Biochemical Pharmacology</i> , 2020, 178, 114051.	2.0	6
1810	Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors. <i>Cancer Letters</i> , 2020, 487, 1-9.	3.2	22
1811	Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 632-636.e1.	0.2	31
1812	Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 699-707.	1.2	27
1813	Traitement des leucémies aiguës de l'enfant: aujourd'hui et demain. <i>Perfectionnement En Pédiatrie</i> , 2018, 1, 185-191.	0.0	1
1814	Building better CAR-T therapies. <i>Nature</i> , 2020, 585, S4-S6.	13.7	3
1815	Cytokine IL-36 β improves CAR T-cell functionality and induces endogenous antitumor response. <i>Leukemia</i> , 2021, 35, 506-521.	3.3	31
1816	Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells. <i>Cellular and Molecular Immunology</i> , 2020, 17, 600-612.	4.8	82
1817	MR1-restricted T cells: the new dawn of cancer immunotherapy. <i>Bioscience Reports</i> , 2020, 40, .	1.1	5
1818	Immunotherapies and immunomodulatory approaches in clinical trials - a mini review. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1897-1909.	1.4	23
1819	STING agonist promotes CAR T cell trafficking and persistence in breast cancer. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	84
1820	Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell Infusion. , 2020, 2, e0071.		22

#	ARTICLE	IF	CITATIONS
1821	Combination Therapy With Chemotherapy, Donor Lymphocyte Infusion With Concurrent Blinatumomab in Relapsed/Refractory Acute Precursor B-Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e280-e283.	0.3	2
1822	Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, 152-154.	0.3	9
1829	Boosting engineered T cells. <i>Science</i> , 2019, 365, 119-120.	6.0	10
1830	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
1831	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
1832	A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 599-613.	7.7	90
1833	Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 645-660.	0.9	31
1834	ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. <i>JCI Insight</i> , 2019, 4, .	2.3	139
1835	Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkinâ€™s lymphoma. <i>JCI Insight</i> , 2019, 4, .	2.3	14
1836	T cell optimization for graft-versus-leukemia responses. <i>JCI Insight</i> , 2020, 5, .	2.3	23
1837	T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 1551-1565.	3.9	108
1838	CD19 CAR T cell product and disease attributes predict leukemia remission durability. <i>Journal of Clinical Investigation</i> , 2019, 129, 2123-2132.	3.9	244
1839	Chimeric antigen receptorâ€™induced BCL11B suppression propagates NK-like cell development. <i>Journal of Clinical Investigation</i> , 2019, 129, 5108-5122.	3.9	16
1840	Improving CAR T cell immunotherapyâ€™mediated remissions for pediatric leukemia. <i>Journal of Clinical Investigation</i> , 2019, 129, 1842-1844.	3.9	7
1841	State of the art in CAR T cell therapy for CD19+ B cell malignancies. <i>Journal of Clinical Investigation</i> , 2020, 130, 1586-1594.	3.9	74
1842	Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. <i>Journal of Clinical Investigation</i> , 2020, 130, 3087-3097.	3.9	110
1843	Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 4652-4662.	3.9	27
1844	Replacing CAR-T cell resistance with persistence by changing a single residue. <i>Journal of Clinical Investigation</i> , 2020, 130, 2806-2808.	3.9	10

#	ARTICLE	IF	CITATIONS
1845	Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. <i>Journal of Clinical Investigation</i> , 2020, 130, 6317-6324.	3.9	66
1846	Sleeping Beautyâ€“engineered CAR T cells achieve antileukemic activity without severe toxicities. <i>Journal of Clinical Investigation</i> , 2020, 130, 6021-6033.	3.9	102
1847	Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. <i>Blood</i> , 2020, 136, 516-519.	0.6	25
1848	Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. <i>Blood Advances</i> , 2020, 4, 5702-5715.	2.5	24
1849	Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 24-29.	0.9	16
1850	Moving immunotherapy into the front line in ALL. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 209-217.	0.9	13
1851	Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 487-493.	0.9	6
1852	Philadelphia Chromosomeâ€“Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>JCO Oncology Practice</i> , 2020, 16, 231-238.	1.4	4
1853	New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies. <i>F1000Research</i> , 2019, 8, 1202.	0.8	3
1854	Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. <i>European Journal of Case Reports in Internal Medicine</i> , 2020, 7, 1.	0.2	17
1855	Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. <i>Oncotarget</i> , 2019, 10, 2384-2396.	0.8	119
1856	Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. <i>Therapeutics and Clinical Risk Management</i> , 2020, 16, 705-714.	0.9	40
1857	A Review of Gene Therapy Delivery Systems for Intervertebral Disc Degeneration. <i>Current Pharmaceutical Biotechnology</i> , 2020, 21, 194-205.	0.9	24
1858	Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 433-457.	1.0	33
1859	A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. <i>Immunotherapy</i> , 2020, 12, 681-696.	1.0	14
1860	Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. <i>Immunotherapy</i> , 2020, 12, 1341-1357.	1.0	3
1861	A brief history of CAR-T cells: from laboratory to the bedside. <i>Acta Haematologica Polonica</i> , 2020, 51, 2-5.	0.1	32
1862	Road to clinical implementation of CAR-T technology in PoznaÅ„. <i>Acta Haematologica Polonica</i> , 2020, 51, 24-28.	0.1	4

#	ARTICLE	IF	CITATIONS
1863	Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 1284-1315.	3.0	12
1864	Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies. <i>Clinical Hematology International</i> , 2019, 1, 79.	0.7	15
1865	Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia. <i>Clinical Hematology International</i> , 2019, 1, 85-93.	0.7	12
1866	CART Cell Toxicities: New Insight into Mechanisms and Management. <i>Clinical Hematology International</i> , 2020, 2, 149.	0.7	19
1867	Pediatric acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, 2524-2539.	1.7	313
1868	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. <i>Haematologica</i> , 2022, 107, 437-445.	1.7	63
1869	Cytokines in CAR T Cell-Associated Neurotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 577027.	2.2	110
1870	Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 580328.	2.2	29
1871	CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 697.	1.3	129
1872	The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities. <i>Cancers</i> , 2021, 13, 38.	1.7	17
1873	Why Immunotherapy Fails in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 1-42.	0.2	5
1874	The Role of Immune Checkpoints after Cellular Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3650.	1.8	7
1875	Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 113-120.	0.6	10
1876	Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. <i>World Journal of Gastroenterology</i> , 2019, 25, 3136-3150.	1.4	51
1877	Exploring the food-gut axis in immunotherapy response of cancer patients. <i>World Journal of Gastroenterology</i> , 2020, 26, 4919-4932.	1.4	17
1878	CAR T cell therapy for gastric cancer: Potential and perspective (Review). <i>International Journal of Oncology</i> , 2020, 56, 889-899.	1.4	5
1879	Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?. <i>Korean Circulation Journal</i> , 2020, 50, 743.	0.7	6
1880	Cancer Immunotherapy: An Impossible Dream for the Common Man?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 312-316.	0.1	1

#	ARTICLE	IF	CITATIONS
1881	Identification of genomic features associated with immunotherapy response in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 270-280.	0.8	8
1882	Too Many Avoidable Suicides Occur Worldwide in Young Patients. <i>Rambam Maimonides Medical Journal</i> , 2019, 10, e0026.	0.4	6
1883	Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 8, .	0.2	3
1884	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 81-112.	2.3	102
1885	Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 899-906.	2.3	24
1886	Cardiovascular Risk Profile of Chimeric Antigen Receptor T-cell Therapy. <i>Cureus</i> , 2020, 12, e7436.	0.2	2
1887	Nanoparticle Systems Applied for Immunotherapy in Various Treatment Modalities. <i>Bioanalysis</i> , 2021, , 117-142.	0.1	0
1888	Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	4
1889	Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment. <i>In Vivo</i> , 2021, 35, 3407-3411.	0.6	3
1890	Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL). <i>Cancer Treatment and Research</i> , 2021, 181, 179-196.	0.2	2
1891	Current Management and New Developments in the Treatment of ALL. <i>Cancer Treatment and Research</i> , 2021, 181, 75-96.	0.2	0
1892	Current and Emerging Therapies for Acute Myeloid Leukemia. <i>Cancer Treatment and Research</i> , 2021, 181, 57-73.	0.2	2
1893	Leukemic and Lymphomatous Optic Neuropathy: A Case Series. <i>Journal of Neuro-Ophthalmology</i> , 2021, 41, e796-e802.	0.4	0
1894	Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1608-1618.	2.5	15
1895	“Off-the-Shelf” Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells. <i>Cells</i> , 2021, 10, 2631.	1.8	7
1896	Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2021, 12, 745320.	2.2	41
1897	An overview of multiplexed analyses of CAR T-cell therapies: insights and potential. <i>Expert Review of Proteomics</i> , 2021, 18, 767-780.	1.3	2
1898	Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 31.e1-31.e9.	0.6	8

#	ARTICLE	IF	CITATIONS
1899	The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11385.	1.8	7
1900	Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells. <i>Human Gene Therapy</i> , 2021, 32, 1044-1058.	1.4	35
1902	Since everyone has a donor, why are some eligible patients still not transplanted?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101321.	0.7	1
1904	Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. , 2021, 9, e003499.		23
1905	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 5-17.	0.6	4
1906	Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 21-29.	0.6	31
1907	CRISPR-derived genome editing therapies: Progress from bench to bedside. <i>Molecular Therapy</i> , 2021, 29, 3125-3139.	3.7	14
1908	Cytokine release syndrome after CAR infusion in pediatric patients with refractory/relapsed B-ALL: is there a role for diclofenac?. <i>Tumori</i> , 2021, , 030089162110533.	0.6	1
1909	Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 138-148.	1.9	9
1910	TNF α increases the risk of bleeding in patients after CAR T cell therapy: A bleeding model based on a real-world study of Chinese CAR T Working Party. <i>Hematological Oncology</i> , 2022, 40, 64-72.	0.8	5
1911	CAR T-cell therapy and critical care. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1318-1325.	1.0	18
1912	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 367.	7.1	31
1913	Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	5
1914	Central Nervous System Metastases. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 161-188.	0.9	10
1915	The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151216.	0.7	13
1916	CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. <i>Journal of Hematology and Oncology</i> , 2021, 14, 162.	6.9	28
1917	Novel Adaptive T-Cell Oncological Treatments Lead to New Challenges for Medical Emergency Teams: A 2-Year Experience From a Tertiary-Care Hospital in Switzerland. , 2021, 3, e0552.		1
1918	CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1797-1805.	15.2	125

#	ARTICLE	IF	CITATIONS
1919	Upregulation of CD22 by Chidamide promotes CAR T cells functionality. <i>Scientific Reports</i> , 2021, 11, 20637.	1.6	10
1920	Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. <i>NeuroMolecular Medicine</i> , 2022, 24, 35-40.	1.8	6
1921	Current Status of CAR-T Cell Therapy in Multiple Myeloma. <i>Hemato</i> , 2021, 2, 660-671.	0.2	2
1922	Regenerative Medicine and Angiogenesis; Focused on Cardiovascular Disease. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	2
1923	The cure of leukemia through the optimist's prism. <i>Cancer</i> , 2022, 128, 240-259.	2.0	17
1924	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. <i>British Journal of Haematology</i> , 2022, 197, 28-40.	1.2	9
1925	Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival In Vivo With Low Cytokines Release. <i>Frontiers in Immunology</i> , 2021, 12, 724211.	2.2	10
1926	Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma. <i>Molecular Therapy</i> , 2022, 30, 534-549.	3.7	20
1927	Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. <i>Nature Nanotechnology</i> , 2021, 16, 1424-1434.	15.6	78
1928	Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 419-431.	3.0	1
1929	Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101331.	0.7	6
1930	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 529-535.	2.0	17
1931	The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. <i>International Reviews of Immunology</i> , 2022, 41, 649-668.	1.5	7
1932	CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 728962.	2.2	11
1934	Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy. <i>Cytotherapy</i> , 2021, , .	0.3	2
1935	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. <i>Molecular Therapy</i> , 2022, 30, 579-592.	3.7	29
1936	Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1800-1813.	1.2	55
1937	Preclinical pharmacology modeling of chimeric antigen receptor T therapies. <i>Current Opinion in Pharmacology</i> , 2021, 61, 49-61.	1.7	11

#	ARTICLE	IF	CITATIONS
1938	Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 359-369.	1.8	7
1939	Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo. <i>Experimental Cell Research</i> , 2021, 409, 112886.	1.2	15
1940	PD-1 and CTLA-4 Inhibitors in the Treatment of Cutaneous Melanoma. <i>Skin Cancer</i> , 2018, 33, 129-133.	0.1	1
1941	In Vivo and In-stantaneous Production of Chimeric Antigen Receptor T Cells: Overcoming Treatment Delays. , 2018, 15, .		0
1942	Prise en charge des cellules CAR-T au sein des établissements de santé français : fabrication, distribution, et aspects réglementaires. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 1431-1440.	0.0	1
1943	Game changers in pediatric cancer. <i>Journal of Community and Supportive Oncology</i> , 2018, 16, e210-e216.	0.1	0
1944	Acute Lymphoblastic Leukemia in Adults. , 2019, , 531-538.		4
1946	Therapy for relapsed multiple myeloma. <i>Panminerva Medica</i> , 2018, 60, 174-184.	0.2	1
1947	From Aminopterin to Tisagenlecleucel: Childhood Acute Lymphoblastic Leukemia at the Forefront of Cancer Breakthroughs. , 2019, 16, .		0
1948	Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit. , 2019, , 1-27.		0
1949	Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies. <i>Clinical Hematology International</i> , 2019, 1, 2.	0.7	8
1950	Introduction to Melanoma Immunology. , 2019, , 1-15.		0
1951	Zulassungsverfahren für neue Arzneimittel in Europa. , 2019, , 31-60.		6
1952	Melanoma Immunology and Immunotherapy. , 2019, , 1-15.		0
1953	Neue Arzneimittel 2018. , 2019, , 61-175.		1
1954	Cancer Therapy. , 2019, , 7-76.		0
1955	Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia. <i>Clinical Pediatric Hematology-Oncology</i> , 2019, 26, 12-26.	0.0	0
1957	III. Chimeric Antigen Receptor T-cell Immune Therapy. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2019, 108, 1375-1383.	0.0	0

#	ARTICLE	IF	CITATIONS
1958	El trasplante alogéneo de progenitores hematopoyéticos en la era de las nuevas terapias en la leucemia linfoblástica aguda. Medicina Clínica, 2019, 153, 28-34.	0.3	2
1961	Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care. , 2020, , 2035-2047.		0
1962	Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit. , 2020, , 201-227.		0
1963	Adding chimeric antigen receptor-induced killer cells to the medical oncology shelf. Journal of Clinical Investigation, 2019, 129, 5077-5078.	3.9	3
1964	Relapsed Pediatric ALL. , 2020, , 123-139.		0
1965	Adolescents and Young Adults with Acute Lymphoblastic Leukemia. , 2020, , 109-122.		0
1966	Infant ALL. , 2020, , 81-91.		0
1968	Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1448-1450.	2.3	0
1969	BASICS OF CAR-T CELL THERAPY AND ITS FUTURE DEVELOPMENT. Japanese Journal of Transfusion and Cell Therapy, 2019, 65, 851-857.	0.1	0
1970	New drug: Tisagenlecleucel for B-cell cancers. Australian Prescriber, 2020, 43, 30-31.	0.5	2
1971	Biopharmaceutical molecules. , 2020, , 31-68.		1
1972	CAR Design, Independent of Costimulatory Domain, Impacts Safety and Immunogenicity of CAR T-cell Therapy. , 2020, 17, .		1
1974	Endocrine Toxicities of Immunotherapy. , 2020, , 187-200.		0
1975	CAR-T cell therapy for Acute Lymphoblastic Leukemia. Journal of Hematopoietic Cell Transplantation, 2020, 9, 93-99.	0.1	0
1976	Chimeric antigen receptor (CAR)-T cell therapy. Okayama Igakkai Zasshi, 2020, 132, 34-36.	0.0	0
1977	Immunotherapy in Pediatric Solid Tumors. Clinical Pediatric Hematology-Oncology, 2020, 27, 22-31.	0.0	1
1978	Leucemia aguda linfoblástica: de la aminopterina a las células CAR T. Medicina Clínica, 2020, 154, 269-274.	0.3	1
1982	Síndrome de neurotoxicidad asociada a células inmunoefectoras: un enfoque terapéutico en el paciente crítico. Medicina Intensiva, 2022, 46, 201-212.	0.4	2

#	ARTICLE	IF	CITATIONS
1983	Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 460-466.	2.0	24
1984	Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 633-643.	1.8	5
1985	Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives. <i>Cancers</i> , 2021, 13, 5387.	1.7	11
1986	High-Throughput and Dosage-Controlled Intracellular Delivery of Large Cargos by an Acoustic-Electric Microvortices Platform. <i>Advanced Science</i> , 2022, 9, e2102021.	5.6	18
1987	Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia. <i>Cancer Science</i> , 2021, , .	1.7	3
1988	Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours. <i>Cells</i> , 2021, 10, 2940.	1.8	5
1989	Specific Inhibitor of Placental Alkaline Phosphatase Isolated from a DNA-Encoded Chemical Library Targets Tumor of the Female Reproductive Tract. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15799-15809.	2.9	8
1990	Systematic review of nutrition support interventions in adult haematology and oncology patients receiving CAR T cell therapy. <i>Clinical Nutrition ESPEN</i> , 2021, 46, 60-65.	0.5	3
1991	Will immunotherapy lead to a breakthrough in the treatment of older adults with ALL?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101319.	0.7	1
1992	Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward. <i>Frontiers in Immunology</i> , 2021, 12, 765097.	2.2	20
1993	Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways. <i>Journal of Investigative Dermatology</i> , 2022, 142, 907-914.	0.3	21
1994	CAR T Cell Therapy's Potential for Pediatric Brain Tumors. <i>Cancers</i> , 2021, 13, 5445.	1.7	10
1995	Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis. <i>Cancers</i> , 2021, 13, 5489.	1.7	2
1996	Biological Therapies in the Treatment of Cancer—Update and New Directions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11694.	1.8	17
1997	CAR-NK Cells from Engineered Pluripotent Stem Cells: Off-the-shelf Therapeutics for all Patients. <i>Stem Cells Translational Medicine</i> , 2021, 10, S10-S17.	1.6	11
1998	GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2643-2652.	1.2	31
1999	CAR-T Cell Clinical Trials Experience – Past, Present and Future. , 2020, , 303-375.		0
2000	Introduction of Chimeric Antigen Receptor T-cell therapy, Tisagenlecleucel in Japan. <i>Drug Delivery System</i> , 2020, 35, 71-75.	0.0	1

#	ARTICLE	IF	CITATIONS
2001	HSCT in Malignancies. Organ and Tissue Transplantation, 2020, , 1-16.	0.0	0
2002	The Future of Transplantation: Hope, Investigative Discipline, and Fairness. Organ and Tissue Transplantation, 2020, , 1-8.	0.0	0
2004	Cellular Immunotherapy Treatment Scheduling to Address Antigen Escape. , 2020, , .		3
2005	REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021012.	0.5	5
2007	Emerging Therapeutic Options in Acute Lymphoblastic Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1781-1784.	2.3	0
2009	Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma. Therapeutic Advances in Hematology, 2021, 12, 204062072110531.	1.1	4
2010	Nonclinical drug development. , 2022, , 573-588.		0
2011	Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity. Current Opinion in Immunology, 2022, 74, 39-45.	2.4	13
2012	T Cell Receptor Engineered T Cell Therapy in Oncology. , 2020, , 377-408.		0
2013	Bringing Immunotherapy to the Front Line in Childhood Leukemia. , 2020, 17, .		0
2014	Commentary on: Combination of Metabolic Intervention and T Cell Therapy Enhances Solid Tumor Immunotherapy. Immunometabolism, 2021, 3, .	0.7	2
2015	Oncologie bij kinderen. , 2020, , 643-651.		0
2016	Pediatric Bone Marrow Transplantation. Organ and Tissue Transplantation, 2020, , 1-41.	0.0	0
2018	Les th�rapeutiques du cancer. , 2020, , 36-47.e1.		1
2020	Akute Leuk�mien. , 2020, , 375-402.		0
2021	Neurological Toxicities of Immunotherapy. , 2020, , 223-242.		0
2022	The Paradigm of Early Phase Studies in Hematological Malignancies. , 2020, , 297-311.		0
2023	CD19 Chimeric Antigen Receptor Natural Killer Cells Can Safely Induce Remission in Lymphoid Malignancies. , 2020, 17, .		0

#	ARTICLE	IF	CITATIONS
2024	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
2026	Infections following CAR-T cells therapy: current state-of-the-art review and recommendations. Acta Haematologica Polonica, 2020, 51, 11-16.	0.1	7
2027	Adoptive Cell Therapies: Keeping Pace With New and Emerging Advances. Journal of the Advanced Practitioner in Oncology, 2020, 11, 240-244.	0.2	0
2028	Immunotherapy in Pediatric Hematologic Malignant Neoplasms. Clinical Pediatric Hematology-Oncology, 2020, 27, 14-21.	0.0	0
2029	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Advances, 2022, 6, 2055-2068.	2.5	60
2030	Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies. Biomedicines, 2021, 9, 1631.	1.4	3
2031	Generation of an NF κ B-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy. Frontiers in Immunology, 2021, 12, 751138.	2.2	11
2032	Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interaction. Scientific Reports, 2021, 11, 21902.	1.6	12
2033	Microfluidic transfection of mRNA into human primary lymphocytes and hematopoietic stem and progenitor cells using ultra-fast physical deformations. Scientific Reports, 2021, 11, 21407.	1.6	17
2034	Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients. Frontiers of Medicine, 2021, , 1.	1.5	1
2035	Hematopoietic Stem Cells and Regeneration. Cold Spring Harbor Perspectives in Biology, 2022, 14, a040774.	2.3	3
2036	Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application. Frontiers in Oncology, 2021, 11, 763806.	1.3	6
2037	Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. International Journal of Molecular Sciences, 2021, 22, 12015.	1.8	9
2038	Teenagers and young adults with a past of allogeneic hematopoietic stem cell transplantation are at significant risk of chronic kidney disease. Pediatric Nephrology, 2021, , 1.	0.9	0
2039	Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia (Review). Oncology Letters, 2020, 20, 36.	0.8	2
2040	Optimal therapy for adolescents and young adults with acute lymphoblastic leukemia-current perspectives. Blood Research, 2020, 55, S27-S31.	0.5	3
2041	Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL). Hematologic Malignancies, 2021, , 193-204.	0.2	0
2042	Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia. Hematologic Malignancies, 2021, , 205-218.	0.2	0

#	ARTICLE	IF	CITATIONS
2043	Ph-Like ALL: Diagnosis and Management. Hematologic Malignancies, 2021, , 235-247.	0.2	0
2044	Management of Relapsed and Refractory ALL. Hematologic Malignancies, 2021, , 277-289.	0.2	0
2045	Immunotherapy for Pediatric Sarcomas. Pediatric Oncology, 2021, , 165-180.	0.5	0
2047	Isolated Intraocular Relapse of Pediatric B-cell Precursor Acute Lymphoblastic Leukaemia Following Chimeric Antigen Receptor T-lymphocyte Therapy. Cureus, 2020, 12, e10937.	0.2	4
2048	A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. Aging, 2020, 12, 18741-18753.	1.4	19
2050	CAR T-cells: hot news in cancer therapy. Vnitřní Lekarství, 2020, 66, 420-424.	0.1	0
2051	A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?. Archives of Pathology and Laboratory Medicine, 2021, 145, 704-716.	1.2	1
2052	Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia. Journal of the Advanced Practitioner in Oncology, 2018, 9, 537-544.	0.2	6
2056	Innovative strategies to advance CAR T cell therapy for solid tumors. American Journal of Cancer Research, 2020, 10, 1979-1992.	1.4	2
2057	Fueling chimeric antigen receptor T cells with cytokines. American Journal of Cancer Research, 2020, 10, 4038-4055.	1.4	5
2058	A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. American Journal of Cancer Research, 2021, 11, 3285-3293.	1.4	0
2059	High Prevalence of PNH-phenotype Cells in Patients Who Received CD19-targeted CAR T-cell Therapy. HemaSphere, 2021, 5, e628.	1.2	0
2061	Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. Current Research in Translational Medicine, 2022, 70, 103320.	1.2	9
2062	Hematopoietic stem cell transplantation and cellular therapy. , 2022, , 623-657.		0
2063	Immunotherapie. , 2022, , 53-58.		0
2064	Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature. Cancers, 2021, 13, 5814.	1.7	3
2065	Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse. Transplantation and Cellular Therapy, 2022, 28, 71.e1-71.e8.	0.6	6
2066	Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union. Frontiers in Pharmacology, 2021, 12, 773712.	1.6	9

#	ARTICLE	IF	CITATIONS
2067	Targeting tumor microenvironment and metastasis in children with solid tumors. <i>Current Opinion in Pediatrics</i> , 2022, 34, 53-60.	1.0	7
2068	Sensitivity and Specificity of CD19-CAR-T Cell Detection by Flow Cytometry and PCR. <i>Cells</i> , 2021, 10, 3208.	1.8	13
2069	CAR-T CELL OPENIA: Chimeric antigen receptor T cell therapy-associated cytopenias. <i>EJHaem</i> , 2022, 3, 32-38.	0.4	16
2070	Associa�o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, S54-S63.	0.1	0
2071	Associa�o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, S13-S21.	0.1	0
2072	Born to survive: how cancer cells resist CAR T cell therapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 199.	6.9	59
2073	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. <i>Neuro-Oncology Advances</i> , 2021, 3, v108-v120.	0.4	6
2074	CRISPR/Cas9-mediated TGF�RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. <i>Journal of Translational Medicine</i> , 2021, 19, 482.	1.8	14
2075	Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells. , 2021, 9, e003176.		10
2076	Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. <i>EJHaem</i> , 2022, 3, 6-10.	0.4	63
2077	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. <i>Cancers</i> , 2021, 13, 5722.	1.7	17
2078	Commercialization of Investigational Cell Therapy Products. , 2022, , 161-178.		0
2079	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 1961-1968.	2.5	47
2080	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	1.3	24
2081	Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments. <i>Journal of Neuro-Oncology</i> , 2022, 156, 81-96.	1.4	9
2082	Polymer-Mediated Cryopreservation of Bacteriophages. <i>Biomacromolecules</i> , 2021, 22, 5281-5289.	2.6	8
2083	New indications and platforms for CAR-T therapy in lymphomas beyond DLBCL. <i>EJHaem</i> , 2022, 3, 11-23.	0.4	2
2084	Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. <i>Journal of Clinical Oncology</i> , 2022, 40, 932-944.	0.8	93

#	ARTICLE	IF	CITATIONS
2085	Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma—A Report from the ALL-REZ Study Group. <i>Journal of Clinical Medicine</i> , 2021, 10, 5292.	1.0	5
2086	Role of bridging therapy during chimeric antigen receptor T cell therapy. <i>EJHaem</i> , 2022, 3, 39-45.	0.4	9
2087	Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 777073.	2.2	5
2088	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, S3-S12.	0.1	3
2089	T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. <i>Frontiers in Immunology</i> , 2021, 12, 780442.	2.2	42
2090	Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 772862.	1.3	8
2091	Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. <i>Science Translational Medicine</i> , 2021, 13, eabh0272.	5.8	123
2092	CAR Treg: A new approach in the treatment of autoimmune diseases. <i>International Immunopharmacology</i> , 2022, 102, 108409.	1.7	12
2093	Disease-specific outcomes after chimeric antigen receptor T-cell therapy. <i>European Journal of Cancer</i> , 2021, , .	1.3	2
2094	Current landscape of clinical development and approval of advanced therapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 606-618.	1.8	21
2095	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 66-81.	2.6	70
2096	Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. <i>Future Oncology</i> , 2022, 18, 277-289.	1.1	20
2097	ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature. <i>Frontiers in Medicine</i> , 2021, 8, 713047.	1.2	3
2098	Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. <i>Blood</i> , 2022, 139, 2156-2172.	0.6	33
2099	Rare Sequences Make Sense of CAR T-cell Therapy Outcomes. <i>Blood Cancer Discovery</i> , 2022, 3, 2-4.	2.6	1
2100	Antigen multimers: Specific, sensitive, precise, and multifunctional high-avidity CAR-staining reagents. <i>Matter</i> , 2021, 4, 3917-3940.	5.0	4
2101	CAR T Cells. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 297-317.	0.8	4
2102	Neurologic Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 417-429.	0.8	2

#	ARTICLE	IF	CITATIONS
2103	Research progress on treatment of extramedullary multiple myeloma. <i>Hematology</i> , 2021, 26, 985-994.	0.7	3
2104	An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 273-295.	0.8	1
2105	Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting. <i>Oncolimmunology</i> , 2021, 10, .	2.1	16
2108	Mechanisms of Resistance and Relapse After CAR-T Cell Therapy. <i>Cancer Drug Discovery and Development</i> , 2022, , 207-219.	0.2	1
2110	Off-the-Shelf CAR-T. <i>Cancer Drug Discovery and Development</i> , 2022, , 109-120.	0.2	2
2111	Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. <i>Lung Cancer</i> , 2022, 165, 1-9.	0.9	15
2112	A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. <i>Clinical and Translational Oncology</i> , 2022, 24, 968-980.	1.2	3
2113	Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05209.	0.2	13
2114	Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells. <i>Gene Therapy</i> , 2023, 30, 222-231.	2.3	4
2115	Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. <i>Cancer Gene Therapy</i> , 2022, 29, 1080-1096.	2.2	52
2116	Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). , 2022, 10, e003847.		44
2119	Co-Expression of miR155 or LSD1 shRNA Increases the Anti-Tumor Functions of CD19 CAR-T Cells. <i>Frontiers in Immunology</i> , 2021, 12, 811364.	2.2	11
2120	Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies. <i>Pharmacological Research</i> , 2022, 175, 106036.	3.1	31
2121	Therapeutic potential of CAR T cell in malignancies: A scoping review. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112512.	2.5	56
2122	Therapeutic efficacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models. <i>Neoplasia</i> , 2022, 24, 98-108.	2.3	6
2123	Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model. <i>Journal of Surgical Research</i> , 2022, 272, 37-50.	0.8	4
2124	An impedimetric immunosensor for the selective detection of CD34+ T-cells in human serum. <i>Sensors and Actuators B: Chemical</i> , 2022, 356, 131306.	4.0	8
2125	CAR-T-Zellen in der Praxis: Lebende Onkologika in der "Routineversorgung". , 0, , .		0

#	ARTICLE	IF	CITATIONS
2126	Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy. <i>Translational Cancer Research</i> , 2020, 9, 7310-7322.	0.4	2
2127	El Plan Profarma y las células CAR-T. <i>Revista De Investigación Y Educación En Ciencias De La Salud (RIECS)</i> , 2020, 5, 116-121.	0.0	0
2128	CAR-T-Zelltherapie: Konzept "One and Done". , 0, , .		0
2129	High Prevalence of PNH-phenotype Cells in Patients Who Received CD19-targeted CAR T-cell Therapy. <i>HemaSphere</i> , 2021, 5, e628.	1.2	2
2132	CAR-T cells, from principle to clinical applications. <i>Bulletin Du Cancer</i> , 2021, 108, S4-S17.	0.6	15
2133	CAR T-cells in acute lymphoblastic leukemia: Current results. <i>Bulletin Du Cancer</i> , 2021, 108, S40-S54.	0.6	3
2136	CAR-T cell: Toxicities issues: Mechanisms and clinical management. <i>Bulletin Du Cancer</i> , 2021, 108, S117-S127.	0.6	7
2138	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. <i>Nature Medicine</i> , 2022, 28, 325-332.	15.2	182
2139	Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. <i>Blood</i> , 2022, 139, 2173-2185.	0.6	39
2140	CD81 costimulation skews CAR transduction toward naive T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	6
2141	Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	2
2142	Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. <i>BMC Cancer</i> , 2022, 22, 98.	1.1	15
2143	Off-the-shelf, steroid-resistant, IL13R α 2-specific CAR T cells for treatment of glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1318-1330.	0.6	32
2144	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. <i>Frontiers in Pediatrics</i> , 2021, 9, 784024.	0.9	13
2145	Haematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukaemia: Special Considerations and Challenges. <i>Frontiers in Pediatrics</i> , 2021, 9, 796426.	0.9	4
2149	Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering. <i>ACS Synthetic Biology</i> , 2022, 11, 1-15.	1.9	14
2150	Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer. <i>Reviews in Medical Virology</i> , 2022, 32, e2325.	3.9	6
2151	Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies. <i>Cytotherapy</i> , 2022, 24, 405-412.	0.3	6

#	ARTICLE	IF	CITATIONS
2152	The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues. <i>Frontiers in Oncology</i> , 2022, 12, 815726.	1.3	1
2153	The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL). <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	0.6	0
2154	Continuous blood purification successfully treated severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy: A case report. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29563.	0.8	2
2155	Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 497.	1.7	17
2156	Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. <i>Blood Advances</i> , 2022, 6, 3022-3026.	2.5	13
2157	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. <i>Biomedicines</i> , 2022, 10, 307.	1.4	9
2158	Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti-Leukemia Efficacy of CAR-T Cells via SOCE-Calcineurin-NFAT and Glycolysis Pathways. <i>Advanced Science</i> , 2022, 9, e2103508.	5.6	21
2160	Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission. <i>Frontiers in Immunology</i> , 2021, 12, 731435.	2.2	4
2161	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. <i>Journal of Clinical Oncology</i> , 2022, 40, 956-967.	0.8	42
2163	Should CD19 CAR-T Cells for ALL be Followed by Allogeneic Stem Cell Transplant?. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 1-2.	0.6	3
2164	Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing. <i>Cells</i> , 2022, 11, 269.	1.8	10
2165	CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 800110.	1.3	7
2166	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. <i>Neurological Research and Practice</i> , 2022, 4, 1.	1.0	9
2167	The Evolving Role of Allogeneic Stem Cell Transplant in the Era of Molecularly Targeted Agents. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 78-84.	1.0	0
2168	Post-transplant GVHD in the era of molecularly targeted therapy. <i>Journal of Illusion</i> , 2022, 11, 53-63.	0.0	0
2169	Confused about Confusion. <i>New England Journal of Medicine</i> , 2022, 386, 80-87.	13.9	9
2170	The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. <i>Scientific Reports</i> , 2022, 12, 378.	1.6	18
2171	Recent advances in systemic therapy for hepatocellular carcinoma. <i>Biomarker Research</i> , 2022, 10, 3.	2.8	94

#	ARTICLE	IF	CITATIONS
2172	Transforming Glia to Neurons Effectively Treats Temporal Lobe Seizures. <i>Epilepsy Currents</i> , 2022, 22, 130-131.	0.4	1
2173	Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. , 2022, , 405-430.		0
2174	Emerging strategies for biomaterial-assisted cancer immunotherapy. <i>Korean Journal of Chemical Engineering</i> , 2022, 39, 227-240.	1.2	1
2176	Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. <i>Cells</i> , 2022, 11, 139.	1.8	6
2177	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	2.5	22
2178	Chimeric antigen receptorâ€‘engineered adoptive cell therapy for AML: Current status and future perspectives. <i>Immunomedicine</i> , 2022, 2, .	0.7	0
2179	Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. <i>Cells</i> , 2022, 11, 410.	1.8	9
2180	Future prospects for cancer immunotherapy - Strategies for ineffective cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-3.	1.4	7
2181	The Hematology of Tomorrow Is Hereâ€‘Preclinical Models Are Not: Cell Therapy for Hematological Malignancies. <i>Cancers</i> , 2022, 14, 580.	1.7	5
2182	CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. <i>Nature Communications</i> , 2022, 13, 587.	5.8	41
2183	From Myth to Reality: Achieving a Second Remission in Acute Lymphoblastic Leukemia. , 2022, 19, .		0
2184	HLA-independent T cell receptors for targeting tumors with low antigen density. <i>Nature Medicine</i> , 2022, 28, 345-352.	15.2	73
2185	Targeted Therapy in Leukaemia, Lymphoma and Myeloma. <i>Journal of Personalized Medicine</i> , 2022, 12, 74.	1.1	1
2187	Prospect of CAR T-cell therapy in acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 211-220.	1.9	4
2188	Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. <i>Science Translational Medicine</i> , 2022, 14, eabg3072.	5.8	47
2189	Current global trends in the development of CAR-T therapy. <i>Journal of Illusion</i> , 2022, 11, 1-9.	0.0	0
2190	CD55, a potential immunotherapeutic target for MYCN-amplified neuroblastoma. <i>Neuro-Oncology</i> , 2022, , .	0.6	0
2191	Pediatric Acute Myeloid Leukemiaâ€‘Past, Present, and Future. <i>Journal of Clinical Medicine</i> , 2022, 11, 504.	1.0	27

#	ARTICLE	IF	CITATIONS
2192	PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function. <i>Frontiers in Immunology</i> , 2022, 13, 770132.	2.2	7
2193	Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e7.	1.6	8
2194	Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. <i>Oncotarget</i> , 2022, 11, 2033528.	2.1	19
2195	Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 73.e1-73.e9.	0.6	20
2196	Strategies Towards Antigen-Specific Treatments for Membranous Nephropathy. <i>Frontiers in Immunology</i> , 2022, 13, 822508.	2.2	8
2197	In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 722-733.	2.6	32
2198	Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. <i>European Journal of Cancer</i> , 2022, 164, 1-17.	1.3	24
2199	Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 24, 181-198.	1.8	14
2200	Anti-CAIX BB-951 CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 385-399.	2.0	15
2201	Presumptive Recurrence of Intra-ocular Lymphoma Despite Chimeric Antigen Receptor T-cell Therapy. <i>Retinal Cases and Brief Reports</i> , 2022, Publish Ahead of Print, .	0.3	1
2203	Generation of CAR T-cells using β -retroviral vector. <i>Methods in Cell Biology</i> , 2022, 167, 171-183.	0.5	4
2204	Preclinical testing of CAR T cells in zebrafish xenografts. <i>Methods in Cell Biology</i> , 2022, 167, 133-147.	0.5	1
2207	Methods to monitor in vivo expansion and efficacy of CAR-T cells in preclinical models. <i>Methods in Cell Biology</i> , 2022, 167, 185-201.	0.5	0
2208	Pharmacological Aspects of Clinically Approved Gene Therapy Drugs and Products. , 2022, , .		0
2209	Current Immunotherapeutic Approaches for Malignant Gliomas. <i>Brain Tumor Research and Treatment</i> , 2022, 10, 1.	0.4	5
2210	Management of Hypogammaglobulinaemia and B-Cell Aplasia. , 2022, , 147-149.		3
2211	Adult Acute Lymphoblastic Leukaemia. , 2022, , 61-66.		1
2212	Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors. <i>Molecular Cancer Research</i> , 2022, 20, 823-833.	1.5	2

#	ARTICLE	IF	CITATIONS
2213	Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. <i>Blood Advances</i> , 2022, 6, 1969-1976.	2.5	36
2214	Management of haemostatic complications of chimaeric antigen receptor T-cell therapy. <i>British Journal of Haematology</i> , 2022, 197, 250-259.	1.2	0
2215	Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel. <i>Pediatric Hematology and Oncology</i> , 2022, , 1-9.	0.3	0
2216	Synthetic Biology-based Optimization of T cell Immunotherapies for Cancer. <i>Current Opinion in Biomedical Engineering</i> , 2022, 22, 100372.	1.8	0
2217	A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell surface proteins on target cells. <i>International Journal of Molecular Medicine</i> , 2022, 49, .	1.8	2
2218	Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. <i>Experimental Hematology</i> , 2022, 108, 1-7.	0.2	9
2219	CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection. <i>PLoS Pathogens</i> , 2022, 18, e1009831.	2.1	20
2220	Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine. <i>Diagnostics</i> , 2022, 12, 409.	1.3	5
2221	Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold in tumors. , 2022, 10, e003958.		4
2222	Future Developments in the Treatment of AL Amyloidosis. <i>Hemato</i> , 2022, 3, 131-152.	0.2	2
2223	Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	6
2224	The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy. <i>Pharmaceuticals</i> , 2022, 15, 207.	1.7	5
2225	Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. <i>Journal of Controlled Release</i> , 2022, 343, 703-723.	4.8	25
2226	Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). <i>Annals of Oncology</i> , 2022, 33, 259-275.	0.6	139
2227	Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells. <i>Journal of Controlled Release</i> , 2022, 343, 379-391.	4.8	12
2228	Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. <i>International Immunopharmacology</i> , 2022, 106, 108587.	1.7	15
2229	Relapsed ALL: CAR T vs transplant vs novel therapies. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 1-6.	0.9	13
2230	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 629-639.	13.9	243

#	ARTICLE	IF	CITATIONS
2231	A human orthogonal IL-2 and IL-2R β system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. <i>Science Translational Medicine</i> , 2021, 13, eabg6986.	5.8	64
2232	Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. <i>Science Translational Medicine</i> , 2021, 13, eabh1962.	5.8	49
2233	Modified T cells as therapeutic agents. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 296-302.	0.9	3
2234	Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies. <i>American Journal of Cancer Research</i> , 2021, 11, 5263-5281.	1.4	0
2235	2021, 110, 414-419.	0.0	0
2236	Development of drugs and vaccines. , 2022, , 29-34.		0
2237	Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. <i>Experientia Supplementum (2012)</i> , 2022, 113, 253-294.	0.5	1
2239	Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. <i>European Journal of Inflammation</i> , 2022, 20, 1721727X2210787.	0.2	0
2240	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	1.1	7
2241	OUP accepted manuscript. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, , .	0.6	0
2242	VCN Analysis Using Droplet Digital PCR Method in Hematopoietic Stem Cells and T Lymphocytes after Lentiviral Transduction: Optimization and Limitations. <i>Re:GEN Open</i> , 2022, 2, 28-36.	0.7	0
2243	Neurologic complications of immune modulatory therapy. , 2022, , 537-551.		0
2244	Conflicts of interest and the self-picture of medicine and scientists. , 2022, , 141-157.		0
2245	Delivery strategies in treatments of leukemia. <i>Chemical Society Reviews</i> , 2022, 51, 2121-2144.	18.7	17
2246	Gene Transduction of Natural Killer Cells for Clinical Application. <i>Methods in Molecular Biology</i> , 2022, 2463, 311-328.	0.4	1
2248	Mantle cell lymphoma management trends and novel agents: where are we going?. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	1.1	8
2249	Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas. <i>Current Treatment Options in Oncology</i> , 2022, 23, 89-98.	1.3	3
2250	Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody. <i>Immune Network</i> , 2022, 22, e4.	1.6	12

#	ARTICLE	IF	CITATIONS
2251	CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application. International Journal of Biological Sciences, 2022, 18, 2609-2626.	2.6	40
2252	Long-term clinical efficacy of cytokine-induced killer cell-based immunotherapy in early-stage esophageal squamous cell carcinoma. Cytotherapy, 2022, , .	0.3	2
2253	Parameters of long-term response with <scp>CD28</scp>-based <scp>CD19</scp> chimaeric antigen receptor-modified T cells in children and young adults with <scp>B-acute lymphoblastic leukaemia</scp>. British Journal of Haematology, 2022, 197, 475-481.	1.2	10
2254	CAR T targets and microenvironmental barriers of osteosarcoma. Cytotherapy, 2022, 24, 567-576.	0.3	11
2256	Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy. Scientific Reports, 2022, 12, 2830.	1.6	2
2257	Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. Haematologica, 2022, 107, 2096-2107.	1.7	17
2258	Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. Journal of Allergy and Clinical Immunology, 2022, 149, 1525-1560.	1.5	53
2259	A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunology Research, 2022, 10, 512-524.	1.6	12
2260	CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. , 2022, 10, e004128.		18
2261	Targeting of the alpha_v beta₃ integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma. , 2022, 10, e003816.		24
2262	Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Research, 2022, 32, 530-542.	5.7	54
2263	Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Current Treatment Options in Oncology, 2022, 23, 155-170.	1.3	17
2265	Emerging CAR T Cell Strategies for the Treatment of AML. Cancers, 2022, 14, 1241.	1.7	24
2266	Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond. Frontiers in Pediatrics, 2022, 10, 807992.	0.9	5
2267	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 2022, 12, 32.	2.8	73
2268	Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy. Journal of Immunotherapy, 2022, 45, 150-161.	1.2	14
2269	Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy. Cancers, 2022, 14, 967.	1.7	5
2270	Safety and efficacy of a humanized <scp>CD19</scp> chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2022, 97, 711-718.	2.0	3

#	ARTICLE	IF	CITATIONS
2271	Disseminated tuberculosis infection in a CAR T-cell recipient. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29615.	0.8	3
2272	Cardiac adverse events associated with chimeric antigen receptor T- cell therapy. <i>American Journal of Emergency Medicine</i> , 2022, 57, 225-226.	0.7	2
2273	The evolving landscape of chimeric antigen receptor T-cell therapy associated cardiotoxicity. <i>American Journal of Emergency Medicine</i> , 2022, 57, 220-221.	0.7	1
2274	Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill. <i>Medicina Intensiva (English Edition)</i> , 2022, , .	0.1	2
2275	CAR T-cell therapy for B-cell lymphoma. <i>Current Problems in Cancer</i> , 2022, 46, 100826.	1.0	26
2276	Immunotherapy Associated Neurotoxicity in Pediatric Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 836452.	1.3	5
2277	Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance. <i>Frontiers in Immunology</i> , 2022, 13, 842746.	2.2	5
2278	A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy. <i>Experimental Hematology and Oncology</i> , 2022, 11, 15.	2.0	19
2279	Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. <i>Frontiers in Oncology</i> , 2022, 12, 841117.	1.3	9
2280	Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem. <i>Cancers</i> , 2022, 14, 1501.	1.7	43
2281	Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors. <i>Cancer Research Communications</i> , 2022, 2, 158-171.	0.7	8
2282	Neurology's vital role in preventing unnecessary and potentially harmful pediatric studies. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 209-219.	1.4	1
2283	Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. <i>Blood</i> , 2022, 139, 3376-3386.	0.6	36
2284	A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021. <i>Frontiers in Immunology</i> , 2022, 13, 840956.	2.2	30
2285	Prognostic factors of children and adolescents with T-cell acute lymphoblastic leukemia after allogeneic transplantation. <i>Hematological Oncology</i> , 2022, 40, 457-468.	0.8	3
2286	CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2022, 24, 841-849.	0.3	12
2287	Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review (protocol). <i>Open Research Europe</i> , 0, 2, 38.	2.0	1
2288	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. <i>Nature Medicine</i> , 2022, 28, 713-723.	15.2	117

#	ARTICLE	IF	CITATIONS
2289	Large cohort humanized NPI mice reconstituted with CD34 ⁺ hematopoietic stem cells are feasible for evaluating preclinical cancer immunotherapy. <i>FASEB Journal</i> , 2022, 36, e22244.	0.2	4
2290	Promising therapeutic approaches for relapsed/refractory multiple myeloma. <i>Hematology</i> , 2022, 27, 343-352.	0.7	4
2291	PSMA-targeting TGF β 2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 724-734.	15.2	171
2292	Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 845540.	1.3	10
2293	Results of ARI0001 CART19 cell therapy in patients with relapsed/refractory CD19 ⁺ acute lymphoblastic leukemia with isolated extramedullary disease. <i>American Journal of Hematology</i> , 2022, 97, 731-739.	2.0	6
2294	Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy. <i>Cells</i> , 2022, 11, 994.	1.8	18
2295	Very rare near-haploid acute lymphoblastic leukemia resistant to immunotherapy and CAR-T therapy in 19-year-old male patient. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05545.	0.2	2
2297	Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 858590.	2.2	4
2298	Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. <i>Nature Biotechnology</i> , 2022, 40, 1250-1258.	9.4	63
2299	Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia. <i>Case Reports in Oncology</i> , 2022, 15, 257-262.	0.3	5
2300	T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion. , 2022, 10, e003715.		10
2301	Emerging Strategies in TCR-Engineered T Cells. <i>Frontiers in Immunology</i> , 2022, 13, 850358.	2.2	20
2302	Allogeneic Hematopoietic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Second Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 326.e1-326.e10.	0.6	4
2304	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 945-955.	0.8	79
2305	Antitumor activity of T cells secreting β CD133- β CD3 bispecific T-cell engager against cholangiocarcinoma. <i>PLoS ONE</i> , 2022, 17, e0265773.	1.1	3
2306	Harnessing the chemokine system to home CAR-T cells into solid tumors. <i>Cell Reports Medicine</i> , 2022, 3, 100543.	3.3	24
2307	STAT3 Role in T-Cell Memory Formation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2878.	1.8	10
2309	Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. <i>Cytotherapy</i> , 2022, 24, 282-290.	0.3	4

#	ARTICLE	IF	CITATIONS
2310	Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies. <i>OncImmunity</i> , 2022, 11, 2054106.	2.1	7
2311	CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2663-2675.	2.0	11
2312	Human induced-T-to-natural killer cells have potent anti-tumour activities. <i>Biomarker Research</i> , 2022, 10, 13.	2.8	4
2313	Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 294-302.	0.6	17
2314	Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study. <i>Leukemia</i> , 2022, 36, 1274-1282.	3.3	1
2315	SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0
2316	Successful administration of CD19 chimeric antigen receptor T cells in association with severe cyanotic congenital heart disease. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29671.	0.8	1
2317	Targeting cancer-associated glycans as a therapeutic strategy in leukemia. <i>International Journal of Transgender Health</i> , 2022, 15, 378-433.	1.1	2
2318	Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 719-728.	2.0	12
2319	Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. <i>European Heart Journal</i> , 2022, 43, 1928-1940.	1.0	39
2320	Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 304.e1-304.e9.	0.6	12
2321	Antifungal use in children with acute leukaemia: state of current evidence and directions for future research. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1508-1524.	1.3	7
2322	Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. <i>Journal of Immunology Research</i> , 2022, 2022, 1-9.	0.9	20
2323	Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?. <i>Frontiers in Pediatrics</i> , 2022, 10, 796994.	0.9	0
2324	Controversies in the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Current Oncology Reports</i> , 2022, , 1.	1.8	0
2325	Characterization of extramedullary disease in B-ALL and response to CAR-T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2167-2182.	2.5	29
2326	Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. <i>Journal of Hematology and Oncology</i> , 2022, 15, 38.	6.9	20
2327	In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE) Tj ETQq1 1 0.784314 rgBT /Overlock 1	6.9	9

#	ARTICLE	IF	CITATIONS
2328	A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells. <i>Frontiers in Oncology</i> , 2022, 12, 726985.	1.3	4
2329	The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective. <i>Nature Communications</i> , 2022, 13, 1613.	5.8	12
2330	Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	5
2331	Immunotherapies in acute leukemia. <i>Therapie</i> , 2022, 77, 241-250.	0.6	3
2332	HLA-matched allogeneic anti-CD19 CAR-T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden. <i>Immunomedicine</i> , 2022, 2, .	0.7	0
2333	Clinically relevant T-cell expansion media activate distinct metabolic programs uncoupled from cellular function. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 24, 380-393.	1.8	12
2334	Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma. <i>Value in Health</i> , 2022, 25, 1344-1351.	0.1	9
2335	Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 5774-5785.	2.5	43
2336	CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 119.	3.5	167
2337	Case Report: Cardiac Tamponade in Association With Cytokine Release Syndrome Following CAR-T Cell Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 848091.	1.1	4
2338	Big splashes & ripple effects: a narrative review of the short- & long-term impact of publications supported by an NIH CTSA pediatrics program. <i>Translational Pediatrics</i> , 2022, 11, 411-422.	0.5	4
2339	SAHA Enhances Differentiation of CD34+CD45+ Hematopoietic Stem and Progenitor Cells from Pluripotent Stem Cells Concomitant with an Increase in Hemogenic Endothelium. <i>Stem Cells Translational Medicine</i> , 2022, 11, 513-526.	1.6	5
2340	Toxicity and Local Irritation Action of the Biomedical Cell Product Anti-HER2-CAR-T-NK Upon Multiply Repeated Administration. <i>Pharmaceutical Chemistry Journal</i> , 2022, 55, 1276-1281.	0.3	1
2341	Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel. <i>Frontiers in Immunology</i> , 2022, 13, 830773.	2.2	21
2342	Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 342-355.	12.5	113
2343	CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 834002.	1.3	8
2344	Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults. <i>Cancers</i> , 2022, 14, 1805.	1.7	10
2345	Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function. <i>Frontiers in Immunology</i> , 2022, 13, 845499.	2.2	8

#	ARTICLE	IF	CITATIONS
2346	Specific targeting of cancer stem cells by immunotherapy: A possible stratagem to restrain cancer recurrence and metastasis. <i>Biochemical Pharmacology</i> , 2022, 198, 114955.	2.0	12
2348	Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 98.	7.1	19
2349	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	4.9	18
2350	Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. <i>Leukemia and Lymphoma</i> , 2022, 63, 1849-1860.	0.6	14
2351	CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. <i>Nature Biomedical Engineering</i> , 2022, 6, 830-841.	11.6	25
2352	Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!. <i>JCO Oncology Practice</i> , 2022, 18, 479-487.	1.4	17
2353	Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. <i>Expert Review of Hematology</i> , 2022, 15, 305-320.	1.0	25
2354	The Effects of Chimeric Antigen Receptor (CAR) Hinge Domain Post-Translational Modifications on CAR-T Cell Activity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4056.	1.8	7
2355	Stem cell transplant for mantle cell lymphoma in Taiwan. <i>Scientific Reports</i> , 2022, 12, 5662.	1.6	3
2356	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	2.3	124
2357	Targeting vascular inflammation through emerging methods and drug carriers. <i>Advanced Drug Delivery Reviews</i> , 2022, 184, 114180.	6.6	17
2358	Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells. <i>Cancer Letters</i> , 2022, 536, 215668.	3.2	11
2359	Tumor Lysis Syndrome. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 438-446.e1.	0.6	15
2360	Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 367.	3.5	72
2361	Convection-enhanced delivery for high-grade glioma. <i>Neuro-Oncology Practice</i> , 2022, 9, 24-34.	1.0	6
2362	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 67-88.	0.5	36
2363	Identification of the minimum requirements for successful haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2022, 196, 711-723.	1.2	1
2364	Extracorporeal Membrane Oxygenation Candidacy in Pediatric Patients Treated With Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy: An International Survey. <i>Frontiers in Oncology</i> , 2021, 11, 798236.	1.3	7

#	ARTICLE	IF	CITATIONS
2365	Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials. <i>Frontiers in Immunology</i> , 2021, 12, 780145.	2.2	11
2366	Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies. <i>Cancers</i> , 2022, 14, 183.	1.7	8
2368	Pro-Apoptotic Potential of <i>Pseudevernia furfuracea</i> (L.) Zopf Extract and Isolated Physodic Acid in Acute Lymphoblastic Leukemia Model In Vitro. <i>Pharmaceutics</i> , 2021, 13, 2173.	2.0	8
2369	Toward Engineered Biosynthesis of Drugs in Human Cells. <i>ChemBioChem</i> , 2022, 23, .	1.3	3
2370	Aspartate \hat{I}^2 -Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target. <i>Frontiers in Oncology</i> , 2021, 11, 783744.	1.3	2
2371	Acoustofluidic-mediated molecular delivery to human T cells with a three-dimensional-printed flow chamber. <i>Journal of the Acoustical Society of America</i> , 2021, 150, 4534-4547.	0.5	5
2372	Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing. <i>Cells</i> , 2022, 11, 21.	1.8	16
2373	Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Transplantation. <i>Engineering</i> , 2022, 10, 30-43.	3.2	3
2374	T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. <i>Nature Biotechnology</i> , 2022, 40, 488-498.	9.4	12
2376	Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 798352.	1.3	7
2377	Acute Lymphoblastic Leukemia Relapse Limited to the Anterior Chamber of the Eye and Treated with Novel CAR T-Cell Therapy. <i>Case Reports in Ophthalmology</i> , 2022, 12, 994-1001.	0.3	0
2378	A Novel Peptide-MHC Targeted Chimeric Antigen Receptor T Cell Forms a T Cell-like Immune Synapse. <i>Biomedicines</i> , 2021, 9, 1875.	1.4	4
2379	Treatment of AML Relapse After Allo-HCT. <i>Frontiers in Oncology</i> , 2021, 11, 812207.	1.3	16
2380	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. <i>Frontiers of Medicine</i> , 2021, 15, 783-804.	1.5	3
2382	Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy. <i>Chinese Medical Journal</i> , 2022, 135, 890-900.	0.9	7
2383	Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 504-513.	0.9	4
2384	Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy. <i>Journal of Interferon and Cytokine Research</i> , 2021, 41, 469-476.	0.5	9
2385	Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)-expressing T cells. <i>Haematologica</i> , 2022, 107, 970-974.	1.7	6

#	ARTICLE	IF	CITATIONS
2386	A Review of Acute and Long-Term Neurological Complications Following Haematopoietic Stem Cell Transplant for Paediatric Acute Lymphoblastic Leukaemia. <i>Frontiers in Pediatrics</i> , 2021, 9, 774853.	0.9	3
2388	The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review. <i>Biomarkers</i> , 2022, 27, 22-34.	0.9	1
2389	Potential Role of IFN γ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. <i>Blood Cancer Discovery</i> , 2022, 3, 90-94.	2.6	23
2390	Myeloid Immune Cells CARrying a New Weapon Against Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 784421.	1.8	4
2391	Allogeneic Hematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukemia: Shifting Indications in the Era of Immunotherapy. <i>Frontiers in Pediatrics</i> , 2021, 9, 782785.	0.9	11
2392	CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2022, 63, 751-754.	0.6	10
2393	Factors associated with the clinical outcome of patients with relapsed/refractory CD19 ⁺ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. , 2021, 9, e003644.		11
2394	NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development. <i>Cells</i> , 2021, 10, 3390.	1.8	17
2395	Recent developments in cancer therapy: A brief journey during the last 12 years. <i>Indian Journal of Pharmacy and Pharmacology</i> , 2022, 9, 1-2.	0.1	0
2396	Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. <i>BMC Cancer</i> , 2022, 22, 393.	1.1	11
2397	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1508-1515.	3.3	21
2398	Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 930-939.	3.0	10
2399	Chimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases. <i>Gematologiya I Transfuziologiya</i> , 2022, 67, 8-28.	0.1	1
2400	Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 777775.	1.6	3
2401	Lineage switch and relapse in sanctuary site: Some lessons to learn about plasticity in <i>KMT2Ar</i> acute leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29683.	0.8	0
2402	Review: Neurological Complications From Therapies for Pediatric Brain Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 853034.	1.3	5
2403	Humanized Germ-Free Mice for Investigating the Intervention Effect of Commensal Microbiome on Cancer Immunotherapy. <i>Antioxidants and Redox Signaling</i> , 2022, 37, 1291-1302.	2.5	0
2404	Ultrasound and microbubble-mediated drug delivery and immunotherapy. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, , 1.	0.6	6

#	ARTICLE	IF	CITATIONS
2405	Incidence of Elevated Aminotransferases With or Without Bilirubin Elevation During Treatment With Immune Checkpoint Inhibitors: A Retrospective Study of Patients From Community Oncology Clinics in the United States. <i>Cureus</i> , 2022, 14, e24053.	0.2	1
2406	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptorâ€”T Cell Therapy for Hematological Malignant Neoplasms. <i>JAMA Network Open</i> , 2022, 5, e228161.	2.8	22
2407	Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia. <i>Cancers</i> , 2022, 14, 2021.	1.7	24
2408	Immunotherapy of Neuroblastoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2022, 28, 3196-3206.	3.2	29
2409	Next-Generation CAR T-cell Therapies. <i>Cancer Discovery</i> , 2022, 12, 1625-1633.	7.7	53
2410	A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 365.e1-365.e7.	0.6	8
2411	CAR T cell killing requires the IFNÎ³R pathway in solid but not liquid tumours. <i>Nature</i> , 2022, 604, 563-570.	13.7	150
2412	CAR T-Cell Therapy in the Older Person: Indications and Risks. <i>Current Oncology Reports</i> , 2022, 24, 1189-1199.	1.8	11
2413	Development of CAR T Cell Therapy in Childrenâ€”A Comprehensive Overview. <i>Journal of Clinical Medicine</i> , 2022, 11, 2158.	1.0	12
2414	Impact of Manufacturing Procedures on CAR T Cell Functionality. <i>Frontiers in Immunology</i> , 2022, 13, 876339.	2.2	54
2415	Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. <i>Bone Marrow Transplantation</i> , 2022, 57, 1025-1027.	1.3	27
2416	Modulating tumor physical microenvironment for fueling CAR-T cell therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114301.	6.6	28
2439	Chimeric antigen receptor Tâ€”cell therapy for a patient with Philadelphia chromosomeâ€”positive acute lymphoblastic leukemia and leukoencephalopathy who relapsed after bone marrow transplantation. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29734.	0.8	1
2440	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. <i>Leukemia</i> , 2022, 36, 1525-1532.	3.3	27
2441	CARâ€”T cell therapy in paediatric acute lymphoblastic leukaemia â€” past, present and future. <i>British Journal of Haematology</i> , 2020, 191, 617-626.	1.2	5
2442	Haploidentical donor-derived memory CAR-T cells: first in human experience and in vitro correlative study. <i>Blood Advances</i> , 2022, , .	2.5	2
2443	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. <i>Blood Advances</i> , 2022, 6, 5737-5749.	2.5	20
2452	Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 344-367.	0.9	4

#	ARTICLE	IF	CITATIONS
2453	Pharmacoeconomic Analysis of CAR-T Cell Therapy in Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemias. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2022, 15, 205-212.	0.1	1
2454	Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells. <i>Cancer Treatment and Research</i> , 2022, 183, 255-274.	0.2	0
2455	Dissecting the heterogeneity of exhausted T cells at the molecular level. <i>International Immunology</i> , 2022, 34, 547-553.	1.8	2
2456	Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. <i>Cancer Treatment and Research</i> , 2022, 183, 161-184.	0.2	2
2457	Review of Hematological and Oncological Emergencies. <i>Advanced Emergency Nursing Journal</i> , 2022, 44, 84-102.	0.2	2
2458	Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells. <i>Frontiers in Immunology</i> , 2022, 13, 879030.	2.2	1
2459	The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. <i>Neuro-Oncology</i> , 2022, 24, 1408-1422.	0.6	27
2460	Could (should) we abandon total body irradiation for conditioning in children with leukemia. <i>Blood Reviews</i> , 2022, 56, 100966.	2.8	2
2461	Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. <i>Blood Advances</i> , 2023, 7, 575-585.	2.5	52
2462	New hope to prevent ALL relapse after transplant. <i>Blood</i> , 2022, 139, 2580-2581.	0.6	0
2463	An Overview of Conventional Drugs and Nanotherapeutic Options for the Treatment and Management of Pediatric Acute Lymphoblastic Leukemia. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 3050-3061.	0.9	0
2464	In-situ scalable manufacturing of Epstein-Barr virus-specific T-cells using bioreactor with an expandable culture area (BECA). <i>Scientific Reports</i> , 2022, 12, 7045.	1.6	1
2465	Efficacy and safety of CAR-T cell therapy in minorities. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0
2466	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , 2022, 9, e374-e384.	2.2	11
2467	Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1195-1206.	1.9	18
2468	NEONATAL LEUKEMIA: ASPECTS OF DIFFERENTIAL DIAGNOSIS. <i>Neonatology Surgery and Perinatal Medicine</i> , 2022, 12, 55-59.	0.0	0
2469	Targeting Apoptosis in ALL. <i>Current Hematologic Malignancy Reports</i> , 2022, , 1.	1.2	2
2471	CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2022, 14, 2287.	1.7	6

#	ARTICLE	IF	CITATIONS
2472	Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. <i>Blood</i> , 2022, 140, 11-15.	0.6	23
2473	The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets. <i>Cancers</i> , 2022, 14, 2283.	1.7	6
2475	Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation. <i>International Journal of Hematology</i> , 2022, 116, 594-602.	0.7	4
2476	The CD8 α hinge is intrinsically disordered with a dynamic exchange that includes proline cis-trans isomerization. <i>Journal of Magnetic Resonance</i> , 2022, 340, 107234.	1.2	5
2477	Demographic differences among patients treated with chimeric antigen receptor α cell therapy in the United States. <i>Cancer Medicine</i> , 2022, 11, 4440-4448.	1.3	6
2478	Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. <i>Nature Medicine</i> , 2022, 28, 1189-1198.	15.2	190
2479	α VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome α negative B α precursor acute lymphoblastic leukaemia in first relapse. <i>British Journal of Haematology</i> , 2022, , .	1.2	2
2480	Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2022, 140, 25-37.	0.6	29
2481	A novel adoptive synthetic α TCR and antigen receptor (α STAR) α Cell therapy for α Cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, 992-1004.	2.0	8
2482	Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma. <i>Cytotherapy</i> , 2022, 24, 940-953.	0.3	5
2483	Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	11
2484	An integrated approach to cardioprotection in lymphomas. <i>Lancet Haematology</i> , the, 2022, 9, e445-e454.	2.2	5
2486	Current challenges in the manufacture of clinical-grade autologous whole cell vaccines for hematological malignancies. <i>Cytotherapy</i> , 2022, 24, 979-989.	0.3	2
2487	The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5242.	1.8	7
2488	Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?. <i>Clinical Hematology International</i> , 0, , 1.	0.7	3
2489	The translational challenges of precision oncology. <i>Cancer Cell</i> , 2022, 40, 458-478.	7.7	38
2490	Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	31
2491	CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	66

#	ARTICLE	IF	CITATIONS
2492	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
2493	Exploiting adaptive immune receptor recombination read recoveries from exome files to identify subsets of <sc>ALL</sc> and to establish <sc>TCR</sc> features that correlate with better outcomes. <i>International Journal of Laboratory Hematology</i> , 2022, , .	0.7	0
2494	Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. <i>Cell</i> , 2022, 185, 1745-1763.e22.	13.5	88
2495	CAR-T Cell Performance: How to Improve Their Persistence?. <i>Frontiers in Immunology</i> , 2022, 13, 878209.	2.2	42
2496	Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	3
2497	Novel immunotherapies in multiple myeloma. <i>International Journal of Hematology</i> , 2022, 115, 799-810.	0.7	3
2498	éřáCD19âµĈâæš—ăžŸă—ă1/2“Tç»†èfžæ²»ç—æĈŸæĈSBæ<â·ç»†èfžç™1/2è;Ĉç—...ă1/4 é“â—ăâæ, fèĈ...çš,,â%â.1.æĈSâ'Ĉæç%æ		
2499	Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5515.	1.8	7
2500	THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA. <i>Blood</i> , 2022, , .	0.6	7
2501	Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy. <i>Biomolecules and Therapeutics</i> , 2022, 30, 418-426.	1.1	2
2502	Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4251-4255.	2.5	20
2503	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	1.3	119
2504	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
2505	Time 2EVOLVE: predicting efficacy of engineered T-cells â€“ how far is the bench from the bedside?. , 2022, 10, e003487.		13
2506	Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. , 2022, 10, e004483.		21
2507	Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects. <i>Cancer Immunology Research</i> , 2022, 10, 856-870.	1.6	7
2508	Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges. <i>JCO Oncology Practice</i> , 2022, , OP2200237.	1.4	1
2509	Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment. <i>International Review of Cell and Molecular Biology</i> , 2022, , 123-147.	1.6	8

#	ARTICLE	IF	CITATIONS
2510	Emerging Concepts in Managing Malignancy in Kidney Transplant Patients. <i>Seminars in Nephrology</i> , 2022, 42, 63-75.	0.6	4
2511	Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports). <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210994.	1.1	1
2512	CAR-Tç»†èfžâœ`è;æ¶²ç³»ç»Ÿæ¶æ€Sè,¿ç~æ²»ç—çš,,ç”ç©¶è;â±•. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University of Medicine, 2022, 53(10), 1099-1104.		
2513	Precision medicine: InÂvivo CAR therapy as a showcase for receptor-targeted vector platforms. <i>Molecular Therapy</i> , 2022, 30, 2401-2415.	3.7	28
2514	Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. <i>Cytotherapy</i> , 2022, 24, 962-973.	0.3	6
2515	Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives. <i>Chemical Engineering Journal</i> , 2022, 446, 137147.	6.6	35
2516	The role of neoantigens in tumor immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113118.	2.5	17
2517	Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies. <i>Translational Oncology</i> , 2022, 22, 101459.	1.7	8
2518	Targeted Therapeutics for Rare Disorders. , 2024, , 249-271.		1
2519	Preliminary Assessment of Cardiotoxicity in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2520	Systematic Review of Available CAR-T Cell Trials around the World. <i>Cancers</i> , 2022, 14, 2667.	1.7	31
2521	CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies. <i>Cells</i> , 2022, 11, 1804.	1.8	1
2523	Overcoming resistance to antiâ€CD19 CAR Tâ€cell therapy in Bâ€cell malignancies. <i>Hematological Oncology</i> , 2022, 40, 821-834.	0.8	3
2524	Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	8
2525	Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive Bâ€cell <sc>nonâ€Hodgkin</sc> lymphoma. <i>Cancer Medicine</i> , 2022, 11, 4889-4899.	1.3	8
2526	BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events. <i>Expert Review of Hematology</i> , 2022, 15, 503-517.	1.0	1
2527	Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
2528	Glioblastoma, an opportunity T cell trafficking could bring for the treatment. <i>Molecular Biology Reports</i> , 0, , .	1.0	4

#	ARTICLE	IF	CITATIONS
2529	CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia. <i>Cancer Letters</i> , 2022, , 215762.	3.2	4
2530	CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. <i>Blood</i> , 2022, 140, 451-463.	0.6	56
2531	Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	27
2532	CAR-T cells for cancer immunotherapy—the barriers ahead and the paths through. <i>International Reviews of Immunology</i> , 2022, 41, 567-581.	1.5	1
2533	Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective. <i>Journal of Clinical Oncology</i> , 2022, 40, 3501-3509.	0.8	9
2534	The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
2535	Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 4-14.	1.8	5
2536	Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy. <i>Bone Marrow Transplantation</i> , 2022, 57, 1350-1353.	1.3	2
2537	Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. <i>Oncimmunology</i> , 2022, 11, .	2.1	15
2538	CAR-T Therapy in Clinical Practice: Technical Advances and Current Challenges. <i>Advanced Biology</i> , 2022, 6, .	1.4	2
2539	Current and future perspectives of chimeric antigen receptors against glioblastoma. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	3
2540	Next Generation Natural Killer Cells for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	14
2541	Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2542	Bispecific CAR T-cells for B-cell Malignancies. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1005-1015.	1.4	5
2543	Oncologic emergencies and urgencies: A comprehensive review. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 570-593.	157.7	18
2544	Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103473.	0.5	1
2545	Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2546	Genetic therapeutic advancements for Dravet Syndrome. <i>Epilepsy and Behavior</i> , 2022, 132, 108741.	0.9	10

#	ARTICLE	IF	CITATIONS
2547	Acute and chronic leukemias. , 2023, , 403-411.		0
2548	Cancer therapeutic drug guide. , 2023, , 451-506.		0
2551	Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview. Methods in Molecular Biology, 2022, , 25-39.	0.4	1
2552	CAR T Cell therapy for solid tumors: Fatal attraction requires adhesion. Med, 2022, 3, 353-354.	2.2	1
2553	Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. Cytotherapy, 2022, 24, 869-878.	0.3	23
2554	Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report. Acta Haematologica, 2022, 145, 537-541.	0.7	5
2555	Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives. Frontiers in Immunology, 0, 13, .	2.2	3
2556	CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Frontiers in Immunology, 0, 13, .	2.2	55
2557	Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland. , 2022, 152, .		5
2558	Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?. Cancers, 2022, 14, 2994.	1.7	12
2560	Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy. Current Cardiology Reviews, 2022, 18, .	0.6	1
2561	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2022, 386, 2399-2411.	13.9	31
2562	CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity. International Journal of Molecular Sciences, 2022, 23, 6931.	1.8	3
2563	Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T cell therapy development. Clinical and Translational Science, 2022, 15, 2057-2074.	1.5	9
2564	The Past, Present, and Future of Non-Viral CAR T Cells. Frontiers in Immunology, 0, 13, .	2.2	39
2565	B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?. Science Translational Medicine, 2022, 14, .	5.8	4
2567	Quantitative Clinical Pharmacology of CAR T Cell Therapy. Clinical Pharmacology and Therapeutics, 2022, 112, 11-15.	2.3	2
2568	Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Molecular Therapy, 2022, 30, 3155-3175.	3.7	21

#	ARTICLE	IF	CITATIONS
2569	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
2570	Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice. <i>Pharmaceutical Medicine</i> , 2022, 36, 163-171.	1.0	19
2571	Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	14
2572	Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer. <i>Biomedicines</i> , 2022, 10, 1493.	1.4	14
2573	Overcome tumor relapse in CAR T cell therapy. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	2
2574	Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	7
2575	Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia. , 2022, 10, e004774.		0
2576	A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity. <i>Nature Communications</i> , 2022, 13, .	5.8	29
2577	Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective. <i>Cancers</i> , 2022, 14, 2912.	1.7	4
2578	Fertility and CAR T-cells: Current practice and future directions. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 605.e1-605.e8.	0.6	5
2579	Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. <i>Annals of Oncology</i> , 2022, 33, 916-928.	0.6	30
2580	A Bridge To CAR. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 282-283.	0.6	1
2581	Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2582	Cancer Immunotherapy and Cytotoxicity: Current Advances and Challenges. , 0, , .		0
2583	Blinatumomab with donor lymphocyte infusions post haploidentical hematopoietic stem cell transplantation as salvage therapy for relapsed refractory acute lymphoblastic leukemia post chimeric antigen receptor T cell therapy. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	0.8	3
2584	Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACTiVe-2 trial). <i>BMJ Open</i> , 2022, 12, e060431.	0.8	4
2585	CAR T Cell Locomotion in Solid Tumor Microenvironment. <i>Cells</i> , 2022, 11, 1974.	1.8	15
2586	CD58 loss in tumor cells confers functional impairment of CAR T cells. <i>Blood Advances</i> , 2022, 6, 5844-5856.	2.5	20

#	ARTICLE	IF	CITATIONS
2587	Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2588	Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. <i>Advances in Therapy</i> , 2022, 39, 3678-3695.	1.3	3
2589	Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. <i>Science Advances</i> , 2022, 8, .	4.7	63
2590	T-cell Immunotherapy and Cardiovascular Disease. <i>Heart Failure Clinics</i> , 2022, 18, 443-454.	1.0	2
2591	Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud. <i>Cytokine</i> , 2022, 156, 155920.	1.4	4
2592	InÂvivo generation of CAR T cells in the presence of human myeloid cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 144-156.	1.8	8
2593	Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211006.	1.1	4
2594	mRNA delivery technologies: Toward clinical translation. <i>International Review of Cell and Molecular Biology</i> , 2022, , 207-293.	1.6	5
2595	Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers. , 2022, , 245-281.		0
2596	Tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia in the Irish healthcare setting: cost-effectiveness and value of information analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, .	0.2	4
2597	Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma. <i>Annals of Hematology</i> , 2022, 101, 1755-1767.	0.8	2
2598	Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy. <i>Cancer Immunology Research</i> , 2022, 10, 1055-1068.	1.6	3
2599	Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. <i>Cancers</i> , 2022, 14, 3230.	1.7	23
2600	Healthcare utilization and costs associated with acute lymphoblastic leukemia in children with and without Down syndrome. <i>Pediatric Blood and Cancer</i> , 0, , .	0.8	0
2601	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
2602	Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. <i>Nature Communications</i> , 2022, 13, .	5.8	21
2603	Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	23
2604	Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors. <i>Cancer Immunology Research</i> , 2022, 10, 962-977.	1.6	12

#	ARTICLE	IF	CITATIONS
2605	Enhancing adoptive T cell therapy with fucoidan-based IL-2 delivery microcapsules. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	4
2606	Clinically Applicable Assessment of Tisagenlecleucel CAR T Cell Treatment by Digital Droplet PCR for Copy Number Variant Assessment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7573.	1.8	2
2607	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. <i>Cancer Discovery</i> , 2022, 12, 2330-2349.	7.7	22
2608	Avoiding fratricide: a T-ALL order. <i>Blood</i> , 2022, 140, 3-4.	0.6	3
2609	CAR T cell therapy in advanced B-ALL with heavy disease burden. <i>Immunomedicine</i> , 0, , .	0.7	0
2612	Case Report: Clinical and Serological Hallmarks of Cytokine Release Syndrome in a Canine B Cell Lymphoma Patient Treated With Autologous CAR-T Cells. <i>Frontiers in Veterinary Science</i> , 0, 9, .	0.9	4
2613	Immunotherapy of sarcomas with modified T cells. <i>Current Opinion in Oncology</i> , 2022, 34, 362-370.	1.1	5
2614	Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. <i>Nature Cancer</i> , 2022, 3, 976-993.	5.7	23
2615	Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CAR) Therapy Access. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 345-346.	0.6	2
2616	Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies. <i>Clinical Cancer Research</i> , 2022, 28, 3940-3949.	3.2	4
2617	Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T cell therapy. <i>Immunomedicine</i> , 0, , .	0.7	1
2618	KIR-favorable TCR- $\alpha\beta$ /CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial. <i>Blood</i> , 2022, 140, 2556-2572.	0.6	9
2619	A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2757-2769.	1.2	4
2620	B-cell acute lymphoblastic leukemia promotes an immune suppressive microenvironment that can be overcome by IL-12. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
2621	Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 903-914.	1.1	1
2622	Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions. <i>Current Opinion in Hematology</i> , 2022, 29, 225-232.	1.2	3
2623	Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	27
2624	Immunosenescence, inflammaging, and cancer immunotherapy efficacy. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 915-926.	1.1	12

#	ARTICLE	IF	CITATIONS
2625	Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 4821-4830.	2.5	20
2626	CD34-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 4715-4718.	2.5	20
2627	Advances and challenges of CAR T-cell therapy and suitability of animal models (Review). <i>Molecular and Clinical Oncology</i> , 2022, 17, .	0.4	4
2628	Severe acute heart failure during or following cytokine release syndrome after CAR T-cell therapy. <i>Leukemia Research Reports</i> , 2022, , 100338.	0.2	1
2630	Current landscape of gene editing technology in biomedicine: Applications, advantages, challenges, and perspectives. <i>MedComm</i> , 2022, 3, .	3.1	2
2631	Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. <i>Bone Marrow Transplantation</i> , 2022, 57, 1477-1488.	1.3	28
2632	Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 745-768.	0.9	1
2633	Genome-Edited T Cell Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 729-744.	0.9	0
2634	Chimeric Antigen Receptor T-cell Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 701-727.	0.9	6
2635	Gene therapy clinical trials, where do we go? An overview. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113324.	2.5	68
2636	Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. <i>OncoTargets and Therapy</i> , 0, Volume 15, 799-813.	1.0	3
2637	Discovery of a Transferrin Receptor 1-Binding Aptamer and Its Application in Cancer Cell Depletion for Adoptive T-Cell Therapy Manufacturing. <i>Journal of the American Chemical Society</i> , 2022, 144, 13851-13864.	6.6	20
2638	Natural killer cells in antitumour adoptive cell immunotherapy. <i>Nature Reviews Cancer</i> , 2022, 22, 557-575.	12.8	208
2640	CAR T-cells in relapsed Burkitt lymphoma – a promising test drive in a rare disease. <i>Leukemia and Lymphoma</i> , 0, , 1-2.	0.6	1
2641	Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 727-736.	0.6	5
2642	A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 413-425.	2.3	9
2643	Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	47
2644	T cell receptor β -chain-targeting chimeric antigen receptor T cells against T cell malignancies. <i>Nature Communications</i> , 2022, 13, .	5.8	10

#	ARTICLE	IF	CITATIONS
2645	Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8242.	1.8	4
2646	Micro-hydrogel injectables that deliver effective CAR-T immunotherapy against 3D solid tumor spheroids. <i>Translational Oncology</i> , 2022, 24, 101477.	1.7	9
2648	Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. <i>Cancer Discovery</i> , 2022, 12, 2372-2391.	7.7	19
2649	Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2650	Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome. <i>Anticancer Research</i> , 2022, 42, 3853-3856.	0.5	6
2651	Real time experience applying CAR T-cells for B-cell lymphomaâ€”What we have learned so far: Acute toxicity management. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	0
2652	CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
2653	Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma. , 2022, 1, .		0
2654	Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 625-636.	0.6	5
2655	Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	0
2656	Prognostic significance of copy number variation in B-cell acute lymphoblastic leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2657	Recent Advances and Challenges in Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 3972.	1.7	26
2658	Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i>-rearranged acute lymphoblastic leukemia. <i>Haematologica</i> , 2023, 108, 457-471.	1.7	11
2659	Chimeric Antigen Receptor-T Cell Therapy. <i>Korean Journal of Medicine</i> , 2022, 97, 229-237.	0.1	0
2660	Understanding CAR T-Cell-tumor interactions: Paving the way for successful clinical outcomes. <i>Med</i> , 2022, 3, 538-564.	2.2	11
2661	Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
2662	Secretory co-factors in next-generation cellular therapies for cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2663	Overcoming tumor resistance mechanisms in CAR-NK cell therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22

#	ARTICLE	IF	CITATIONS
2664	A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments. <i>Cancers</i> , 2022, 14, 3796.	1.7	3
2665	Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study. <i>Hematology</i> , 2022, 27, 917-927.	0.7	3
2666	Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL. <i>Cancer Research Communications</i> , 2022, 2, 1089-1103.	0.7	3
2667	Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. <i>Pharmaceutics</i> , 2022, 14, 1762.	2.0	4
2668	Microraft arrays for <sc>serialâ€killer CD19</sc> chimeric antigen receptor T cells and single cell isolation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2023, 103, 208-220.	1.1	2
2669	The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. <i>Blood Advances</i> , 2022, 6, 6040-6050.	2.5	8
2670	Editorial: Allogeneic haematopoietic stem cell transplantation for children with acute lymphoblastic leukaemia in the era of immunotherapy. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	0
2672	CAR-NK Cells: A Chimeric Hope or a Promising Therapy?. <i>Cancers</i> , 2022, 14, 3839.	1.7	15
2673	Interferon-Î³ blockade in CAR T-cell therapyâ€associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2023, 7, 533-536.	2.5	9
2674	The use of ICU resources in CAR-T cell recipients: a hospital-wide study. <i>Annals of Intensive Care</i> , 2022, 12, .	2.2	9
2675	Approved gene therapies in Australia: coming to a store near you. <i>Internal Medicine Journal</i> , 2022, 52, 1313-1321.	0.5	3
2676	Regulatory T-cell therapy approaches. <i>Clinical and Experimental Immunology</i> , 2023, 211, 96-107.	1.1	7
2677	CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma. <i>Oncolmmunology</i> , 2022, 11, .	2.1	2
2678	A high-throughput microfluidic device based on controlled incremental filtration to enable centrifugation-free, low extracorporeal volume leukapheresis. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
2679	Cancer Immunotherapy and Delivery System: An Update. <i>Pharmaceutics</i> , 2022, 14, 1630.	2.0	12
2680	Monitoring antiâ€CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2023, 103, 16-26.	1.1	10
2681	A unique hubâ€andâ€spoke model to optimize patient management in lymphoma using novel chimeric antigen receptorâ€T cell therapy in Southeast and South Asia. <i>Hematological Oncology</i> , 0, , .	0.8	1
2684	Application of nanotechnology in CAR-T-cell immunotherapy. <i>Chinese Chemical Letters</i> , 2023, 34, 107747.	4.8	5

#	ARTICLE	IF	CITATIONS
2685	Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. <i>Blood Advances</i> , 2023, 7, 541-548.	2.5	21
2686	Advanced Cell Therapies for Glioblastoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
2687	Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy. <i>Chinese Medical Journal</i> , 2022, 135, 1639-1641.	0.9	4
2688	Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
2689	Case report: B7-H3 CAR-T therapy partially controls tumor growth in a basal cell carcinoma patient. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2690	CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
2691	<sc>CARâ€ therapy as a consolidation in remission <sc>Bâ€ALL</sc> patients with poor prognosis. <i>Cancer Reports</i> , 2022, 5, .	0.6	3
2692	Epigenetic engineering for optimal CARâ€ cell therapy. <i>Cancer Science</i> , 0, , .	1.7	4
2693	Emerging advances in engineered macrophages for tumor immunotherapy. <i>Cytotherapy</i> , 2022, , .	0.3	1
2694	Successful provision of CAR-T therapy during a pandemic: low SARS-CoV-2 infection rates and reduction in ICU admissions following modification of patient pathway. <i>Leukemia and Lymphoma</i> , 2022, 63, 3265-3267.	0.6	1
2695	Harnessing nucleic acid technologies for human health on earth and in space. <i>Life Sciences in Space Research</i> , 2022, 35, 113-126.	1.2	2
2696	Allogeneic <sc>CD34</sc>â€selected stem cell boost as salvage treatment of lifeâ€threatening infection and severe cytopenias after <sc>CARâ€ cell therapy. <i>Transfusion</i> , 2022, 62, 2143-2147.	0.8	5
2697	Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	18
2698	Nucleic acid-based therapy for brain cancer: Challenges and strategies. <i>Journal of Controlled Release</i> , 2022, 350, 80-92.	4.8	11
2699	Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	21
2701	Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2023, 41, 354-363.	0.8	28
2702	Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. <i>Lancet Haematology</i> , the, 2022, 9, e766-e775.	2.2	18
2703	EXABS-211-CT Building Your CAR-T Program. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, S104-S105.	0.2	0

#	ARTICLE	IF	CITATIONS
2704	CD19 CAR T cells for infants and young children. <i>Lancet Haematology</i> , 2022, 9, e712-e714.	2.2	0
2705	EXABS-134-ALL Dual CAR T-Cell for ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, S42-S43.	0.2	0
2706	Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 179, 103807.	2.0	6
2707	Applying a clinical lens to animal models of CAR-T cell therapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 17-31.	1.8	18
2708	Research Advances of Traditional Chinese Medicine in Cancer Immunotherapy. <i>Chinese Medicine and Culture</i> , 2020, 3, 245-253.	0.2	5
2709	Enhancement of T Cell Infiltration via Tumor-Targeted Th9 Cell Delivery Improves the Efficacy of Antitumor Immunotherapy of Solid Tumors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2710	Preservation and Storage of Cells for Therapy: Current Applications and Protocols. <i>Reference Series in Biomedical Engineering</i> , 2022, , 1-69.	0.1	2
2711	Recent advances in organotypic tissue slice cultures for anticancer drug development. <i>International Journal of Biological Sciences</i> , 2022, 18, 5885-5896.	2.6	16
2712	Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211184.	0.8	2
2713	A tractable microscopy- and flow cytometry-based method to measure natural killer cell-mediated killing and infiltration of tumor spheroids. <i>Methods in Cell Biology</i> , 2023, , 43-61.	0.5	1
2714	Oncolytic Adenovirus-Mediated Expression of CCL5 and IL12 Facilitates CA9-Targeting CAR-T Therapy Against Renal Cell Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2715	Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. , 2022, , 111-173.		0
2716	Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2718	Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. <i>BMJ, The</i> , 0, , e068956.	3.0	4
2719	Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2720	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 4192.	1.7	6
2721	High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance. <i>Nature Communications</i> , 2022, 13, .	5.8	14
2722	CAR-T cell potency: from structural elements to vector backbone components. <i>Biomarker Research</i> , 2022, 10, .	2.8	14

#	ARTICLE	IF	CITATIONS
2723	Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2724	Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	15
2725	Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 4747-4756.	3.2	28
2726	Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel. <i>British Journal of Haematology</i> , 2022, 199, 720-727.	1.2	7
2727	CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. <i>Nature Communications</i> , 2022, 13, .	5.8	35
2728	Universal chimeric antigen receptor T cell therapy – The future of cell therapy: A review providing clinical evidence. <i>Cancer Treatment and Research Communications</i> , 2022, 33, 100638.	0.7	5
2729	Novel Insights into Fungal Infections Prophylaxis and Treatment in Pediatric Patients with Cancer. <i>Antibiotics</i> , 2022, 11, 1316.	1.5	0
2730	GPRC5D-Targeted CAR T Cells for Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 1196-1206.	13.9	114
2731	Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1455-1476.	2.0	8
2732	CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
2733	Rethinking cancer targeting strategies in the era of smart cell therapeutics. <i>Nature Reviews Cancer</i> , 2022, 22, 693-702.	12.8	21
2734	The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia. <i>Biomedicines</i> , 2022, 10, 2286.	1.4	1
2735	Autologous Anti-CD19 CAR T-Cells immunotherapy in relapsed/refractory acute lymphoblastic leukemia patients. A systematic review and meta-analysis. , 2022, 101, .	0.0	0
2736	Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	21
2737	Do you need the immune system to cure ALL?. <i>Blood</i> , 2022, 140, 1457-1458.	0.6	0
2739	Targeted Treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia. <i>Current Pediatric Reviews</i> , 2023, 19, 150-156.	0.4	1
2740	Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies. <i>Cancers</i> , 2022, 14, 4452.	1.7	1
2741	Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	8

#	ARTICLE	IF	CITATIONS
2742	Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2743	What Surgeons Need to Know About Gene Therapy for Cancer. <i>Advances in Surgery</i> , 2022, 56, 151-168.	0.6	1
2744	A unique hub-and-spoke model to optimize patient management in lymphoma using novel CAR-T cell therapy in Southeast and South Asia. <i>Hematological Oncology</i> , 2022, 40, 4-12.	0.8	0
2746	Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. <i>Nature Medicine</i> , 2022, 28, 1860-1871.	15.2	80
2747	Introduction: Redefining T-cell Exhaustion Special Issue. <i>International Immunology</i> , 2022, 34, 545-546.	1.8	0
2748	Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12366.	1.2	17
2749	Current Progress of CAR-NK Therapy in Cancer Treatment. <i>Cancers</i> , 2022, 14, 4318.	1.7	14
2750	Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. <i>Leukemia</i> , 2022, 36, 2596-2604.	3.3	17
2751	Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. <i>Cell Research</i> , 2022, 32, 995-1007.	5.7	47
2752	Lymphomas in cartilage-hair hypoplasia – A case series of 16 patients reveals advanced stage DLBCL as the most common form. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2753	Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
2754	The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 975-975.	0.7	2
2755	Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL). <i>Cancers</i> , 2022, 14, 4290.	1.7	6
2756	Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia. , 2022, 10, e005400.		16
2757	Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience. <i>Pharmacoeconomics</i> , 0, , .	1.7	0
2758	Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 529-537.	0.7	11
2759	Co-Stimulatory Receptor Signaling in CAR-T Cells. <i>Biomolecules</i> , 2022, 12, 1303.	1.8	11
2760	Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9

#	ARTICLE	IF	CITATIONS
2761	Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. <i>Nature Medicine</i> , 2022, 28, 2124-2132.	15.2	244
2762	GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. , 2022, 10, e005187.		30
2763	Cardiovascular disease and chimeric antigen receptor cellular therapy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
2764	CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. <i>Science Advances</i> , 2022, 8, .	4.7	19
2765	New therapeutic modalities in the treatment of childhood acute lymphoblastic leukemia. <i>Cesko-Slovenska Pediatrie</i> , 2022, 77, 265-271.	0.0	0
2767	Liver Gene Therapy. <i>Human Gene Therapy</i> , 2022, 33, 879-888.	1.4	9
2768	Outcomes of Critically Ill Children With Acute Lymphoblastic Leukemia and Cytokine Release Syndrome Due to Chimeric Antigen Receptor T Cell Therapy: US, Multicenter PICU, Cohort Database Study. <i>Pediatric Critical Care Medicine</i> , 2022, 23, e595-e600.	0.2	2
2769	A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. <i>Clinical Cancer Research</i> , 2022, 28, 5088-5097.	3.2	12
2770	The T Cell Journey: A Tour de Force. <i>Advanced Biology</i> , 2023, 7, .	1.4	4
2771	Impact of cryopreservation on CAR T production and clinical response. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2772	Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, e14-e18.	0.2	1
2773	Treatment Options for Recurrent Primary CNS Lymphoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1548-1565.	1.3	1
2774	Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptorâ€œnatural killer cells. <i>Cytotherapy</i> , 2022, 24, 1087-1094.	0.3	8
2775	From inborn errors of immunity to lymphoma: A hematologistâ€™s point of view. <i>Medicinski Pregled</i> , 2022, 75, 66-71.	0.1	0
2776	Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211329.	0.8	2
2777	Cytokine release syndrome after CAR T-cell therapy: a review of the literature and our experience. <i>Anestezilogie A Intenzivni Medicina</i> , 2022, 33, 90-96.	0.1	0
2778	Ultrasound-mediated Delivery of Natural Killer Cells with Microbubble for Cancer Treatment. , 2022, , .		0
2779	Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25Âyears. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	8

#	ARTICLE	IF	CITATIONS
2780	The journey of CAR-T therapy in hematological malignancies. <i>Molecular Cancer</i> , 2022, 21, .	7.9	45
2781	A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2782	Anakinra to Mitigate Hemophagocytic Lymphohistiocytosis-Like Toxicity Following Chimeric Antigen Receptor T-cell Therapy in Pediatric B-cell ALL. <i>Clinical Pediatric Hematology-Oncology</i> , 2022, 29, 92-96.	0.0	2
2783	Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	52
2784	Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2023, 37, 53-60.	3.3	5
2785	NK cell therapy in relapsed refractory multiple myeloma. <i>Clinical Immunology</i> , 2023, 246, 109168.	1.4	2
2786	Clinical application of cellâ€based therapies opportunities and challenges. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	0
2789	CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2790	Whole-process management of complications during CAR-T therapy. , 2022, 1, .		0
2792	Novel technologies for improving the safety and efficacy of CAR-T cell therapy. <i>International Journal of Hematology</i> , 2023, 117, 647-651.	0.7	4
2793	What are the key considerations for deciding on the use of CAR T-cell therapy for patients with follicular lymphoma?. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-3.	1.1	0
2794	Perspectives for the Use of Fucoidans in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11821.	1.8	13
2795	Acute kidney injury after CAR-T cell infusion. <i>Bulletin Du Cancer</i> , 2022, , .	0.6	1
2796	Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2023, 108, 747-760.	1.7	12
2797	Tumor buster - where will the CAR-T cell therapy â€missileâ€™ go?. <i>Molecular Cancer</i> , 2022, 21, .	7.9	23
2798	Comparison of Acoustofluidic and Static Systems for Ultrasound-Mediated Molecular Delivery to T Lymphocytes. <i>Ultrasound in Medicine and Biology</i> , 2023, 49, 90-105.	0.7	1
2801	Next generations of CAR-T cells - new therapeutic opportunities in hematology?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
2802	Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells. <i>Cancers</i> , 2022, 14, 4854.	1.7	1

#	ARTICLE	IF	CITATIONS
2804	Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells. <i>Blood</i> , 2023, 141, 835-845.	0.6	11
2805	Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC. <i>Bone Marrow Transplantation</i> , 2023, 58, 72-79.	1.3	7
2806	Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>HemaSphere</i> , 2022, 6, e790.	1.2	3
2807	Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 957-968.	2.0	3
2808	Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. <i>Cancers</i> , 2022, 14, 5108.	1.7	9
2809	Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing. <i>Cancer Immunology Research</i> , 2023, 11, 13-19.	1.6	3
2810	Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas. <i>Cancers</i> , 2022, 14, 5022.	1.7	3
2811	Clinical implications of T cell exhaustion for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 775-790.	12.5	182
2812	Emerging frontiers in immuno- and gene therapy for cancer. <i>Cytotherapy</i> , 2023, 25, 20-32.	0.3	3
2813	The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
2814	Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity. <i>Cells</i> , 2022, 11, 3147.	1.8	3
2815	Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology. <i>OncolImmunology</i> , 2022, 11, .	2.1	1
2816	Spermidine Promotes Nb CAR-T Mediated Cytotoxicity to Lymphoma Cells Through Elevating Proliferation and Memory. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1229-1243.	1.0	3
2817	Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1. <i>International Journal of Hematology</i> , 2023, 117, 78-89.	0.7	3
2818	Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project. <i>Molecular Therapy - Oncolytics</i> , 2022, 27, 182-194.	2.0	1
2820	Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe. <i>Cancers</i> , 2022, 14, 5351.	1.7	1
2821	Exploring the mechanisms of CD19 CAR T-cell failure and salvage strategies in B-cell lymphoma. , 2022, 1, .		0
2822	Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL. <i>Clinical Cancer Research</i> , 2023, 29, 742-753.	3.2	11

#	ARTICLE	IF	CITATIONS
2823	Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 876-880.	1.3	1
2824	Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy. <i>Cancer Immunology Research</i> , 2022, 10, 1433-1440.	1.6	8
2825	Characteristics of clinical trials for non-small cell lung cancer therapeutic vaccines registered on ClinicalTrials.gov. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2826	Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement. <i>Pharmacoeconomics</i> , 2023, 41, 175-186.	1.7	5
2827	Advances in immunotherapy for glioblastoma multiforme. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
2828	UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. <i>Lancet Haematology</i> , the, 2022, 9, e833-e843.	2.2	35
2829	Migratory Engineering of T Cells for Cancer Therapy. <i>Vaccines</i> , 2022, 10, 1845.	2.1	8
2830	Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13332.	1.8	10
2831	Nanomedicine for advanced cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 351, 1017-1037.	4.8	7
2832	Toxicities following CAR-T therapy for hematological malignancies. <i>Cancer Treatment Reviews</i> , 2022, 111, 102479.	3.4	13
2833	Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice. <i>Biomaterials</i> , 2022, 291, 121872.	5.7	12
2834	Recent Update on Immunotherapy and Its Combination With Interventional Therapies for Hepatocellular Carcinoma. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492211348.	0.6	2
2835	CAR T Cell Immunotherapy That Revolutionary Breakthrough in Human Oncology Treatment: A Review. <i>Pharmacology & Pharmacy</i> , 2022, 13, 483-515.	0.2	0
2836	Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss. <i>Annual Review of Medicine</i> , 2023, 74, 279-291.	5.0	10
2837	A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. <i>Blood Advances</i> , 2023, 7, 2479-2493.	2.5	4
2838	Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial. <i>BMJ Open</i> , 2022, 12, e065109.	0.8	3
2839	Blinatumomab Prior to CAR-T Cell Therapyâ€”A Treatment Option Worth Consideration for High Disease Burden. <i>Biomedicines</i> , 2022, 10, 2915.	1.4	1
2841	Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia. <i>Cancer Research Communications</i> , 2022, 2, 1520-1531.	0.7	6

#	ARTICLE	IF	CITATIONS
2842	Population dynamics and gene regulation of T cells in response to chronic antigen stimulation. <i>International Immunology</i> , 2023, 35, 67-77.	1.8	0
2843	Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	37
2844	Enhanced T cell effector activity by targeting the Mediator kinase module. <i>Science</i> , 2022, 378, .	6.0	37
2845	Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2846	Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. <i>Annals of Medicine</i> , 2022, 54, 2950-2964.	1.5	5
2847	Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. <i>Blood</i> , 2023, 141, 609-619.	0.6	6
2848	Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
2849	Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic Differentiation. <i>Cancers</i> , 2022, 14, 5576.	1.7	4
2851	Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 1267-1275.	2.3	4
2852	A prospective multicenter study on varicella-zoster virus infection in children with acute lymphoblastic leukemia. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
2853	Expression levels and patterns of Bâ€cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 462-470.	0.7	1
2854	Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells. <i>Cytotherapy</i> , 2023, 25, 148-161.	0.3	5
2855	Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy. <i>Pediatric Blood and Cancer</i> , 0, , .	0.8	0
2856	Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101414.	0.7	2
2857	Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	22
2858	Role of CAR T Cell Metabolism for Therapeutic Efficacy. <i>Cancers</i> , 2022, 14, 5442.	1.7	10
2859	Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 1670-1683.	0.8	35
2860	BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	25

#	ARTICLE	IF	CITATIONS
2861	Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	27
2862	Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2863	Preclinical models for development of immune-“oncology therapies. <i>Immuno-oncology Insights</i> , 2022, 03, 396-398.	0.0	2
2864	Cytokine Release Syndrome in the Pediatric Population and Implications for Intensive Care Management. <i>Critical Care Clinics</i> , 2022, , .	1.0	0
2865	Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs). <i>International Journal of Molecular Sciences</i> , 2022, 23, 14255.	1.8	8
2867	Engineered T-Cell therapy for viral and non-viral epithelial cancers. <i>Cancer Cell</i> , 2023, 41, 58-69.	7.7	13
2868	Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 1664-1669.	0.8	73
2869	Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. <i>International Journal of Hematology</i> , 2023, 117, 251-259.	0.7	2
2870	Immunotherapy for the treatment of pediatric brain tumors: a narrative review. <i>Translational Pediatrics</i> , 2022, 11, 2040-2056.	0.5	2
2871	Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers. , 2023, , 117-155.		1
2872	Infection Associated with the Use of CAR T Cells. , 2022, , 315-331.		0
2873	CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211421.	1.1	5
2874	Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T-cells are as effective as freshly infused cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2023, 28, 51-61.	1.8	3
2875	Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics. <i>Bioactive Materials</i> , 2023, 23, 438-470.	8.6	13
2876	Enhancement of T cell infiltration via tumor-targeted Th9 cell delivery improves the efficacy of antitumor immunotherapy of solid tumors. <i>Bioactive Materials</i> , 2023, 23, 508-523.	8.6	1
2877	Immune-Targeted Therapies for COVID-19. , 2022, , 451-468.		0
2878	HCDT: an integrated highly confident drug-“target resource. <i>Database: the Journal of Biological Databases and Curation</i> , 2022, 2022, .	1.4	2
2880	CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24

#	ARTICLE	IF	CITATIONS
2881	CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Cancer Discovery</i> , 2023, 13, 580-597.	7.7	18
2882	How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL. <i>Blood</i> , 2023, 141, 1251-1264.	0.6	14
2883	Relapses Children's Acute Lymphoblastic Leukemia, Single Center Experience. <i>Children</i> , 2022, 9, 1874.	0.6	0
2884	Circulating CD22 ⁺ CD19 ⁺ CD24 ⁺ progenitors and CD22 ⁺ CD19 ⁺ CD24 ⁺ mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2023, 104, 294-303.	0.7	4
2886	Immunotherapy approaches for rare pediatric solid tumors: advances and future directions. <i>Current Opinion in Pediatrics</i> , 2023, 35, 63-74.	1.0	0
2887	Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. <i>Current Oncology</i> , 2022, 29, 8975-9005.	0.9	9
2888	Multiplexed engineering and precision gene editing in cellular immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2889	Advances in CAR T cell immunotherapy for paediatric brain tumours. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2890	Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. , 2022, 10, e005459.		4
2891	Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. <i>Oncolmmunology</i> , 2023, 12, .	2.1	7
2892	A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
2893	Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0
2894	CD7 CAR-T therapy for an AML patient with CD7 expression. , 2022, 1, .		0
2895	NR4A1 mediates NK cell dysfunction in hepatocellular carcinoma via the IFN γ /STAT1/IRF1 pathway. <i>Immunology</i> , 2023, 169, 69-82.	2.0	6
2896	Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse. , 2022, 10, e005360.		9
2897	Cancer-associated fibroblasts in acute leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2898	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	1.7	1
2899	Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
2900	Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations. AACN Advanced Critical Care, 2022, 33, 301-307.	0.6	1
2901	Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13R α 2-Targeted Chimeric Antigen Receptor T Cells. Cancer Research Communications, 2023, 3, 66-79.	0.7	4
2902	Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial. Bone Marrow Transplantation, 2023, 58, 288-294.	1.3	2
2903	Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. Cancers, 2022, 14, 5983.	1.7	6
2904	Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. Genome Medicine, 2022, 14, .	3.6	15
2905	New developments in ALL in AYA. Hematology American Society of Hematology Education Program, 2022, 2022, 190-196.	0.9	1
2906	Engineered hydrogels for mechanobiology. Nature Reviews Methods Primers, 2022, 2, .	11.8	37
2907	CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. Frontiers in Immunology, 0, 13, .	2.2	5
2908	Central Nervous System Prophylaxis and Treatment in Acute Leukemias. Current Treatment Options in Oncology, 2022, 23, 1829-1844.	1.3	3
2909	Allogeneic CD34 ⁺ selected hematopoietic stem cell boost following CAR T cell therapy in a patient with prolonged cytopenia and active infection. Pediatric Blood and Cancer, 2023, 70, .	0.8	5
2910	Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment. Expert Opinion on Therapeutic Targets, 2022, 26, 923-936.	1.5	6
2911	Chimeric antigen receptor T-cell therapy for multiple myeloma. Frontiers in Immunology, 0, 13, .	2.2	4
2912	Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma. Cells, 2022, 11, 4085.	1.8	1
2913	How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia. Blood, 2023, 141, 1379-1388.	0.6	10
2914	Phase I CAR-T Clinical Trials Review. Anticancer Research, 2022, 42, 5673-5684.	0.5	0
2915	Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica, 2022, 107, 2783-2793.	1.7	12
2916	Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes. Radiology and Oncology, 2022, 56, 409-419.	0.6	2
2917	Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities. JCO Oncology Practice, 2023, 19, e407-e416.	1.4	2

#	ARTICLE	IF	CITATIONS
2918	Acute Kidney Injury in Cancer Immunotherapy Recipients. <i>Cells</i> , 2022, 11, 3991.	1.8	4
2919	Targeting TGF- β signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	5
2920	Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. <i>Blood Advances</i> , 0, , .	2.5	2
2921	Recent progress in pediatric lymphoblastic leukemia. <i>International Journal of Hematology</i> , 0, , .	0.7	0
2922	Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
2923	Novel modular chimeric antigen receptor spacer for T cells derived from signal regulatory protein alpha Ig-like domains. <i>Frontiers in Molecular Medicine</i> , 0, 2, .	0.6	2
2924	Cardiotoxicity of T-Cell Antineoplastic Therapies. <i>JACC: CardioOncology</i> , 2022, 4, 616-623.	1.7	10
2925	A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture. <i>Cytotherapy</i> , 2023, 25, 323-329.	0.3	8
2926	Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. <i>Molecular Therapy</i> , 2023, 31, 676-685.	3.7	4
2927	Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR. <i>Cancer Immunology Research</i> , 2023, 11, 150-163.	1.6	5
2928	Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1845-1860.	1.3	2
2930	Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1045.	1.8	2
2931	Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. <i>Nature Medicine</i> , 2023, 29, 104-114.	15.2	31
2932	CAR Exosome-Based Therapeutics. , 2023, , 1-14.		0
2933	Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells. <i>International Journal of Nanomedicine</i> , 0, Volume 18, 49-63.	3.3	7
2934	Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions. <i>OncoTargets and Therapy</i> , 0, Volume 16, 1-16.	1.0	1
2935	Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy. <i>Molecular Therapy</i> , 2023, 31, 686-700.	3.7	7
2936	A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia. <i>Blood Advances</i> , 2023, 7, 4218-4232.	2.5	5

#	ARTICLE	IF	CITATIONS
2938	CAR T-Cells for Cure in Pediatric B-ALL. <i>Journal of Clinical Oncology</i> , 2023, 41, 1646-1648.	0.8	1
2939	Signaling pathways in brain tumors and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	13
2940	CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
2941	Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 254.e1-254.e9.	0.6	3
2942	Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy. <i>Current Oncology</i> , 2023, 30, 1146-1150.	0.9	2
2943	Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	1
2944	Molecular and therapeutic effect of CRISPR in treating cancer. , 2023, 40, .		2
2945	Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. <i>Cancer Cell</i> , 2023, 41, 210-225.e5.	7.7	32
2946	A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	7
2947	Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma. , 2023, 11, e005881.		3
2948	Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2949	Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy. <i>Current Research in Translational Medicine</i> , 2023, 71, 103378.	1.2	2
2950	Interaction Between Immune and Cancer Cells and Promising CAR T-cell Therapy. <i>Journal of Student Research</i> , 2022, 11, .	0.0	0
2951	Top advances of the year: Leukemia. <i>Cancer</i> , 0, , .	2.0	0
2952	Advancements in Cancer Immunotherapies. <i>Vaccines</i> , 2023, 11, 59.	2.1	8
2953	PRECLINICAL MOUSE MODELS IN ADOPTIVE CELL THERAPIES OF CANCER. <i>Slovenian Veterinary Research</i> , 2022, 59, .	0.0	0
2954	Chimeric antigen receptor T (<sc>CAR</sc>) cells: Novel cell therapy for hematological malignancies. <i>Cancer Medicine</i> , 2023, 12, 7844-7858.	1.3	15
2955	Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer. <i>Cancers</i> , 2023, 15, 263.	1.7	2

#	ARTICLE	IF	CITATIONS
2956	Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 165.e1-165.e7.	0.6	6
2957	Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. <i>Nature Biotechnology</i> , 2023, 41, 1229-1238.	9.4	22
2958	Modulating Glycolysis to Improve Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2606.	1.8	40
2959	Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy. <i>Cytometry Part B - Clinical Cytometry</i> , 2023, 104, 205-223.	0.7	7
2960	Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march. , 2023, , 97-131.		0
2961	Tumor immunology. , 2023, , 245-452.		0
2962	Lymphodepletion and cellular immunotherapy. , 2023, , 181-196.		0
2963	Immunotherapy using CAR T: What we have learned from trials and where we are heading. , 2023, , 369-384.		0
2964	Determination of the Binding Epitope of an Anti-Mouse CCR9 Monoclonal Antibody (C9Mab-24) Using the 1Å— Alanine and 2Å— Alanine-Substitution Method. <i>Antibodies</i> , 2023, 12, 11.	1.2	0
2965	Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 314-320.	0.6	3
2966	Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies. , 2023, , .		0
2967	Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. <i>Cancers</i> , 2023, 15, 648.	1.7	6
2968	CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany. <i>Blood Advances</i> , 2023, 7, 2436-2448.	2.5	8
2971	CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. <i>Molecular Cancer</i> , 2023, 22, .	7.9	65
2972	Chimeric antigen receptor T-cell as a significant player in the innovative treatment of hematological cancers. <i>Journal of Education, Health and Sport</i> , 2023, 13, 134-139.	0.0	0
2973	Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 269-286.	2.5	0
2974	Highly efficient mRNA delivery with nonlinear microfluidic cell stretching for cellular engineering. <i>Lab on A Chip</i> , 2023, 23, 1758-1767.	3.1	7
2975	Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0

#	ARTICLE	IF	CITATIONS
2976	Aberrant N-glycosylation in cancer: MGAT5 and Î²1,6-GlcNAc branched N-glycans as critical regulators of tumor development and progression. Cellular Oncology (Dordrecht), 2023, 46, 481-501.	2.1	3
2977	Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells. Biomedicines, 2023, 11, 345.	1.4	0
2978	Zamtocabtagene Autoleucl (MB-CART2019.1): An Investigational CAR-T Cell Product with Tandem Targeting of CD19 and CD20 as a Potential Treatment Option for Patients with Relapsed/ Refractory B Cell Non-Hodgkin Lymphoma. European Medical Journal Hematology, 0, , 29-31.	0.0	0
2979	Lymphoid Leukemias. , 2023, , 984-999.		0
2980	Durable remissions achieved with reinfusion of CD19â€directed CARâ€T despite failure to induce or maintain Bâ€cell aplasia and singleâ€center experience with reinfusion of tisagenlecleucel. Pediatric Blood and Cancer, 2023, 70, .	0.8	3
2981	The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2023, 24, 3727.	1.8	0
2982	CAR-T cells for cancer immunotherapy. Chinese Chemical Letters, 2023, 34, 108202.	4.8	3
2983	Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Gene Therapy, 2023, 30, 845-854.	2.2	12
2984	The adrenal stress response is an essential host response against therapy-induced lethal immune activation. Science Signaling, 2023, 16, .	1.6	0
2985	Early Stage Professionals Committee Proceedings from the International Society for Cell & Gene Therapy 2022 Annual Meeting. Cytotherapy, 2023, , .	0.3	0
2986	Therapeutic effects of antiâ€GM2 CARâ€T cells expressing ILâ€7 and CCL19 for GM2â€positive solid cancer in xenograft model. Cancer Medicine, 2023, 12, 12569-12580.	1.3	1
2987	Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2023, 29, 430-437.	0.6	15
2988	Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation. Immunotherapy, 2023, 15, 401-407.	1.0	1
2989	Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL. Frontiers in Immunology, 0, 14, .	2.2	6
2990	Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882.	1.7	2
2991	A secondâ€generation <sc>CD38â€CARâ€T</sc> cell for the treatment of multiple myeloma. Cancer Medicine, 0, , .	1.3	1
2992	Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity. Frontiers in Immunology, 0, 14, .	2.2	1
2993	Liposomal ATM siRNA delivery for enhancing triple-negative breast cancer immune checkpoint blockade therapy. Journal of Biomaterials Applications, 2023, 37, 1835-1846.	1.2	1

#	ARTICLE	IF	CITATIONS
2994	GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. <i>New England Journal of Medicine</i> , 2023, 388, 1284-1295.	13.9	104
2995	Liquid biopsy in pancreatic cancer – Current perspective and future outlook. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188868.	3.3	5
2996	Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia. <i>Blood Reviews</i> , 2023, 59, 101042.	2.8	2
2997	Non-viral chimeric antigen receptor (CAR) T cells going viral. <i>Immuno-Oncology Technology</i> , 2023, 18, 100375.	0.2	8
2998	Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review. <i>Current Drug Research Reviews</i> , 2023, 15, 241-261.	0.7	2
3000	Updated insights on cardiac risks of CD19-directed chimeric antigen receptor T-cell therapy: a pharmacovigilance study. <i>Immunotherapy</i> , 2023, 15, 443-456.	1.0	0
3002	Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review. <i>HemaSphere</i> , 2022, 6, e802.	1.2	7
3003	Natural Killer Cell-Based Immunotherapy against Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2111.	1.8	4
3004	Sequencing <sc>antigen-targeting</sc> antibodies and cellular therapies in adults with relapsed/refractory <sc>B-cell</sc> acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2023, 98, 666-680.	2.0	3
3007	Delivery of macromolecules in unstimulated T cells by photoporation with polydopamine nanoparticles. <i>Journal of Controlled Release</i> , 2023, 354, 680-693.	4.8	5
3008	Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies. <i>Current Treatment Options in Oncology</i> , 2023, 24, 184-211.	1.3	6
3009	SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. , 2023, 11, e005957.		3
3010	Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. <i>Cancers</i> , 2023, 15, 777.	1.7	3
3011	Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
3012	Synapse-tuned CARs enhance immune cell anti-tumor activity. <i>Nature Biotechnology</i> , 2023, 41, 1434-1445.	9.4	12
3013	Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer. <i>Immunology Letters</i> , 2023, 255, 1-9.	1.1	1
3014	Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 5-15.	1.0	1
3015	Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input. <i>Cancers</i> , 2023, 15, 1003.	1.7	16

#	ARTICLE	IF	CITATIONS
3016	The potential role of the thymus in immunotherapies for acute myeloid leukemia. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
3017	Recent advancement in breast cancer treatment using CAR T cell therapy:- A review. <i>Advances in Cancer Biology Metastasis</i> , 2023, 7, 100090.	1.1	2
3018	Highly-sensitive chimerism analysis in blood after allogeneic hematopoietic cell transplantation in childhood leukemia: Results from the Nordic Microchimerism Study. , 0, 2, .		0
3019	Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
3020	Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome. <i>Lancet Haematology</i> ,the, 2023, 10, e161-e162.	2.2	1
3021	CXCR3 predicts the prognosis of endometrial adenocarcinoma. <i>BMC Medical Genomics</i> , 2023, 16, .	0.7	0
3022	CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy. <i>Cancers</i> , 2023, 15, 1052.	1.7	4
3023	Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis. <i>Cells</i> , 2023, 12, 531.	1.8	1
3024	Challenges and opportunities of CAR T-cell therapies for CLL. <i>Seminars in Hematology</i> , 2023, 60, 25-33.	1.8	3
3025	Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy. <i>Blood Advances</i> , 2023, 7, 2825-2830.	2.5	1
3026	CAR-T Cell Therapy: the Efficacy and Toxicity Balance. <i>Current Hematologic Malignancy Reports</i> , 2023, 18, 9-18.	1.2	15
3027	HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	1
3028	A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	4
3029	Comparative Pre-Clinical Analysis of CD20-Specific CAR T Cells Encompassing 1F5-, Leu16-, and 2F2-Based Antigen-Recognition Moieties. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3698.	1.8	1
3030	Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma. <i>Pharmacological Research</i> , 2023, 189, 106701.	3.1	5
3031	Anti-ROR1 CAR-T cells: Architecture and performance. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
3032	Racing CARs to veterinary immuno-oncology. <i>Frontiers in Veterinary Science</i> , 0, 10, .	0.9	0
3033	Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome. <i>Biomolecules</i> , 2023, 13, 382.	1.8	8

#	ARTICLE	IF	CITATIONS
3034	Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia. <i>Leukemia Research Reports</i> , 2023, 19, 100364.	0.2	0
3035	The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 311.e1-311.e7.	0.6	2
3036	Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
3037	Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL. , 2023, 11, e005701.		7
3038	Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL. <i>Cancers</i> , 2023, 15, 1349.	1.7	0
3039	Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	4
3040	CAR immune cells: design principles, resistance and the next generation. <i>Nature</i> , 2023, 614, 635-648.	13.7	96
3041	Clinical use of CAR T-cells in treating acute lymphoblastic leukemia. <i>Transfusion and Apheresis Science</i> , 2023, 62, 103666.	0.5	0
3042	In vitro differentiation of myeloid suppressor cells (MDSC-like) from an immature myelomonocytic precursor THP-1. <i>Journal of Immunological Methods</i> , 2023, 515, 113441.	0.6	0
3043	Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies. <i>Translational Pediatrics</i> , 2023, 12, 487-502.	0.5	2
3044	Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD. , 2023, 11, e004851.		0
3045	Pediatric Acute Lymphoblastic Leukemia Emerging Therapiesâ€”From Pathway to Target. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4661.	1.8	4
3046	â€œCAR Tâ€”Asian Thinking. , 2023, , 693-697.		0
3047	Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL. <i>OncolImmunology</i> , 2023, 12, .	2.1	0
3048	HLH-like toxicities predict poor survival following use of tisagenlecleucel in children and young adults with B-ALL. <i>Blood Advances</i> , 0, , .	2.5	1
3049	Chimeric antigen receptor T cells therapy in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 2279-2296.	1.2	2
3050	ImmuneScore of eight-gene signature predicts prognosis and survival in patients with endometrial cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
3051	Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy. <i>Tissue Engineering and Regenerative Medicine</i> , 2023, 20, 371-387.	1.6	8

#	ARTICLE	IF	CITATIONS
3052	Combining chemotherapy with CAR-T cell therapy in treating solid tumors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	10
3053	Human <scp>EGFRvIII</scp> chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma. <i>Clinical and Translational Immunology</i> , 2023, 12, .	1.7	1
3054	Progression in immunotherapy for advanced prostate cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
3055	Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	13
3056	Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant. <i>Cell Transplantation</i> , 2023, 32, 096368972311581.	1.2	0
3057	High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with <scp>Philadelphiaâ€like</scp> fusions. <i>American Journal of Hematology</i> , 2023, 98, 848-856.	2.0	4
3058	Infectious complications of chimeric antigen receptor (CAR) T-cell therapies. <i>Seminars in Hematology</i> , 2023, 60, 52-58.	1.8	2
3059	Co-opting signalling molecules enables logic-gated control of CAR T cells. <i>Nature</i> , 2023, 615, 507-516.	13.7	60
3060	Novel pathophysiological insights into CAR-T cell associated neurotoxicity. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	4
3061	Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 438.e1-438.e16.	0.6	36
3062	Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. <i>Blood Research</i> , 2023, 58, S20-S28.	0.5	3
3063	Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2023, 7, 4913-4925.	2.5	3
3064	More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	1
3065	Metabolic reprogramming via an engineered PGC-1 β improves human chimeric antigen receptor T-cell therapy against solid tumors. , 2023, 11, e006522.		8
3066	Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead. <i>Blood Advances</i> , 2023, 7, 3350-3360.	2.5	2
3067	LYMPHAPHERESIS FOR CAR-T CELL THERAPY: PREDICTION OF CD3+ CELL COUNTS USING AN AUTOMATED HEMATOLOGY ANALYZER. <i>Japanese Journal of Transfusion and Cell Therapy</i> , 2023, 69, 8-14.	0.1	0
3068	Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. <i>Nature Biotechnology</i> , 2023, 41, 1618-1632.	9.4	15
3069	ErbB- and MUC1-targetted CAR-T cell immunotherapy of oral squamous cell carcinoma. <i>Frontiers in Dental Medicine</i> , 0, 4, .	0.5	1

#	ARTICLE	IF	CITATIONS
3070	Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. , 2023, 11, e006292.		5
3071	A Review of CART-T Therapy in Pediatric and Young Adult B-Lineage Acute Leukemia: Clinical Perspectives in Singapore. OncoTargets and Therapy, 0, Volume 16, 165-176.	1.0	0
3073	The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. Journal of Hematology and Oncology, 2023, 16, .	6.9	18
3074	Recent advances in immunotherapy and molecular targeted therapy for gastric cancer. Future Science OA, 2023, 9, .	0.9	2
3075	Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis. Clinical and Experimental Medicine, 2023, 23, 2041-2050.	1.9	1
3076	Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncology Practice, 0, , .	1.4	0
3077	Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 7363-7378.	1.2	1
3079	Cellular Therapies in Chronic Lymphocytic Leukemia and Richterâ€™s Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant. Cancers, 2023, 15, 1838.	1.7	3
3080	Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. European Heart Journal, 2023, 44, 2029-2042.	1.0	7
3081	Inflammation, Infiltration, and Evasionâ€™Tumor Promotion in the Aging Breast. Cancers, 2023, 15, 1836.	1.7	2
3082	The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Frontiers in Immunology, 0, 14, .	2.2	23
3083	The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors. Frontiers in Immunology, 0, 14, .	2.2	4
3084	T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy. Trends in Immunology, 2023, 44, 397-398.	2.9	1
3085	Development and Clinical Application of CAR-T Therapy. , 0, 36, 1269-1276.		0
3086	Remote control of cellular immunotherapy. , 2023, 1, 440-455.		4
3087	CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study. Blood Cancer Journal, 2023, 13, .	2.8	6
3088	Arenaviruses: Old viruses present new solutions for cancer therapy. Frontiers in Immunology, 0, 14, .	2.2	1
3089	Immune-related adverse events associated with the use of immunotherapy in patients with B-cell lymphoblastic leukemia: A protocol for a systematic review and meta-analysis. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock		

#	ARTICLE	IF	CITATIONS
3090	Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphoblastic Leukemia Patients. Transplantation and Cellular Therapy, 2023, 29, 356.e1-356.e7.	0.6	7
3091	Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy. Journal of Translational Medicine, 2023, 21, .	1.8	2
3092	Cytokine Storm Syndromes in Pediatric Patients. Journal of Allergy and Clinical Immunology: in Practice, 2023, , .	2.0	1
3094	Fungal Infections Associated with CD19-Targeted Chimeric Antigen Receptor T Cell Therapy. Current Fungal Infection Reports, 0, , .	0.9	0
3095	Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. Cancers, 2023, 15, 1989.	1.7	2
3096	Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2023, 29, 399-402.	0.6	2
3097	Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematology,the, 2023, 10, e382-e388.	2.2	7
3098	Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardio-Oncology, 2023, 9, .	0.8	0
3099	CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Valueâ€™s Worth. Current Oncology, 2023, 30, 4033-4040.	0.9	0
3100	Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. Cancer Research Communications, 2023, 3, 821-829.	0.7	9
3101	Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	4
3102	T _{STEM}-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Science Translational Medicine, 2023, 15, .	5.8	20
3103	CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?. Frontiers in Neurology, 0, 14, .	1.1	6
3104	Self-interest of institutions. , 2023, , 245-250.		0
3106	Mismatched donor cell infusion-related syndrome following microtransplant in patients with acute myeloid leukemia. Chinese Medical Journal, 0, Publish Ahead of Print, .	0.9	0
3107	Immunotherapy for Acute Leukemia. , 2022, , 1-41.		0
3108	The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer. Nature Communications, 2023, 14, .	5.8	8
3109	Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health. Translational Medicine Communications, 2023, 8, .	0.5	3

#	ARTICLE	IF	CITATIONS
3110	The Transfer of the Hepatocyte Growth Factor Gene by Macrophages Ameliorates the Progression of Peritoneal Fibrosis in Mice. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6951.	1.8	1
3111	Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies. <i>Annual Review of Cancer Biology</i> , 2023, 7, 23-42.	2.3	1
3112	Bridging the Gap Between Innate and Adaptive Immunity in the Lung: Summary of the Aspen Lung Conference 2022. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 0, , .	1.4	0
3113	Challenges of Detecting Measurable/Minimal Disease in Acute Leukemia. <i>Seminars in Diagnostic Pathology</i> , 2023, , .	1.0	0
3114	Long-term outcomes following CAR T cell therapy: what we know so far. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 359-371.	12.5	119
3115	The Current Status and Future Perspectives of Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Endometrial Cancer. <i>Current Issues in Molecular Biology</i> , 2023, 45, 3359-3374.	1.0	0
3117	BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia. <i>Hemato</i> , 2023, 4, 135-157.	0.2	1
3118	Apoptosis: a Janus bifrons in T-cell immunotherapy. , 2023, 11, e005967.		3
3119	Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients. <i>BMC Cancer</i> , 2023, 23, .	1.1	13
3120	Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. <i>Frontiers of Medicine</i> , 2023, 17, 699-713.	1.5	5
3121	Cell Therapy, Nursing Implications and Care. , 2023, , 101-122.		0
3122	œ just wanted to speak to someone- and there was no oneœ using Burden of Treatment Theory to understand the impact of a novel ATMP on early recipients. <i>Orphanet Journal of Rare Diseases</i> , 2023, 18, .	1.2	1
3123	Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies. , 2023, 2, 106-119.		3
3124	Take a spin: Apheresis in the care of adult leukaemia patients. <i>Best Practice and Research in Clinical Haematology</i> , 2023, 36, 101467.	0.7	0
3125	CAR-T-sejtes kezelése a hematológiai betegeknél. <i>Transfusio</i> , 2023, 55, 164-170.	0.0	0
3126	Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T. <i>Molecular Therapy - Oncolytics</i> , 2023, 29, 107-117.	2.0	2
3127	Neurofibromatosis Symptom-Lacking B-Cell Lineage Acute Lymphoblastic Leukemia with Only an NF1 Gene Pathogenic Variant. <i>Diagnostics</i> , 2023, 13, 1486.	1.3	1
3128	Immunotherapy and Cancer Stem Cells. , 2023, , 165-235.		0

#	ARTICLE	IF	CITATIONS
3129	Crystal Structure of a Chimeric Antigen Receptor (CAR) scFv Domain Rearrangement Forming a VL-VL Dimer. <i>Crystals</i> , 2023, 13, 710.	1.0	0
3130	Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2023, 10, .	3.1	2
3131	The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	0
3132	Functional Validation of the RQR8 Suicide /Marker Gene in CD19 CAR-T Cells and CLL1CAR-T Cells. <i>Annals of Hematology</i> , 2023, 102, 1523-1535.	0.8	0
3177	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
3181	Advances in PET imaging of cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 474-490.	12.8	20
3185	Emerging evidence for adapting radiotherapy to immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 543-557.	12.5	36
3200	CAR T-Cell Therapy and Critical Care Considerations. , 2023, , 427-435.		0
3223	Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia. , 2024, , 233-245.		0
3224	Preparative Regimens Used in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapies. , 2024, , 125-143.		0
3225	Miscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy. , 2024, , 537-547.		0
3226	Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy. , 2024, , 509-524.		0
3227	Process and General Management of Patients Undergoing Chimeric Antigen Receptor Therapies. , 2024, , 115-122.		0
3231	Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
3267	Immunotherapy for Meningiomas. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 225-234.	0.8	0
3270	Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	0
3275	Limited utility of chimeric antigen receptor (CAR) T-cell retreatment: experience with a human anti-CD19 CAR. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	0
3279	Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casualty or a new entity?. <i>Annals of Hematology</i> , 0, , .	0.8	0

#	ARTICLE	IF	CITATIONS
3288	Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 85-110.	0.8	0
3300	The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer. , 2023, , 1-43.		1
3303	Acute Lymphoblastic Leukemia with Central Nervous System Involvementâ€”Challenges in Management. <i>Indian Journal of Pediatrics</i> , 0, , .	0.3	1
3311	Immunotherapy for Ocular Tumors. , 2023, , 1-61.		0
3329	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	5
3339	Drug delivery systems for CRISPR-based genome editors. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 875-894.	21.5	9
3379	Gene Editing and Gene Therapy in Oncology. , 2023, , 155-180.		4
3380	Second Chances. , 2023, , 129-144.		0
3387	Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
3388	Editorial: Translation of genetically engineered T cells in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
3390	New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. , 2024, , 165-192.		0
3394	Recent Developments in Cancer Detection and Treatment. , 2023, , 1-10.		1
3404	In the Pipelineâ€”Emerging Therapy for ALL. , 2023, , 353-394.		0
3405	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. , 2023, , 329-339.		0
3406	Management of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-Like ALL). , 2023, , 311-327.		0
3407	Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia. , 2023, , 289-310.		0
3408	Immunotherapy for ALL. , 2023, , 341-352.		0
3418	Childhood Acute Lymphoblastic Leukemia. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
3451	T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 996-1017.	21.5	7
3453	CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. <i>Experimental and Molecular Medicine</i> , 2023, 55, 2287-2299.	3.2	7
3457	Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy. <i>Current Neurology and Neuroscience Reports</i> , 0, , .	2.0	0
3461	β T cells: origin and fate, subsets, diseases and immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	7
3496	Cellular Therapies: A Description of the Types of Existing Cellular Therapies and Associated Toxicities. , 2023, , 55-67.		0
3514	Rapid Screening of CAR T Cell Functional Improvement Strategies by Highly Multiplexed Single-Cell Secretomics. <i>Methods in Molecular Biology</i> , 2024, , 135-149.	0.4	0
3526	Immune System, Redox Signaling, and Cancer Immunity. , 2023, , 207-235.		0
3552	Hämatopoetische Stammzelltransplantation: seit Jahrzehnten etablierte Zelltherapie. , 2023, , 161-181.		0
3553	Technologien und Lösungsansätze für die effiziente Herstellung von Zelltherapeutika für die CAR-Immuntherapie. , 2023, , 123-137.		0
3558	Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond. <i>Advances in Protein Chemistry and Structural Biology</i> , 2024, , .	1.0	0
3615	Waldenstrom Macroglobulinemia. , 2024, , .		0
3621	The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. <i>Annals of Hematology</i> , 0, , .	0.8	0
3630	Akute Leukämien. , 2024, , 403-430.		0
3646	Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Therapy and Coagulopathies. , 2024, , .		0
3650	Current Trends in Treatment and New Generation of Trials in Thyroid Cancer. , 2023, , 307-324.		0
3651	Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma. <i>Frontiers in Neurology</i> , 0, 15, .	1.1	0
3676	Adoptive T-Cell Therapy for the Treatment of Lung Cancer. , 2024, , 101-130.		0